Calcium Signalling in Cancer
Calcium Signalling in Cancer Gajanan V. Sherbet Cancer Research Unit The Medical School ...
116 downloads
2166 Views
7MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Calcium Signalling in Cancer
Calcium Signalling in Cancer Gajanan V. Sherbet Cancer Research Unit The Medical School University of Newcastle upon Tyne,UK and The Institute for Molecular Medicine Huntington Beach, CA USA
CRC Press Boca Raton London New York Washington, D.C.
Library of Congress Cataloging-in-Publication Data Sherbet, G. V. (Gajanan V.) Calcium signalling in cancer : the role of calcium binding proteins in signal transduction, cell proliferation, invasion, and metastasis / Gajanan V. Sherbet. p. cm. Includes bibliographical references and index. ISBN 0-8493-0982-4 (alk. paper) 1. Carcinogenesis. 2. Calcium-binding proteins. 3. Metastasis. 4. Cancer invasiveness. I. Title. [DNLM: 1. Neoplasm Proteins—physiology. 2. Calcium Signaling—physiology. 3. Calcium-Binding Proteins—physiology. 4. Cell Differentiation—physiology. 5. Neoplasm Invasiveness. 6. Neoplasm Metastasis. QZ 200 S551c 2000] RC268.5 .S53 2000 616.99′407—dc21 00-062115
This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher. The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying. Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.
© 2001 by CRC Press LLC No claim to original U.S. Government works International Standard Book Number 0-8493-0982-4 Library of Congress Card Number 00-062115 Printed in the United States of America 1 2 3 4 5 6 7 8 9 0 Printed on acid-free paper
Dedication to Shri Sai Baba
Preface
The perfect messenger commands respect, delivers the message uncorrupted, at the right time, at the right place, with integrity. Thiru Valluvar (Tamil poet, second century, India) Thirukkural, Chapter 69, verse 688
Calcium signalling occupies a preeminent position in the signal transduction system of the cell by virtue of its participation in a wide range of physiological functions and in the biological events associated with genetic expression, cell proliferation and apoptosis, and cell differentiation and morphogenesis. Calcium signalling is an important feature of cell adhesion and motility, and of cancer invasion and metastasis. The calcium ion virtually unifies several pathways of signal transduction. It has rightly been described as a second messenger. Calcium-binding proteins are an important link in the calcium-signalling pathway. These proteins not only maintain the integrity of the calcium signal, but they are also responsible for transmitting the message in a temporally and spatially coordinated manner. It follows therefore that the integrity of the calcium binding proteins themselves is a basic requirement of normal biological function. This concept is encapsulated most eloquently in the Tamil quotation given above. If their integrity is compromised or lost from abnormal or inappropriate expression, or by genetic changes, that could lead to a profound deregulation of signal transduction with dramatic and wide-ranging effects on the life of the cell and its biological behaviour. That is the simple and singular justification for focusing on this protein species in this book. This volume is a natural sequel to my previous works. They are: The Biochemical and Biophysical Characterisation of the Cell Surface (Academic Press, 1978), The Biology of Tumour Malignancy (Academic Press, 1982), The Metastatic Spread of Cancer (Macmillan, 1987), and The Genetics of Cancer (Academic Press, 1997). In these one can discern the evolution of thought relating to the biological behaviour of cells and the pathogenesis of cancer, from inception of the tumour to its progression to the overt metastatic state. This book has not been written with the specialist only in mind. The discussion of topics is self-contained, as far as it was practicable, and I believe, therefore, it would be useful to students and research scientists alike.
Also, the presentation and discussions cater to the needs of scientists in related but peripheral fields of discipline. I had considerable help from my colleagues in the preparation of this book. Professor P.A. Riley of the University College School of Medicine and Dr. M.S. Lakshmi very kindly read the entire manuscript. Their comments and criticisms have been taken and consequently the manuscript has greatly improved in presentation and coverage. Dr. Lakshmi also kindly provided the Tamil quotation and its translation. I wish to thank them most sincerely for their help. It is needless to say, however, that the responsibility for errors and omissions rests solely with me. I thank Paula Rutter of the Audio-visual Centre for preparing the figures and for the patience and skill that she has displayed. CRC Press LLC received this book most enthusiastically and with great fervour. It has been a considerable pleasure working with them, especially with Fequiere Vilsaint, on this project. Finally, the North of England Cancer Research Campaign largely supported the research work in my laboratory and I wish to record my gratitude to them. Gajanan V. Sherbet Cancer Research Unit The Medical School University of Newcastle upon Tyne, UK and The Institute for Molecular Medicine Huntington Beach, CA, USA
Abbreviations βAPP ABP ACTH ACV aFGF ALS ANN APC AR BA-1p BAE BDNF bFGF BMD bp BPH BrDU CAI CaM cAMP CAMPK Capn CAR CBD CBD9K CBP cdk cGMP CH CHO CK CNS CP CRE CREB CS DAG DAGK db-cAMP
β-amyloid precursor protein Amyloid-β protein Adrenocorticotropic hormone Acyclovir Acidic fibroblast growth factor Amyotrophic lateral sclerosis Artificial neural network Adenomatous polyposis coli (protein) Androgen receptor Bone-specific alkaline phosphatase Bovine aortic endothelial (cell) Brain-derived neurotropic factor Basic fibroblast growth factor Becker muscular dystrophy Base pair(s) Benign prostatic hyperplasia Bromo-deoxyuridine Carboxyamido-triazole Calmodulin Cyclic 3′,4′-adenosine monophosphate Calcium/calmodulin-dependent protein kinase Calpain Cancer-associated retinopathy Calbindin D-28K Calbindin D-9K Calcium-binding protein Cyclin-dependent protein kinase Cyclic guanosine monophosphate Calponin homology (domain) Chinese hamster ovary (cell line) Casein kinase Central nervous system (Actin) capping protein Cyclic AMP response element Cyclic AMP response element binding protein Cowden’s syndrome 1,2-Diacylglycerol Diacylglycerol kinase Dibutyryl cyclic AMP
DD DMD DMSO EAE EC ECM EDC EFABP EGF EGFr eNOS Ep-ICAM ER ER ERK ES FC FN FGF FLG FSP1 GABA GAP GC GCAP GDNF GDP GFAP GRP GRPr GTP GTPase 4-HNE HO-1 HSP HUVEC ICAM ICE ICTP IF IFN IGF IL IP3 IP3R IP3R-P
Darier’s disease Duchenne muscular dystrophy Dimethyl sulphoxide Experimental allergic encephalomyelitis Endothelial cell Extracellular matrix Epidermal differentiation complex Epidermal-type fatty acid-binding protein Epidermal growth factor Epidermal growth factor receptor Endothelial nitric oxide synthase Epithelial intercellular adhesion molecule Endoplasmic reticulum Oestrogen receptor Extracellular signal-regulated receptor kinase (or MAPK) Embryonic stem (cells) Follistatin-like (domain) Fibronectin Fibroblast growth factor Profilaggrin Fibroblast-specific protein 1 (S100A4) Gamma-amino butyric acid GTPase-activating protein Guanylate cyclase Guanylate cyclase-activating protein Glial cell-derived growth factor Guanosine diphosphate Glial fibrillary acidic protein Gastrin-releasing peptide Gastrin-releasing peptide receptor Guanosine triphosphate Guanosine triphosphatase 4-Hydroxynonenal Heme oxygenase-1 Heat shock protein Human umbilical vein endothelial cell Intercellular adhesion molecule Interleukin-1β-converting enzyme Pyridinoline cross-linked telopeptide of type I procollagen Intermediate filaments Interferon Insulin-like growth factor Interleukin Inositol 1,4,5-trisphosphate Inositol 1,4,5-trisphosphate receptor Phosphorylated form of inositol 1,4,5-trisphosphate receptor
JAK LAK LGMD L-NAME LOH LPS MAP MAPK MB-40 MBP MBPK 5-MC MDBK MHC MHC MLC MLCK MMP MMTV MS MSH MTase NAD NCAM NCBP NDP NF2 NF-AT NFT NGF NMDA NOS NSCLC NT3 NMU OA OM ORF OSE OSE-bp OT PA PAI PARP PCNA PCR
Janus tyrosine kinase Lymphokine-activated killer (cells) Limb girdle muscular dystrophy NG-Nitro-l-arginine methyl ester Loss of heterozygosity Lipopolysaccharide Microtubule associated protein Mitogen-activated protein kinase (or ERK) Basement membrane-40 protein (SPARC, osteonectin) Myelin basic protein Myelin basic protein kinase 5-Methylcytosine Madin-Darby bovine kidney (cell line) Major histocompatibility complex Myosin heavy chain Myosin light chain Myosin light chain kinase Matrix metalloproteinases Murine mammary tumour virus Multiple sclerosis Melanocyte-stimulating hormone Methyltransferase Nicotinamide adenine dinucleotide Neural cell adhesion molecule Neural calcium binding protein Nucleoside diphosphate Neurofibromatosis type 2 Nuclear factor of activated T cells Neurofibrillary tangles Nerve growth factor N-Methyl-d-aspartate Nitric oxide synthase Non-small cell lung carcinoma Neurotropin-3 N-methyl-N-nitrosourea Osteoarthritis Oncomodulin Open reading frame Osteonectin silencer element Osteonectin silencer element-binding protein Oxytocin Plasminogen activator Plasminogen activator inhibitor Poly (ADP-ribose) polymerase Proliferating cell nuclear antigen Polymerase chain reaction
PDE PDGF PDI PEP1 PEST PGE PgR PH PHF PI3K PICP PIIINP PIP PIP2 PIP3 PIP4 PKA PKC PLA2 PLC PMA PMCA PMN PP-1A/PP-1B PS PSA PSA-NCAM PT PTTH PV RA RA rb RBP RCN RGS RP rptn RSV RT RTK RT-PCR RV RXR RyR SCCA
Phosphodiesterase Platelet-derived growth factor Protein disulphide isomerase Profilaggrin endopeptidase 1 Pro, Asp/Glu, Ser, Thr sequence (in proteins) Prostaglandin E Progesterone receptor Pleckstrin homology [domain] Paired helical filaments Phosphoinositide-3 kinase C-Terminal peptide of type I procollagen N-Terminal peptide of type III procollagen Phosphatidyl inositol-3 phosphate Phosphatidyl inositol 4,5-bisphosphate Phosphatidyl inositol 3,4,5-trisphosphate Phosphatidyl inositol 1,3,4,5-tetrakisphosphate Protein kinase A Protein kinase C Phospholipase A2 Phospholipase C Phorbol 12-myristate 13-acetate Plasma membrane Ca2+-ATPase Polymorphonuclear leukocyte Protein phosphatases 1A and 1B Presenilin (genes 1 and 2 in Alzheimer’s disease) Prostate-specific antigen Polysialylated NCAM Demyelinating paralytic tremor rabbit mutant Prothoracicotropic hormone Parvalbumin Retinoic acid Rheumatoid arthritis Retinoblastoma susceptibility (gene product) Retinol-binding protein Recoverin Regulator of G-protein signalling (proteins) Retinitis pigmentosa Repetin Rous sarcoma virus Reverse transcriptase Receptor tyrosine kinase Reverse transcriptase polymerase chain reaction Rubella virus Retinoid X receptor Ryanodine receptor Squamous cell lung carcinoma antigen
SCLC SDK SERCA SLE SMS SPARC SR STAT SVZ Tβ TCR TGF THH TIMP TK Tn TNF TPA tPA uPA VASP VCAM VD3 VDR VDRE VEGF VGCC VILIP VP WAS WASP
Small cell lung carcinoma Sphingosine-dependent kinase Sarcoplasmic–endoplasmic reticulum Ca2+-ATPase Systemic lupus erythematosus Smith–Magenis syndrome Secreted protein, acidic, rich in cysteine (osteonectin; BM-40) Sarcoplasmic reticulum Signal transducer and activator of transcription factors Subventricular zone Beta thymosins T-cell antigen receptor Transforming growth factor Trichohyalin Tissue inhibitor of metalloproteinase Thymidine kinase Troponin Tumour necrosis factor 12-O-Tetradecanoyl phorbol 13-acetate Tissue plasminogen activator Urokinase-type plasminogen activator Vasodilator-stimulated phosphoprotein Vascular cell adhesion molecule Vitamin D3 Vitamin D3 receptor Vitamin D response element Vascular endothelial growth factor Voltage-gated calcium channel Visinin-like protein Vasopressin Wiskott–Aldrich syndrome Wiskott–Aldrich syndrome protein
Author Dr. Gajanan Sherbet is a professor at the Institute for Molecular Medicine, Huntington Beach, CA. He received his D.Sc. and M.Sc. degrees from the University of London, and Ph.D., M.Sc., and B.Sc. degrees from the University of Poona. Dr. Sherbet was reader in Experimental Oncology and deputy director of the Cancer Research Unit in the Medical School of the University of Newcastle upon Tyne, England. Previous to this Dr. Sherbet was a staff member of the Chester Beatty Research Institute, Institute of Cancer Research, and University College Hospital Medical School in London. He has held prestigious fellowships such as the Beit Memorial and Williams Fellowship of the University of London. He held a career fellowship awarded by the North of England Cancer Research Campaign. For a brief period, he was a fellow of Harvard University, Cambridge, MA. Dr. Sherbet is a fellow of the Royal College of Pathologists (FRCPath), Royal Society of Chemistry (FRSC), and The Institute of Biology (FIBiol) of U.K. He served as editor of Oncology and Experimental Cell Biology and was senior editor of Pathobiology. Currently, he is a member of the editorial boards of Pathobiology and Anticancer Research. Dr. Sherbet’s major interest is in cancer metastasis. In recent years he has been investigating the role of the calcium binding protein S100A4 in cell proliferation, cancer invasion, and metastasis, focusing mainly on melanomas, neuroectodermal tumors, and breast cancer. He recently demonstrated the potential value of S100A4 as a marker for assessing the progression of breast cancer. He is also studying the potential of artificial neural networks in the management of breast cancer, especially the analysis of expression of cancer markers and image cytometric data of breast cancer by using artificial neural networks. Dr. Sherbet has published numerous scientific papers in international journals. He has written and edited several books on cancer. Notable among them are The Metastatic Spread of Cancer (Macmillan, 1987), The Biology of Tumour Malignancy (Academic Press, 1982), and The Biochemical and Biophysical Characterisation of the Cell Surface (Academic Press, 1978). His latest book, The Genetics of Cancer (Academic Press, 1997), was co-authored with Dr. M.S. Lakshmi. He was guest editor of Retinoids: Their Physiological Function and Therapeutic Potential (1997). Dr. Sherbet is co-editor of Artificial Neural Networks in Cancer Diagnosis, Prognosis, and Patient Management to be published soon by CRC Press LLC.
Contents Preface Abbreviations Chapter 1 Introduction................................................................................................................1 Chapter 2 The Calcium Signalling Pathway..............................................................................5 Homeostasis of Cell Calcium...........................................................................5 The Plasma Membrane Ca2+-ATPase Pump ........................................5 The Sarcoplasmic-Endoplasmic Reticulum Ca2+-ATPase Pump .....................................................................................................7 Voltage-Gated Calcium Channels.........................................................8 The Deregulation of Calcium Homeostasis as a Primary Event in Carcinogenesis .......................................................................9 Phospholipid Signalling..................................................................................10 PTEN Phosphatase in the Regulation of Lipid Signalling ............................11 The Protein Kinase C Pathway ......................................................................13 Protein Kinase C and Its Isoforms in Signal Transduction ...........................14 Inositol Phosphates in Calcium Signal Transduction ....................................16 Deregulation of Inositol 1,4,5-Trisphosphate Pathway and Its Consequences ............................................................................................18 Ryanodine and Related Receptors in Calcium Mobilisation.........................20 Cyclic AMP in Calcium Signalling ...............................................................21 Architectural Aspects of the Signal Transduction Machinery.......................25 The Role of Caveolae in Signal Transduction ...................................25 Caveolin Expression in Cancer ..........................................................28 Chapter 3 Calcium Binding Proteins and Their Natural Classification ..................................29 Chapter 4 Non-EF-Hand Calcium Binding Proteins ...............................................................35 Annexins .........................................................................................................35 Structure..............................................................................................35 Biologic Functions..............................................................................36 Annexins in Cancer Growth and Progression....................................38 Annexins in Morphogenesis and Differentiation ...............................39
The Gelsolin Family of Calcium Binding Proteins .......................................40 Gelsolin in Severing and Capping of Actin Filaments ......................40 Gelsolin in Embryonic Development and Morphogenesis ................41 Gelsolin Expression in Amyloidosis ..................................................42 Gelsolin in Cancer ..............................................................................42 Severin and Cytoskeletal Reorganisation...........................................44 Villin in Differentiation and Neoplasia..............................................44 Calreticulin and Its Functional Diversity .......................................................46 Structure and Molecular Features of Calreticulin..............................46 Regulation of Calreticulin Expression ...............................................46 Phosphorylation of Calreticulin..........................................................47 Intracellular Distribution of Calreticulin............................................48 Calreticulin in Intracellular Calcium Storage ....................................48 Calreticulin and Calnexin as Molecular Chaperones.........................49 Calreticulin in Cell Proliferation and Differentiation ........................50 Calreticulin in Cell Adhesion .............................................................50 Calreticulin in Neoplasia ....................................................................51 Immunological Implications of Calreticulin Function.......................52 Calsequestrin and Intracellular Calcium Storage...........................................53 Osteocalcin in Bone Metabolism and Osteotropism of Cancer ....................54 The Biology of Osteocalcin ...............................................................54 Calcium-Binding Properties of Osteocalcin.......................................55 Osteocalcin Gene Structure and Function..........................................55 Regulation of Osteocalcin by Vitamin D3 .........................................56 Osteocalcin in Cell Proliferation and Differentiation ........................57 Osteotropism of Metastatic Dissemination ........................................60 Chapter 5 The EF-Hand Calcium-Binding Proteins ................................................................63 Molecular Organisation of Calcium Binding EF-Hand Proteins ..................63 Calcium Binding and the Molecular Configuration of Calcium-Binding Proteins ...........................................................................................................65 The Structure and Organisation of S100 Family Genes................................68 Alternatively Spliced Variants of S100A4 .....................................................68 Functional Significance of Alternatively Spliced Isoforms ...........................69 Regulation of Expression of S100 Family Genes..........................................71 Transcriptional Regulation of S100 Genes ........................................71 Regulation of Gene Expression by DNA Methylation......................72 DNA Methylation in Cancer ..............................................................72 Regulation of S100 Gene Transcription by Methylation...................74 Chapter 6 The Calmodulin Family of Calcium Binding Proteins...........................................75 Calmodulin and Its Physiological Function...................................................75 Structure and Mode of Action of Calmodulin ...................................75
Calmodulin-Mediated Signal Transduction........................................76 Calmodulin and Cell Proliferation .....................................................77 Calmodulin in Neoplasia ....................................................................78 Recoverin Subfamily of Neural Calcium-Binding Proteins and Their Function ..........................................................................................................79 The G-Protein Signalling Pathway.....................................................79 Recoverin and Its Function ................................................................80 Mode of Action of Recoverin.............................................................82 Post-translational Modification of Recoverin ....................................82 Recoverin and Cancer-Associated Retinopathy .................................83 Recoverin and Cancer-Associated Retinopathy in Small Cell Lung Cancer ......................................................83 Retinopathy Associated with Other Forms of Human Cancer .....................................................................84 Is Recoverin Involved in Retinitis Pigmentosa? .................85 Guanylate Cyclase-Activating Proteins..........................................................85 Chapter 7 The Structure of Contractile Proteins .....................................................................87 The Actin Component of Contractile Machinery of the Cell........................87 Actin Isoforms ....................................................................................87 Regulation of Actin Dynamics ...........................................................88 Cofilin in the Regulation of Actin Dynamics ....................................88 Profilin in the Regulation of Actin Dynamics ...................................90 Rho GTPases in Actin Dynamics and Signal Transduction ..............90 Interaction of Formin with Profilin and Rho GTPases......................92 The Role of Thymosin Family Actin-Binding Proteins in Actin Dynamics ..............................................................................................93 Sequestration of Actin by Thymosins ................................................93 Effects of Thymosins on Cell Proliferation .......................................93 Thymosins and Cell Motility and Differentiation .............................94 Expression of Thymosins in Embryonic Development .....................94 Potential Role of Thymosins in Cancer Progression.........................95 The Fimbrin Family of Actin-Binding Proteins............................................. 96 Molecular Features of Fimbrin...........................................................96 Function of Fimbrin in Cytoskeletal Organisation ............................97 Regulation of Fimbrin Expression .....................................................99 Is Fimbrin Involved in Cancer?........................................................100 Modulation of Actin Dynamics and Cancer Cell Dissemination ...................................................................................101 α-Actinin.......................................................................................................102 Molecular Structure of α-Actinin ....................................................102 α-Actinin Isoforms ...........................................................................103 Function of α-Actinin.......................................................................104
Actinins in Cell Adhesion, Motility, and Signal Transduction........104 The Cadherin–Catenin Complex in Signal Transduction and Cell Adhesion ...................................................................................104 Myosin Filaments .........................................................................................110 Myosin Heavy Chain (MHC) Isoforms ...........................................111 Actomyosin Assembly......................................................................112 Myosin Light Chain (MLC) Phosphorylation and Function ...........115 Troponins and Tropomyosins in the Regulation of Muscle Cell Contraction....................................................................................................118 The Regulatory Role of Troponins and Tropomyosins in Muscle Contraction........................................................................................118 Tropomyosin Isoforms in Benign and Malignant Cells ..................119 The Regulatory Role of Caldesmon.................................................121 Calponin: Its Function and Regulation ............................................122 Caltropin-Mediated Reversal of Myosin-ATPase Inhibition by Caldesmon and Calponin..................................................................124 Chapter 8 Structure and Biology of Calbindin ......................................................................125 Calbindin in Neuronal Populations ..............................................................125 Neural Cell Lineage and the Regulation of Calbindin Expression .............125 Calbindin Expression in Embryonic Development and Ageing..................126 Physiological Function of Calbindin............................................................127 Neuroprotective Function of Calbindin........................................................129 Calbindin Expression and the Metastatic Phenotype ..................................129 Chapter 9 Calretinin: Its Role in Cell Differentiation and as a Potential Tumour Marker......................................................................................................131 Calretinin and Its Alternatively Spliced Isoforms........................................131 Regulation of Calretinin Expression ............................................................132 Calretinin Expression in Cell Proliferation and Differentiation..................133 Calretinin and Its Possible Neuroprotective Property..................................133 Calretinin as a Potential Tumour Marker.....................................................133 Chapter 10 Calcineurin in Cell Proliferation, Cell Adhesion, and Cell Spreading ................135 Molecular Features of Calcineurin...............................................................135 Calcineurin in Cell Proliferation and Adhesion-Related Phenomena .........136 Putative Role of Calcineurin in Cell Cycle Progression .................136 The Effects of Calcineurin on Cell Adhesion and Motility ............138 Calcineurin in Alzheimer’s Disease .............................................................140 Calcineurin in Immunosuppression..............................................................141
Chapter 11 Centrins (Caltractins) and Their Biological Functions .........................................145 Chapter 12 Reticulocalbin Family of EF-Hand Proteins.........................................................149 Molecular Features of Reticulocalbin Homologues ....................................150 Putative Functions of Reticulocalbin and Its Homologues .........................150 Chapter 13 Calpains in Normal and Aberrant Cell Physiology ..............................................153 The Calpain Family of Calcium-Binding Proteins ......................................153 Molecular Organisation of Calpains ............................................................154 Regulation of Physiological Events by Proteolytic Function......................155 Involvement of Calpains in Development and Differentiation....................157 Calpains in Cell Proliferation and Apoptosis ..............................................158 Calpains in Cell Spreading and Migration ..................................................160 Calpains in Integrin-Mediated Cell Adhesion and Signal Transduction..................................................................................................161 Calpains in Cancer Growth and Progression ...............................................162 Calpains in Myelodegenerative Diseases .....................................................163 Calpains in Muscular Dystrophy..................................................................165 Association of Calpains with Duchenne Muscular Dystrophy .......165 Calpains and Limb Girdle Muscular Dystrophy..............................166 Chapter 14 Caspases in Apoptosis, Cell Migration, Proliferation, and Neoplasia .................169 Caspases in Apoptotic Cell Death................................................................169 Poly (ADP-Ribose) Polymerase as a Marker of Apoptosis ........................172 Caspase-Mediated Apoptosis and Cell Growth Inhibition in Tumour Expansion........................................................................................173 Caspase-Mediated Proteolysis of Fodrin: Implications for Apoptosis, Cell Adhesion, Cell Migration, and Neoplastic Transformation .................176 Caspases and Neuronal Loss in Alzheimer’s Disease .................................177 Chapter 15 Parvalbumins in Neuronal Development, Differentiation, and Proliferation .......181 Chapter 16 Osteonectin in Cell Function and Behaviour........................................................183 Molecular Structure of Osteonectin .............................................................183 Functions and Functional Domains of Osteonectin.....................................184 Regulation of Osteonectin Expression .........................................................184 Osteonectin in the Remodelling of the Extracellular Matrix ......................186
Osteonectin in Embryonic Development and Differentiation .....................187 Modulation of Cellular Adhesion, Cell Shape, and Motility by Osteonectin ..............................................................................................188 Modulation of Cell Proliferation by Osteonectin ........................................190 Effects of Osteonectin on Angiogenesis ......................................................191 Osteonectin Expression in Cancer Development and Progression..............193 Osteonectin Involvement in Other Disease States .......................................196 Osteonectin Homologues and Their Putative Tumour Suppressor Properties ......................................................................................................197 Chapter 17 S100 Proteins: Their Biological Function and Role in Pathogenesis ..................199 S100 Proteins in Cell Differentiation, Motility, and Cancer Invasion ........202 Profilaggrin (FLG) in Keratinocyte Differentiation.........................202 The Molecular Characteristics of Profilaggrin..................202 Trichohyalin (THH)..........................................................................205 Effects of S100 Proteins on Cell Deformability and Cellular Morphology ..................................................................................................205 Cell Adhesion and Invasive Potential of Cancer Cells ....................210 S100 Proteins in Remodelling of the Extracellular Matrix.............213 S100 Proteins in Cell Proliferation ..................................................214 Cell Cycle-Related Expression of S100 Proteins ............................217 Postulated Mechanism of Cell Cycle Control by S100A4..............219 S100A Isoforms............................................................................................222 S100A2 as a Putative Tumour Suppressor...................................................223 S100A3 Expression in Cell Differentiation and Neoplasia.........................224 Molecular Features of S100A3 ........................................................224 S100A3 Expression in Cell Differentiation and Human Gliomas .............................................................................................225 S100A4 in Cancer Development and Progression.......................................225 S100A4 Expression and Metastatic Potential of Cancers ...............225 Clinical Potential of S100A4 as a Marker for Cancer Prognosis...........................................................................................230 S100A4 in Human Breast Cancer ....................................................230 S100A4 in Other Forms of Human Cancer .....................................234 S100A6 (Calcyclin) in Cancer .....................................................................235 The Biological Properties of S100A7 (Psoriasin) .......................................236 Structure and Molecular Properties of S100A7...........................................236 S100A7 in Skin Pathology ...............................................................237 S100A7 in Neoplastic Disease .........................................................238 S100A8 and S100A9 Proteins in Inflammatory Diseases ...........................239 S100A11 (S100C) and Possible Modes of its Function..............................239 S100P in Cancer Progression .......................................................................241 S100P and Its Putative Functions.....................................................241
Potential Value of S100 Proteins as Markers of Cancer Progression and Prognosis.......................................................................................................243 Epilogue ................................................................................................................245 References .............................................................................................................249 Index......................................................................................................................349
1
Introduction
Calcium-binding proteins (CBPs) are a family of unique importance in normal and aberrant cell biology, by virtue of their participation in a wide spectrum of physiological processes. These proteins appear to function from the inception of life, participating in sperm maturation and motility and implantation of the fertilised ovum, to cell differentiation and morphogenesis. Among other important physiological functions of CBPs are their involvement in Ca2+ transport and the maintenance of intracellular Ca2+ levels, as well as metabolic processes such as nucleotide metabolism. Signal transduction is another area of cellular physiology in which CBPs are heavily involved. Defective signal transduction is often associated with aberrant cell cycle regulation, which in turn can lead to the development and progression of cancer. Besides, several CBPs, especially those belonging to the S100 protein family, have recently been demonstrated to be actively engaged in the regulation of the cell cycle in normal as well as in aberrant cell proliferation and in apoptotic cell death. It follows, therefore, that CBPs may be associated with the pathogenesis of several diseases, including neoplastic disease. Directly relevant in the context of carcinogenesis is the accumulation of a substantial body of evidence demonstrating that CBPs participate in the formation and emergence of neoplastic foci of cells and in the invasive and metastatic spread of these cells constituting the progressive phase of the disease. A major pathway by which CBPs affect neoplastic progression is by altering cell proliferation via the modulation of the process of transduction of proliferative signals imparted by extracellular growth factors and hormones, and thus the regulation of the cell cycle traverse and apoptotic cell death. Influencing cell adhesion and motility by modulating the function of enzymes implicated in the remodelling of the extracellular matrix, leading to metastatic dissemination of cancer cells, are also important features of CBP function in cancer. CBPs are associated with other pathological conditions of the central nervous system (CNS) and skin, such as amyloidosis, Alzheimer’s disease, and Smith–Magenis syndrome (SMS), among others. The purview of the present volume is to review, analyse, and assimilate these apparently diverse functions of CBPs into a coherent picture. The conceptual basis of this book, summarised in Figure 1, is to recognise, redefine, and establish CBPs as second messengers themselves. Intracellular calcium levels modulate in response to extracellular signals and calcium transport across the cell membrane. CBPs play a crucial role in calcium homeostasis, by calcium buffering, calcium transport, and release of calcium from intracellular stores. They carry the information downstream to activate the phosphorylation of target proteins, which leads to enzyme function and metabolism, muscle contraction, and a host of other physiological functions. They also influence cytoskeletal dynamics, actively participate in the remodelling of the extracellular matrix, and consequentially affect cell morphology, motility, and intercellular interactions. A recent development is the 1
2
Calcium Signalling in Cancer
FIGURE 1 Summary of the conceptual basis of this book, providing an outline of the postulate that forms the core of this work: calcium binding proteins (CBPs) are second messengers participating in the calcium signalling cascade. CBPs not only regulate intracellular calcium levels, but they also are involved in the regulation of normal cell physiology, as well as cell behaviour, proliferation, apoptosis, tumorigenesis, and the secondary spread of cancer.
demonstration that certain CBPs may actively control the progression of the cell cycle in consort with other proteins such as p53 and stathmin. Apoptosis or programmed cell death is a calcium-dependent phenomenon, and CBPs can activate several pathways of molecular degradation leading to apoptosis. In light of these multifarious functions, the thesis developed here is that CBPs are an integral component of the mechanisms of cell population homeostasis and tumour growth. Genetic activation is the coup de grace of signal transduction. The inappropriate expression, temporally and spatially, of some CBPs induces invasive behaviour and
Introduction
3
secondary spread of immortalised cells. These genetic and phenotypic changes induced by CBPs are integrated here to provide a postulate for the growth and progression of cancers. The formulation of this postulate underpins the evolution and development of new strategies for controlling the growth of the tumour and its metastatic spread.
2
The Calcium Signalling Pathway
HOMEOSTASIS OF CELL CALCIUM Ion channels are involved in a large number of cell functions and in the induction of cellular responses to extracellular stimuli. There are three types of voltagesensitive ion channels: the sodium channel, the potassium channel, and the calcium channel. These function in a coordinated fashion in determining cellular responses to extraneous signals. The Na+ channel is involved in the generation of action potentials and the K+ channel is involved in the regulation of membrane potential and is significantly involved in synaptic plasticity. The regulation of intracellular levels of calcium is an important element in the signalling process mediated by calcium as a second messenger. There are several mechanisms by which calcium levels in the cell are exquisitely controlled and calcium homeostasis is achieved. These are listed together with their characteristic features and properties in Table 1. The Ca2+-ATPase pumps in the plasma membrane and the sarcoplasmic–endoplasmic reticulum play a highly significant part in the regulation of calcium homeostasis. Calcium homeostasis also involves the ligandgated and voltage-gated channels. Calcium-binding proteins are of special interest in the present context because of their ability to regulate intracellular calcium levels.
THE PLASMA MEMBRANE CA2+-ATPASE PUMP The plasma membrane Ca2+-ATPase extrusion pump (PMCA) and the sarcoplasmic–endoplasmic reticulum Ca2+-ATPase pump (SERCA) are specifically targeted to the two membrane systems of the cell. The N-terminal region of the SERCA molecule contains a domain that has an endoplasmic reticulum (ER)-retention signal sequence. Certain mutations of the PMCA can cause it to become localised to the ER (Guerini et al. 1998). There are four genes which code for four isoforms. These isoforms show differential localisation in different organs and the subcellular compartment. PMCA-1 and PMCA-2 are expressed ubiquitously, but PMCA-3 and PMCA-4 occur specifically in neural cells (Carafoli et al. 1996). The expression of PMCA genes seems to be developmentally regulated. Thus, in mouse development, PMCA genes show an overlapping, but, nonetheless, a distinctive pattern of expression (Zacharias and Kapper, 1999). Furthermore, PMCA and SERCA genes are co-ordinately regulated. The differentiative effects of nerve growth factor (NGF) on PC12 cells are an example of this. NGF not only up-regulates PMCA but also down-regulates SERCA expression (Keller and Grover, 2000).
5
6
Calcium Signalling in Cancer
TABLE 1 Mechanisms of Homeostasis of Cell Calcium Mode of Homeostasis Calcium Pumps Na+/Ca2+ exchanger PMCA Ca2+-ATPase pump SERCA Ca2+-ATPase pump Ligand-gated calcium channels Voltage-gated calcium channels (VGCCs) Subtypes: T L N P/Q R Calcium binding proteins
Characteristics
Plasma membrane–associated low affinity mechanism; pumps out large quantities of Ca2+ Plasma membrane calcium-ATPase pump involved in calcium extrusion High affinity ER-located mechanism; leads to luminal accumulation of Ca2+ and reduces cytosolic levels Initiation of calcium influx upon binding of ligands to respective receptors; direct influx of Ca2+ or mediated by IP3 Ca2+ influx/release from intracellular stores
Transient currents in response to membrane depolarisation Prolonged currents in response to depolarisation Inactivate in response to moderate, not severe depolarisation; not sensitive to intracellular cations Nerve terminals; initiation of neurotransmitter release Regulation of VGCC, PMCA and SERCA (e.g., by CaM); NMDA receptor channel by CaM and references cited in the text
Note: CaM, calmodulin; ER, endoplasmic reticulum; IP3, inositol 1,4,5-triphosphate; NMDA, N-methyl-D-aspartate; PMCA, plasma membrane Ca2+-ATPase; SERCA, sarcoplasmic–endoplasmic reticulum Ca2+-ATPase. Source: Collated from Tsien et al. (1988), Tsunoda (1993), Campbell et al. (1988), Marin et al. (1998); Pascale and Etcheberrigaray (1999); Tsien et al. (1991); Dunlap et al. (1995); Ehlers et al. (1996), and references cited in the text.
Membrane depolarisation can also differentially regulate PMCA and SERCA expression (Guerini et al. 1999). Kuo et al. (1997) had previously reported that their expression might indeed be interdependent. The N-terminal region of PMCA molecule is highly variable and is essential for enzymatic activity. There seems to be an absolute requirement of a specific amino acid sequence for its function (Talgham and Adamo, 1999). The transcription of the PMCA isoforms is controlled by calcium itself. Calciumbinding proteins are intricately connected with this process. In developing neurones calcineurin seems to regulate PMCA expression (Carafoli et al. 1999). Besides, PMCA isoforms show a marked differential sensitivity to calcium, calmodulin (CaM), ATP, and kinases. The calcium pump activity appears to be regulated by phosphorylation, and phosphorylation might be the means by which different
The Calcium Signalling Pathway
7
isoforms become functional in a temporal dimension (Monteith et al. 1998). PMCA is activated by Ca2+/CaM, and the isoforms also show marked differences in their sensitivity to Ca2+/CaM (Elwess et al. 1997, 1998). Human PMCA-4a is phosphorylated at a serine residue that occurs within the CAM-binding domain (Verma et al. 1999; Carafoli, 1997; Carafoli et al. 1996). Phosphorylation appears to prevent CaM binding and lead to the inactivation of the pump (Enyedi et al. 1997; Penniston and Enyedi, 1998).
THE SARCOPLASMIC–ENDOPLASMIC RETICULUM CA2+-ATPASE PUMP SERCA is one of the modes that controls the homeostasis of intracellular calcium. SERCA2 transports Ca2+ into the lumen of the reticulum by an ATP-dependent mechanism. By virtue of this ability, SERCA2 plays an important part in normal physiological function such as the contraction and relaxation cycle of cardiac muscle, as well as in the pathogenesis of certain diseases. In addition, the correct localisation of the SERCA protein in the ER is of the utmost importance. As stated above, the localisation signal occurs in a stretch of 28 amino acids at the N-terminus of the molecule (Guerini et al. 1998). Ankyrin, a cytoskeletal protein, also seems to be involved in the targeting of SERCA. This is indicated by its abnormal localisation in ankyrin –/– mice. In these mutant mice, the absence of ankyrin also affects the localisation of ryanodine and inositol, 1, 4, 5-trisphophate (IP3) receptors (IP3R), both involved in calcium mobilisation (Tuvia et al. 1999). The ATP2A2 gene encodes the sarcoplasmic–endoplasm reticulum ATPase isoform type 2. Periasamy et al. (1999) have demonstrated the loss of calcium sequestering activity and consequent impairment of cardiac function in heterozygous ATP2A2 gene mutants. Mutations of the ATP2A2 gene have been associated with the pathogenesis of Darier’s disease (DD) (keratosis follicularis) (Sakuntabhai et al. 1999a, 1999b). DD is an autosomal dominantly inherited skin disorder. It is characterised by the presence of keratotic papules, and in histology is distinguished by acantholytic dyskeratosis. The keratotic papules occur mainly in the upper trunk, scalp, and palmar pits. Nail dystrophy is also a prominent feature of DD (Soroush and Gurevitch, 1997). Because ATP2A2 controls calcium homeostasis in the cell, it is conceivable that its deregulation by mutation of the ATP2A2 gene might represent an early event in carcinogenesis. It was demonstrated many years ago that thapsigargin, an inhibitor of SERCA2, not only alters intracellular calcium levels, but also functions as a tumour promoter (Hakii, 1986; Thastrup et al. 1990). With the demonstration that ATP2A2 mutations are associated with the genesis of DD, there have also been several attempts to investigate the incidence of neoplasia in association with DD. Soroush and Gurevitch (1997) have pointed out that basal cell carcinomas and other skin neoplasms occur in patients with DD. Downs et al. (1997) described the occurrence of a subungual squamous cell carcinoma in a DD patient. However, in this case the human papilloma virus might have been the aetiological agent. In general, neoplasia may be associated only infrequently with DD. There is an obvious common feature between DD and neoplasia that deserves a mention. This concerns the abnormal expression of the calcium-binding transmembrane glycoprotein cadherin. Some isoforms of cadherin have been regarded as
8
Calcium Signalling in Cancer
invasion suppressors, because there is a significant body of evidence that associates the acquisition of invasive ability by tumour cells with the loss of cadherins. E-type cadherin is found in the cell membrane of epidermal cells. E-cadherin is distributed in the plasma membrane of keratinocytes, in the intercellular space between desmosomes. Interestingly, this cadherin is expressed at greatly reduced levels in the acatholytic cells of DD and Hailey–Hailey disease (benign pemphigus) (Furukawa et al. 1997). Desmosomes provide the adhesion machinery in most epithelia, and abnormalities associated with them may be a key feature of inherited diseases such as DD and Hailey–Hailey disease. Indeed, the loss of cadherin may be the determining factor that causes the characteristic loss of adhesion between epidermal cells encountered in DD. Furukawa et al. (1997) also point out that both E- and Pcadherins are absent in squamous carcinomas, malignant melanomas and in Paget’s disease. But basal cell carcinomas, which are noninvasive, do not show a loss of cadherin. The above discussion underscores the importance of the SERCA2 calcium pump and intracellular calcium homeostasis in the calcium-signalling events associated with cell differentiation and dedifferentiation, and in the pathogenesis of DD and neoplasia.
VOLTAGE–GATED CALCIUM CHANNELS The Voltage-gated calcium channels (VGCCs) are located in the plasma membrane. The high voltage-activated channel subtypes L,N, P, Q, and R occur as heterodimers of four subunits. The largest of the subunits is the α1 subunit, which spans the plasma membrane and the auxiliary subunits, β, γ, and α2δ (Isom et al. 1994). The properties of the calcium channel appear to be determined by the differential expression of α1, which is the pore-forming subunit. The β subunit seems to regulate channel properties and the targeting of α1. The β subunit, of which four isoforms (β1–4) have been identified, is said to interact with α1. This interaction is mediated by certain highly conserved domains (Pragnall et al. 1994; De Waard et al. 1994). The interaction between these subunits appears to regulate channel activity and the diversity of calcium currents (Varadi et al. 1991; Isom et al. 1994; Olcese et al. 1994). The β subunits are believed to modulate the kinetics of channel activation and inactivation by means of phosphorylation. Calcium-binding proteins feature prominently in calcium homeostasis as important regulators of calcium channel activity. The elevation of intracellular levels of calcium can provide a negative feedback and close the channel. On the other hand, the feedback can have a positive element or facilitation, which opens the calcium channel. Zuhlke et al. (1999) have shown that CaM functions as a sensor for both negative and positive regulation of L-type channel activity. CaM appears to do this by binding to the consensus sequence called the IQ motif that occurs in the Cterminal α1C subunit of the channel protein. They substituted the isoleucine residue with alanine and reduced Ca2+-dependent inactivation and enhanced facilitation of the channel. Both inactivation and facilitation were abrogated when the isoleucine residue was converted to glutamate. CaM binds to the IQ motifs of other channel subtypes N, P/Q, and R as well (Peterson et al. 1999). Indeed, calcium-mediated
The Calcium Signalling Pathway
9
modulation of P/Q channel subtypes also seems to involve CaM function. Again the channel activity is regulated CaM binding to the IQ motif of the α1A channel subunit (A. Lee et al. 1999).
THE DEREGULATION OF CALCIUM HOMEOSTASIS AS A PRIMARY EVENT IN CARCINOGENESIS The operation of ligand-gated calcium channels and the role that calcium binding proteins play in calcium homeostasis and as messengers of the calcium signal provide the major focus for this work. There is much justification for the view held by many investigators that the deregulation of calcium homeostasis in the cell might be a primary event in cell transformation and carcinogenesis. Indeed, several agents that block or retard the influx of calcium into cells appear to be able to inhibit the invasive ability of cancer cells, alter their adhesion properties, and inhibit tumour growth and stabilise the disease. Carboxyamido-triazole (CAI) is one such compound. CAI has been reported to be able to inhibit the invasive behaviour of breast carcinoma cell lines in vitro. The matrix metalloproteinases associated with these cells also appear to be inhibited in parallel (Lambert et al. 1997). Not surprising, therefore, is the finding that CAI inhibits the adhesion of glioma cells to collagen type IV coated substrata and also inhibits their invasion in vitro. CAI also appears to be capable of inhibiting cell proliferation (Jacobs et al. 1997). The antiproliferation and anti-invasion properties of CAI have also been described by Wasilenko et al. (1996) using human prostate cancer cell lines. These are clear indications of the variety of downstream pathways activated by calcium influx that are inhibited by CAI. Finally, CAI has been reported to stabilise the disease in patients with a variety of refractory solid tumours (Kohn et al. 1996). Verapamil, a selective L-type calcium channel blocker, also has demonstrable anti-proliferative and anti-invasive properties. These were recognised some years ago. Thus verapamil inhibits tumour growth in vitro (Brocchieri et al. 1996) and seems to arrest cells in the G0G1 phase of the cell cycle (Zeitler et al. 1997). The antiproliferative activity has been confirmed by Hoffman et al. (1998) on retinal pigment cells. Verapamil is able to inhibit the migration of CD4+ and CD8+ T lymphocytes across the endothelium (Blaheta et al. 2000). Other calcium antagonists such as mibefradil can also inhibit the adhesion and diapedesis of lymphocytes across the endothelium (Blaheta et al. 1998). Earlier Hailer et al. (1994) had noticed that the expression of endothelial adhesion molecules was unaltered by verapamil. It may be too simplistic to interpret these findings merely in terms of blocking of calcium channels. Nonetheless, some of these publications also indicate that the Factin levels of the lymphocytes are reduced by the treatment. This could be due to changes in cytoskeletal dynamics that occur after verapamil-mediated modulation of intracellular calcium levels. This in turn could alter cellular motility. Other factors will have serious effects on the permeability of the endothelium. For instance, CD4+ lymphocytes form two subsets known as Th1 and Th2 cells. Upon activation both subsets produce a wide range of cytokines. Th1 cells secrete interleukin (IL)-2 and (IFN)-γ, and Th2 cells secrete IL-4, 5, 10, and 13. Some of these lymphokines are
10
Calcium Signalling in Cancer
bound to affect endothelial permeability. An additional factor that must be reckoned with is the generation of nitric oxide, which is known to inhibit the adhesion and spreading of endothelial cells. Nitric oxide also affects the formation of stress fibres in the cells, which is bound to influence cellular motility. Nitric oxide also actively influences angiogenesis. IFN-γ is a powerful inducer of nitric oxide synthase (NOS), whereas IL-4 from Th2 cells inhibits NOS. It would be well to remember here that endothelial NOS is a Ca2+/CaM-inducible enzyme. It is activated when it is binds the Ca2+/CaM complex. More recently, the effects of verapamil have been tested on the local invasion and metastasis of a murine carcinoma cell line in BALB/C mice. Farias et al. (1998) found that it inhibited local invasion and also produced a 50% reduction in both spontaneous and experimental metastasis. In common with CAI, the cytostatic and anti-invasive effects may be due to the inhibition of membrane-associated proteinases such as matrix metalloproteinases and urokinase-type plasminogen activator (Farias et al. 1998). These events are virtually terminal events in the process of inhibition of adhesion and invasiveness by verapamil. More upstream in the pathway, verapamil has been shown to down-regulate the expression of S100A4 (Parker and Sherbet, 1992), which, as discussed elsewhere in this book, is closely allied with p53 and stathmin genes in the control of cell cycle progression. Furthermore, S100A4 expression is closely linked with the remodelling of the extracellular matrix.
PHOSPHOLIPID SIGNALLING A host of regulatory molecules alter cell behaviour and physiological events. Thus extracellular signals imparted to the cells regulate their growth, proliferation, and apoptosis. They also regulate intercellular adhesion and cell adhesion to substrata, and consequently cell migration and invasive behaviour. A family of second messengers, the inositol phospholipids, transduces the regulatory signals across the membrane. Phospholipids (phosphatides) are a major structural component of the cell membrane and also subserve important functions of transducing the extracellular signals. The second messengers phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and IP3 are generated from these phospholipids by the action of phospholipases A and C (PLC), which are activated by the extracellular signals, and kinases. An intermediary in this process is the phosphatidylinositol (PI) transfer protein, which presents the PI metabolites to lipid kinases. The phosphorylation of the inositol ring at the 3-position gives rise to phosphoinositides PIP (phosphatidylinositol), PIP2, and PIP3. From here the transduction of the signal occurs by the interaction of these second messengers with target proteins that possess specific phosphoinositide-binding domains, such as an FYVE domain or pleckstrin homology (PH) domain. PIP2 and PIP3 show specific binding to PH domains (see Leevers et al. 1999). The second pathway is the generation of IP3 from PIP2 by PLC. As discussed below, IP3 then mediates the mobilisation of calcium from intracellular stores. The depletion of the intracellular stores triggers the so-called capacitative entry of calcium into the cell. Naturally, a deregulation of these pathways will have serious consequences in terms of differentiation, intercellular relationships, adhesion, and
The Calcium Signalling Pathway
11
cellular morphology. Such profound changes might indeed lead to the development of cancers, their invasion, and the formation of metastases.
PTEN PHOSPHATASE IN THE REGULATION OF LIPID SIGNALLING Phosphoinositide-3 kinase (PI3K) is responsible for the phosphorylation and generation of PIP2 and PIP3. This phosphorylation is antagonised by a phosphatase that is encoded by the gene called PTEN/MMAC1/TEP1 located on chromosome 10q23. The phosphatase, referred to here as PTEN, shows sequence homology to tensin (Steck et al. 1997). The phosphatase activity is essential for the normal functioning of PTEN (Tamura et al. 1999b). PTEN regulates the levels of the phosphoinositol phosphates by dephosphorylation of the phosphate group at the 3-position of the inositol ring (Maehama and Dixon, 1998). This seems to inhibit cell proliferation and migration (Furnari et al. 1997; J. Li et al. 1998; Ramaswamy et al. 1999; Tamura et al. 1999c; Podsypanina et al. 1999). Ramaswamy et al. (1999) transfected cells that lack PTEN with wild-type PTEN cDNA and found that cells were arrested in the G1 phase of the cell cycle. Similar transfection studies have been carried out on the glioma cell line U373, which lacks the PTEN gene. In these cells, wild-type PTEN inhibits growth and reduces saturation density of U373 cultures. However, PTEN mutants lacking phosphatase activity have the opposite effect and they indeed enhance cell growth in soft agar (Morimoto et al. 1999), which merely confirms the potential suppressor function of PTEN. PTEN also seems to be able to regulate the apoptotic pathway. PIP3 is known to activate the akt serine/threonine kinase, which has anti-apoptotic properties. It has been shown to inhibit akt kinase activity (Maehama and Dixon, 1999; Ramaswamy et al. 1999), which could push cells into the apoptotic pathway. For instance, extraneous PTEN induces apoptosis of breast cancer cells, which correlates with the down-regulation of akt. Furthermore, akt can rescue cells from PTENinduced apoptosis (J. Li et al. 1998). PTEN also increases the expression of p27kip1 cyclin-dependent kinase (cdk) inhibitor (Y.L. Lu et al. 1999). The cdk inhibitors, kip1 and kip2, inhibit the phosphorylation of rb protein and this prevents the entry of the cells into S-phase. This is consistent with the recent finding of Paramio et al. (1999) that PTEN cannot produce growth arrest in rb-deficient cells, but it induces growth arrest when functional rb is reintroduced. This could provide an alternative mechanism by which PTEN induces cell arrest in the G1 phase. The overall effects of growth arrest could be a combination of G1 arrest and apoptosis (Weng et al. 1999), but Paramio et al. (1999) believe that apoptosis might not contribute to this. It appears that PTEN might regulate cell adhesion and alterations in cell shape and motility by influencing the downstream of the integrin-mediated signalling pathway (Tamura et al. 1999c). Tamura et al. (1999a) have reported that PTEN also may interact with focal adhesion kinase and regulate its phosphorylation and focal adhesions. A further suggestion is that PTEN function might take the nitrogenactivated protein kinase (MAPK) pathway in the regulation of motility (Gu et al. 1999). It ought to be recognised, nonetheless, that these pathways may not be
12
Calcium Signalling in Cancer
mutually exclusive in facilitating the flow of information, and one or more pathways may be involved in the process. Consistent with this, Morimoto et al. (2000) have shown that PTEN not only affects PLC-mediated signalling, but also inhibits the kinases that regulate integrin function as well as the anti-apoptosis kinase akt. PTEN is required at certain stages of embryonic development. Its loss appears to be lethal in early embryogenesis and to lead to abnormalities of the skin, the gastrointestinal tract, and the pancreas. PTEN –/– cells have shown marked changes in their ability to differentiate into cell types characteristic of the three germ layers (i.e., the ectoderm, the endoderm, and the mesoderm) (Di Cristofano et al. 1998). Presumably, inactivation of the gene affects the state of “competence” of the cells to respond to differentiation-inducing stimuli (see Sherbet, 1982). Thus the abnormalities in the various organs seem to have an early developmental history. The PTEN gene is mutated, or there is a consistent loss of heterozygosity (LOH) at this gene locus, in many forms of human cancer. The mutations tend to occur mainly in the phosphatase domain (Steck et al. 1997; J. Li et al. 1997; W.G. Liu et al. 1997; Guldberg et al. 1997; Cairns et al. 1997; Tashiro et al. 1997; Tang et al. 1997; Kong et al. 1997; Okami et al. 1998; Ali et al. 1999). The seemingly consistent association of inactivating mutations and LOH of PTEN with cancers suggests the possibility that the lipid-signalling pathway could be seriously deregulated in the pathogenesis of neoplasia, and the PTEN gene has been suggested as a putative tumour suppressor gene. This is suggested unambiguously by the ability of PTEN to inhibit rasmediated cell transformation, with a concomitant dephosphorylation of PIP-1,3,4,5tetrakisphosphate (Tolkacheva and Chan, 2000). Germline mutations of PTEN also occur with the pathogenesis of Cowden’s syndrome (CS) and the Bannayan-Zonana syndrome (Liaw et al. 1997; Nelen et al. 1997; Tsou et al. 1998; Marsh et al. 1998a, 1988b). CS is an autosomal dominant inherited syndrome. Several benign and malignant neoplastic conditions are associated with this syndrome. Women with CS are believed to be more prone to develop breast cancer, and most of them have been found to develop benign fibrocystic disease. The CS mutations tend to be in exon 5, which contains the phosphatase core motif (Marsh et al. 1998b; Nelen et al. 1997). Although PTEN germline mutations are frequent in the Bannayan–Zonana syndrome, none of them have been found in exon 5 (Marsh et al. 1998a). An overview of the pattern of mutations suggests that those occurring in tumours could differ in nature from germline mutations (see Ali et al. 1999). Perhaps it is premature to speculate whether the generation of these mutations in different tumours is related to their pathogenesis. On the other hand, Guldberg et al. (1997) have found the same missense mutation in both primary and metastatic melanomas. Although further confirmation of this is essential, this has a considerable implication for metastatic dissemination. Nonetheless, while considering the potential tumour suppressor function of PTEN, it should be borne in mind that in PTEN abnormalities do not occur as a generalised event of tumour development. Yeh et al. (2000) examined human hepatocellular carcinomas for aberrant expression of PTEN, but encountered none. Neither did they find any abnormalities associated with the gene itself. Furthermore, the PTEN gene does not seem to be involved in the pathogenesis of acute myeloid leukaemia (T.C. Liu et al. 2000). Therefore, it might be prudent to reserve judgment regarding this issue. On
The Calcium Signalling Pathway
13
the other hand, PTEN overexpression might be a safeguard against progression. In laryngeal papillomas, for example, PTEN is overexpressed and the anti-apoptotic akt kinase is inhibited (P. Zhang and Steinberg, 2000). This should have an overall controlling effect on cell population size, and as a consequence upon progression, because more often than not, tumour progression is related to the rate of tumour expansion.
THE PROTEIN KINASE C PATHWAY Growth factors and hormones are known to increase the intracellular Ca2+ (Ca [i]), either by releasing Ca2+ from intracellular stores or by promoting Ca2+ influx. Ca2+[i] controls several biological functions, mainly by mediating the phosphorylation of cellular effector proteins. Calcium-binding proteins transduce the calcium signals to specific subcellular compartments. The generation of second messengers such as IP3, 1,2-diacylglycerol (DAG), and cyclic 3′,4′-adenosine monophosphate (cAMP) is a major mechanism of activation of the Ca2+ signalling pathway. IP3 and DAG are formed through the agency of an inositide specific phospholipase, which is stimulated by biological response modifiers. This PLC hydrolyses PIP2 into DAG and IP3. IP3 activates the release of Ca2+ from intracellular stores. The activation of appropriate protein kinases is a downstream event, which occurs in the transduction pathway. The major kinases involved are protein kinase C (PKC), the calcium/calmodulin-dependent protein kinases (CAMPKs) and protein kinase A (PKA). The CAMPKs can in turn activate the cAMP-mediated pathway by activating adenylyl cyclase, resulting in an increase in cAMP levels (Figure 2). 2+
Ca
2+
L
L
L
R
R G
R G
PL C
AC cAMP
IP3
PIP 2
2+
DAG
Ca [i]
PK C
CAMP K
PK A
FIGURE 2 The activation of signal transduction pathways upon binding of a ligand (L) to its appropriate receptor (R). AC, adenylyl cyclase; cAMP, cyclic 3′,4′-adenosine monophosphate; CAMPK, calcium/calmodulin-dependent protein kinase; DAG, 1,2-diacyglycerol; G, G-protein; IP3, inositol 1,4,5-trisphosphate; PIP2, phosphatidyl 4,5-bis phosphate; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C.
14
Calcium Signalling in Cancer
Calcium ions and DAG successively activate PKC and induce its translocation to the plasma membrane or the nucleus. Both intracellular calcium and DAG binding to PKC maintain it in a sustained activated state (Oancea and Meyer, 1998). DAG itself is regulated by phosphorylation by DAG kinase (DAGK). DAG phosphorylation seems to reduce PKC activity (Sakane and Kanoh, 1997) (summarised in Figure 3). It may be noted that as many as eight isoforms of DAGK have been identified. These have the characteristic zinc finger structures and PH domains. PH domains are found in many proteins and consist of approximately 120 amino acid residues. They are electrostatically polarised and show binding to G-protein subunits, PKCs, and phospholipids, thus linking PH domains as a characteristic feature of signal transduction proteins. The presence of these domains in DAGK isoforms suggests that these kinases are a component of the signal transduction network. Besides, DAGK-α, -β, and -γ also possess two consecutive EF-hand calcium-binding domains (Sakane et al. 1990; Yamada et al. 1997; Sakane and Kanoh, 1997). Therefore, DAGK isoforms show calcium-dependent activity. This effect is variable, which has been attributed to differences in calcium affinities of and the conformational changes occurring in the EF-hand domains as a response to calcium binding (Yamada et al. 1997). Upon activation, DAG kinases also translocate to the nucleus and remain tightly associated with nuclear matrix (Wada et al. 1996). Some DAGK isoforms, such as DAGK -δ, -ε, -ζ, have no EF-hand domains (Sakane et al. 1996; W. Tang et al. 1996; Bunting et al. 1996). So calcium-mediated activation is not a universal phenomenon in the activation of these kinases.
PROTEIN KINASE C AND ITS ISOFORMS IN SIGNAL TRANSDUCTION DAG, upon being activated by the calcium binding protein DAGK, now activates PKC by enhancing its affinity for Ca2+ and altering its enzymatic activity. This leads to the phosphorylation of substrate proteins, thus effectively transducing the calcium signal into a physiological response. Some CBPs may inhibit PKC-mediated phosphorylation of protein substrates. In other words, CBPs can actively regulate PKC function (see Sherbet, 1987; Sherbet and Lakshmi, 1997a, 1997b, for review). They may also be directly associated with the coupling of calcium signalling with gene regulation. This role is discussed in detail elsewhere in this book. Several isoforms of PKC have been identified and it is believed that they may subserve specific functions in signal transduction. It is well known that PKCs are translocated from cytoplasmic to nuclear location when cells are stimulated by growth factors. In Swiss 3T3 cells, although a number of isoforms are detectable in the cytoplasm, only PKCα is found in nuclei isolated from cells that have been exposed to growth factors (Neri et al. 1994). In HL-60 cells that were induced by all-trans-retinoic acid to differentiate, the translocation of PKCα and ζ to the nucleus has been observed (Zauli et al. 1996). This differential translocation has been attributed to possible linkage with the nuclear inositol lipid cycle (Neri et al. 1994). Further support for this view comes from the observation by Mizukami et al. (1997) concerning the
The Calcium Signalling Pathway
15
Ligand binding
Receptor
Calcium spikes
DAG activation
DAG kinase
PKC activation FIGURE 3 The flow of information of ligand binding to its membrane receptor via intracellular calcium increases and DAG-to-PKC activation and its translocation to specific intracellular sites are illustrated. DAG is in turn regulated by DAG kinases, which are EFhand proteins.
translocation of PKCζ. They reported that translocation of this PKC isoform to the nucleus could be inhibited by inhibiting phosphatidylinositol-3 kinase. With the plethora of PKC isoforms discovered over the years, their occurrence is being rationalised by the postulate that these isoforms might be specifically associated with identifiable signal transduction pathways and signal transduction in different physiological functions in a tissue-specific manner. In PC12 cells, the epidermal growth factor (EGF) signal either is mitogenic or induces differentiation. The flow of information and the phenotypic effect appear to depend on the PKC isoform. EGF induces neurite formation and arrests cell proliferation if the cells overexpress PKC-ε, but not PKC-α or δ. Neurite differentiation is accompanied by phosphorylation of mitogen-activated protein kinase, and inhibition of this phosphorylation event also inhibits neurite differentiation as well as arrest of proliferation. In sharp contrast, overexpression of PKC-α and -δ is strongly associated with the mitogenic function of EGF (Brodie et al. 1999). There are also examples of tissue-specific functioning of PKC isoforms. For instance, calcium-independent vascular smooth muscle contraction seems to involve PKC-ε rather than PKC-ζ, both calcium-independent isoforms of PKC (Walsh et al. 1996). Such specificity of function might reflect the substrate specificity of the kinase. Walsh et al. (1996) suggested the possibility that calponin is the musclespecific protein that might be a substrate of this PKC isoform. DAGKs that activate
16
Calcium Signalling in Cancer
PKCs show considerable tissue-specific distribution themselves. It may be that the tissue-specific function of PKCs might flow from the distribution of the DAGKs.
INOSITOL PHOSPHATES IN CALCIUM SIGNAL TRANSDUCTION The transduction of signals imparted to the cell by the binding of extracellular ligands to their respective membrane receptors generates repetitive calcium spikes or oscillations, and these transient increases of intracellular calcium are a result of the production of IP3 by the mediation of PLC (see Figure 3). The repetitive nature of these oscillations is believed to be a consequence of a positive feedback loop in which calcium induces its own release, and a negative feedback effect which stops calcium release. Such calcium oscillations occur in many physiological phenomena. An increase in intracellular calcium is a critical event in the activation of the egg (ovum) in a wide variety of species. Experimental enhancement of intracellular calcium of mouse eggs using calcium ionophores or ethanol results in activation. Conversely, when intracellular calcium levels are reduced egg activation is prevented (Cuthbertson, 1983; Ducibella et al. 1988; Kline and Kline, 1992). That IP3 mediates egg activation is indicated by the demonstration that microinjection of IP3 produces calcium release from intracellular stores and initiates some of the events associated with activation (Kurasawa et al. 1989; Ducibella et al. 1993). IP3 levels are increased by fertilisation of the egg (Kline, 1996). An increase is also known to take place in the number of IP3 receptors (Mehlmann et al.1996). IP3 receptors occur in the anterior acrosomal region of mammalian sperm, and by implication IP3 is involved in the acrosome reaction of mammalian sperm (Walensky and Snyder, 1996). IP3 regulates intracellular Ca2+ levels by mobilising calcium from intracellular ER-associated stores and probably also by stimulating Ca2+ influx into cells. Only a proportion (up to 50%) of the ER Ca2+ pool is IP3 sensitive, and the remainder can be released by calcium ionophores. The IP3-sensitive calcium pool is clearly associated with IP3R function. IP3R is an intracellular calcium release channel on the ER. IP3 stimulates IP3R, which results in calcium mobilisation from intracellular stores. Jayaraman et al. (1995) stably transfected antisense IP3R cDNA into Jurkat T cells. The transfected cells, which then lacked functional IP3R, failed to elevate Ca2+[i] in response to antigen-specific activation. However, the depletion of intracellular calcium stimulated calcium influx, which suggests that IP3R are required for IP3-mediated mobilisation of calcium from intracellular stores, but not for calcium influx. The function of IP3R seems to be regulated by phosphorylation. Both cyclic guanosine monophosphate (cGMP) and cAMP are known to inhibit the mobilisation of intracellular calcium, and this has been found to be a consequence of the phosphorylation of IP3R by cGMP-dependent kinase (Komalavilas and Lincoln, 1994, 1996) (Figure 4). Komalavilas and Lincoln identified serine 1755 of IP3R as the phosphorylation site. Nonreceptor tyrosine kinases have also been shown to generate IP3, activate IP3R, and raise intracellular calcium levels. Jayaraman et al. (1996) demonstrated the association between nonreceptor tyrosine kinase Fyn and IP3R
The Calcium Signalling Pathway
17
FIGURE 4 Possible mechanisms involved in IP3-mediated mobilisation of intracellular calcium. cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; cGMPK, cGMP kinase; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; IP3R-P, phosphorylated forms of IP3R.
following T-cell receptor stimulation. Furthermore, phosphorylation of tyrosine residues was found to be reduced in thymocytes derived from fyn (–/–) mice. These studies showed that phosphorylation of tyrosine might also regulate IP3R function. It would appear that the phosphorylation of serine and tyrosine might have antagonistic regulatory effects. This situation is somewhat analogous to the activation or inactivation of p34cdc2 kinase, which is involved with the phosphorylation of the retinoblastoma gene product in the regulation of cell cycle progression (see Sherbet and Lakshmi, 1997b). Although the molecular mechanisms by which IP3R raises Ca2+[i] are not fully understood to date, it is obvious that the process of phosphorylation of IP3R is an important event in IP3-mediated calcium signalling. The occurrence of IP3R was recognised many years ago (Supattapone et al. 1988; Snyder and Supattapone, 1989). There are three types of IP3R. Three IP3R genes have been cloned. One of them, the IP3R1, is expressed predominantly in Purkinje neurones of the cerebellum. IP3R1 and IP3R2 genes have been found to be expressed at low levels in several tissues studied to date. The distribution of the mRNA of the three receptor genes appears to display a definable pattern, leading to the suggestion that the different receptor types may have distinct functions (Fujino et al. 1995; T.X. Yang et al. 1995). Indeed, multiple isoforms of IP3R genes may be expressed in cells. Alternatively spliced isoforms could be fulfilling different cellular requirements, that is, they may be functionally different (Iida and Bourguignon, 1995, 1996; Katusic and Stelter, 1995). IP3R1 may be associated with intracellular calcium mobilisation, because IP3R1-deficient T-lymphocytes show a lowered IP3-mediated calcium release by T-cell receptor stimulation (Jayaraman and
18
Calcium Signalling in Cancer
Marks, 1997). The same study also implicated IP3R1 in apoptosis, by the observation that IP3R1-deficient T lymphocytes are resistant to dexamethasone-induced apoptosis. IP3R3 genes have been credited with the capacitative entry of calcium influx, when intracellular Ca2+ is depleted. In Xenopus oocytes IP3R3 was associated with the plasma membrane, which facilitated the influx of calcium (Putney, 1997). The transduction of signals imparted by a variety of biological response modifiers occurs via cytoskeletal structures. Compatible with this generalisation, the signal transduction pathway of IP3 has been linked with cytoskeletal dynamics. Ribeiro et al. (1997) found that the disruption of cytoskeletal structures of NIH3T3 cells by treatment with cytochalasin D resulted in the abolition of intracellular calcium mobilisation normally induced by platelet-derived growth factor (PDGF). The depolymerisation of the tubulin network similarly abolished calcium mobilisation. However, PDGF continued to stimulate the generation of IP3 even in the presence of cytochalasin. This suggests that the cytoskeleton is closely involved in the IP3-mediated transduction of the PDGF proliferative signal. It is of interest to note that Bourguignon and Jin (1995) had previously identified a C-terminal amino acid sequence of GGVGDVLRKPS in IP3R that possesses sequence homology to the ankyrin-binding domain of the intercellular adhesion molecule CD44. They further had demonstrated that an 11 amino acid synthetic peptide with that sequence showed specific binding to ankyrin, which is a cytoskeletal protein.
DEREGULATION OF INOSITOL 1,4,5-TRISPHOSPHATE PATHWAY AND ITS CONSEQUENCES It is hardly surprising that interference with signal transduction pathways and their deregulation should have serious consequences for biological responses in developmental systems as well as in pathogenesis. Ecdysone, a steroid hormone, regulates a variety of developmental processes and metamorphosis in insects. It also influences neuronal responses, apoptosis, and histiolysis in a variety of larval tissues, binds to nuclear receptors, which show tissue- and stage-specific expression (Kamimura et al. 1997); and regulates ecdysone-responsive genes (No et al. 1996; Truman, 1996). The metamorphic changes involve “early” and “late” genes, with the early genes encoding proteins that regulate the expression of late genes (Baehrecke, 1996). Although our knowledge of the mechanics of ecdysone signal transduction is still rudimentary, it is clear that the pathway involves calcium signalling. The prothoracicotropic hormone (PTTH) stimulates the synthesis of ecdysone in the prothoracic gland of Galleria larvae (Birkenbeil, 1996). PTTH increased intracellular Ca2+ levels of prothoracic gland in vitro. This increase could be abolished by removing extracellular calcium and by calcium channel inhibitors. The PTTH-stimulated increase of intracellular calcium was not abolished by agents, which inhibit mobilisation of calcium from intracellular stores. Recently, Venkatesh and Hasan (1997) found that disruption of IP3 receptor gene function in Drosophila larvae grossly affected metamorphosis and ecdysone synthesis and secretion. They generated IP3R gene (itpr) mutants. The mutations delayed moulting and were lethal at early larval stages.
The Calcium Signalling Pathway
19
Feeding ecdysone to mutant larvae partially counteracted the phenotypic effects of the itpr mutation, and down-regulated ecdysone-inducible genes. General or specific abnormalities of signal transduction pathways (e.g., occurrence of abnormalities in one or more components of the transduction pathway) may be associated with disease processes, including the invasive behaviour and metastatic progression of cancers. Such disruptions of the signal transduction cascade in human cancers has been studied by measuring the levels of three enzymes involved in the generation of IP3, namely, phosphatidylinositol 4-kinase, phosphatidyl 4-phosphate 5 kinase, and PLC. Weber et al. (1996) found that all three enzymes were up-regulated with tumour progression. In rat hepatomas the enzyme levels rose by two- to eight-fold compared with normal liver. A three- to four-fold increase in PIP kinase and PI kinase was found in ovarian epithelial cancers. Weber et al. (1996) found a dramatic 16- and 96-fold increase of these enzymes in human breast carcinoma cells compared with normal breast parenchymal cells. These changes clearly correlated with enhanced IP3 expression and proliferative potential. Further evidence has also been reported by Singhal et al. (1997), who investigated the connection between elevated IP3 and DAG with proliferation of the breast cancer cell line MDA-MB-435 and the ovarian cancer cell line OVCAR-5. They demonstrated that quercetin treatment of the cells inhibited PI kinase and reduced IP3 before any inhibition in cell proliferation was evident. The expression of these kinases seems to be up-regulated by differentiation-inducing agents. Thus Ai et al. (1995) found enhanced expression of PI kinase as well as IP3 in murine erythroleukaemia cells induced toward erythroid differentiation by dimethyl sulphoxide (DMSO) treatment. Another line of circumstantial evidence may be cited. For instance, monoterpenes such as limonene and perillyl alcohol have been reported not only to prevent tumour initiation and promotion, but also to inhibit tumour progression. These monoterpenes appear to inhibit the isoprenylation of G-proteins (Gould, 1997), which are a component of the signal transduction machinery (Figure 5). Similarly, abnormalities in the related pathway involving DAG and PKC may also be associated with cancers, as demonstrated by Hoelting et al. (1997) using the PKC agonist TPA (12-O-tetradecanoyl phorbol 13-acetate). They reported a 15% increase in the invasive ability of a follicular thyroid cancer cell line. In contrast, PKC inhibitors such as staurosporine, chelerythrine and calphostin C reduced invasion by 62%. CAI which inhibits calcium influx into cells, has been reported to inhibit the proliferative and invasive capacity of cell lines derived from human prostate cancer (Wasilenko et al. 1996). The neuroendocrine cells of prostate cancer express bombesin and gastrin-releasing peptide (GRP). In vitro bombesin and GRP signals invoke cell proliferation via bombesin receptors of which there are three subtypes: GRP receptors (GRPr), neuromedin B receptor, and bombesin receptor subtype 3. Transcripts of GRPr only, but not neuromedin B or bombesin receptor subtype 3, have been found in androgen-insensitive prostate cancer cell lines PC-3 and DU-145, suggesting the very important role GRPr play in signal transduction in these cells (Aprikian et al. 1996). In all lines derived from advanced prostate cancer, several agents such as GRP, bombesin, and bradykinin, among others, raised intracellular calcium levels.
20
Calcium Signalling in Cancer
FIGURE 5 The cAMP/Ca2+-signalling pathway. The binding of extracellular ligands to specific receptors regulates adenylyl cyclase activity via the linking G-proteins. The cAMP generated activates protein kinases that phosphorylate substrate proteins. Another route starts with the raising of intracellular calcium levels, which in turn regulate adenylyl cyclase activity.
However, bombesin did not influence calcium levels of an immortalised prostate cell line (Wasilenko et al. 1997). The authors have, therefore, suggested not only that there might be multiple receptors that can mediate increases in intracellular calcium levels of androgen-independent prostate cancer cell lines, but also that GRPr expression may be associated with the progression of prostate cancer. Calcitonin-like peptides may also function as neuropeptides in prostate cancer. The peptide binds to high-affinity receptors in the plasma membrane and induces a rapid and marked increase in intracellular calcium. Furthermore, the calcitonin signal is transduced into a clear proliferative response. The pattern of calcium response is biphasic in the form of a spike, and plateau is regarded as indicative of the phospholipid/calciumsignalling system (Shah et al. 1994).
RYANODINE AND RELATED RECEPTORS IN CALCIUM MOBILISATION Besides IP3R, other receptor-mediated pathways are available to the cell for calcium mobilisation, and the activation and availability of the pathways may be developmentally regulated. In embryonic development, the IP3-dependent calcium signalling is switched to an IP3-independent mode of signal transduction. The ryanodine receptor (RyR) is also capable of regulating intercellular calcium. In the early stages of development, IP3R are ubiquitously expressed. But in subsequent development RyR begin to be expressed. Eventually, although most cell types do continue to
The Calcium Signalling Pathway
21
express IP3R, in excitable cells including muscle cells, RyR becomes the major Ca2+ release channel (Rosemblit et al. 1999). Ryanodine receptors, of which there are several isoforms, are activated by calcium influx via voltage-gated Ca2+ channels of the plasma membrane. Recently, cyclic ADP-ribose has been identified as an activator of RyR (Petersen and Cancela, 1999). The fatty acid metabolic products, the fatty acyl-CoA esters, can also activate RyR in skeletal muscle (Fulceri et al. 1994; El-Hayek et al. 1993; Dumonteil et al. 1994). This seems to be mediated by the acyl-CoA binding protein (Fulceri et al. 1997). A reference to the multifunctional receptor called megalin would not be out of place here. Megalin is a member of the low-density lipoprotein receptor family, which function as endocytic receptors. The megalin glycoprotein of rat kidney is approximately 330 kDa in size. The 550-kDa human homologue of megalin is found in the luminal surface of cells of the renal proximal tubule and epididymis. It is expressed in mammary epithelia, thyroid follicular cells, and the ciliary body of the eye (Lundgren et al. 1997). It is also found in parathyroid and trophoblast cells. Mackrill et al. (1999) raised antibodies against RyR from rabbit muscle. These antibodies recognised not only skeletal RyR but also another high-molecular-weight protein (k-HMW) in kidney microsomes thought to be a rabbit homologue of megalin. Antibodies raised against k-HMW were unable to recognise RyR. Furthermore, this protein showed partial sequence homology to RyR. Megalin functions as a receptor for thyroglobulin (Marino et al. 1999; G. Zheng et al. 1998), lipoprotein (a) (Niemeier et al. 1999), and insulin (Orlando et al. 1998). It is implicated in the transport of retinol. Megalin-deficient mice show greatly increased urinary excretion of retinol and retinol-binding protein (RBP). Furthermore, the uptake of retinol and RBP is partially inhibited by antibodies against megalin (Christensen et al. 1999). Megalin also serves as a receptor for aminoglyocoside antibiotics, such as gentamycin, and mediates the endocytosis and accumulation of the antibiotic in renal tubule cells (Decorti et al. 1999). There is a preliminary report that the nephrotoxicity of gentamycin is related to the loss of megalin receptors (Vaamonde et al. 1996). The megalin receptor has also been attributed with a putative role in calcium homeostasis (Friedman, 1999; Christensen et al. 1998). This seems reasonable in light of its similarity to RyR. The deregulation of this function might be responsible for its apparent involvement in pathogenesis. Megalin might function as an autoimmune antigen in the pathogenesis of membranous glomerulonephritis (Mackrill et al. 1999). Its dysfunction might occur also in neoplasia. Apparently, the expression of megalin is down-regulated in hyperplasia of the parathyroid.
CYCLIC AMP IN CALCIUM SIGNALLING A majority of hormones, neurotransmitters, and growth factors generate cellular responses by means of a signal transduction machinery that is composed of three elements. These agents bind to specific receptors, which are linked to the effector component by means of G-proteins (Iyengar and Birnbaumer, 1990a, 1990b). Gilman (1989) identified these as components of the machinery regulating adenylyl cyclase
22
Calcium Signalling in Cancer
activity. A large number of hormones modulate cAMP levels by regulating adenylyl cyclase activity. The G protein family encompasses a number of heterotrimers composed of subunits encoded by three G-protein-type genes, α, β, and γ genes. Several Gα, Gβ, and Gγ genes have been cloned (Iyengar and Birnbaumer, 1990b). The G-protein linker GS mediates stimulatory effects, whereas GI mediates inhibitory effects of hormones. Most G-protein intervention follows the activation of the α subunit by binding to GTP, and this activation occurs upon the receptor being bound by the appropriate ligand. Numerous biological responses to extracellular stimuli are mediated by cAMP synthesised by adenylyl cyclase activity, and in turn cAMP activates cAMP-dependent protein kinase, which phosphorylates a variety of cellular substrate proteins (Krebs, 1989). This pathway involves an elevation of intracellular calcium levels either by increased uptake of extracellular calcium or release of calcium from intracellular stores. Calcium can modulate adenylyl cyclase activity. There is a considerable body of evidence that CBPs such as calmodulin may regulate adenylyl cyclase activity. It has been shown that Ca2+/CaM can stimulate adenylyl cyclase activity (Minocherhomjee et al. 1988), but in some tissues the activity of this enzyme is insensitive to Ca2+/CaM. Furthermore, adenylyl cyclase activity may be related to intracellular distribution, and this may or may not be affected by activated GS. The cellular response generated by biological response modifiers may depend on the G-protein and the appropriate effector component being expressed by cells (Iyengar and Birnbaumer, 1990b). The control of cellular response to external signalling ligands requires that the levels of the second messengers themselves be regulated strictly. Enzymes such as phosphodiesterases that degrade these molecules regulate cAMP. Besides adenylyl cyclase, phosphodiesterases, protein kinase II, and protein phosphatase are also CaM-dependent enzymes. Receptor proteins and kinases may amplify second messenger signals. Indeed, this mechanism, involving their amplification on the one hand and degradation on the other, maintain the steady state levels of second messengers (see Figure 5). Several biological responses have been identified in which the cAMP/calcium pathway of signal transduction is followed upon the binding of specific extracellular ligands. The processes of aggregation and development and chemotactic response of Dictyostelium discoideum involve the cyclic nucleotides cAMP and cGMP. The chemotactic response appears to be a function of the elevation of intracellular Ca2+, which has been shown to correlate with the association of myosin with the cytoskeleton (Menz et al. 1991). This suggests a close involvement of calcium uptake with the process of cell motility. cAMP has been implicated in sperm motility (Garbers and Kopf, 1980). In fact, high extracellular levels of calcium have been known to increase cAMP levels in sperm cells (Garbers et al. 1982), and possibly Ca2+ could be activating adenylyl cyclase activity. Functionally it seems possible to differentiate between influxed calcium and Ca2+ released from intracellular stores. This is illustrated by the modulation of S100A4 expression in B16 murine melanoma cells by agents that modulate intracellular calcium levels. Melanocyte-stimulating hormone (MSH) increases calcium influx and cAMP levels. Verapamil is a calcium channel blocker that reduces cAMP levels (Atlas and Adler, 1981; Janis et al. 1987). Thapsigargin is a sesquiterpene lactone that raises intracellular calcium levels by releasing calcium from intracellular
The Calcium Signalling Pathway
23
stores, by inhibiting the ER-associated Ca2+-ATPase (Takemura et al. 1989; Thastrup et al. 1990). MSH has been reported to up-regulate S100A4, whereas verapamil does the opposite. In contrast, thapsigargin down-regulates its expression despite effecting an increase in intracellular calcium levels (Parker and Sherbet, 1992) (Figure 6). This is compatible with the suggestion by Haverstick et al. (1991) that Ca2+ influx and release from intracellular stores have independent roles. It has also been suggested that a low micromolar range of intracellular calcium levels inhibits adenylyl cyclase, in contrast to calmodulin-stimulated adenylyl cyclase which may be mediated by calcium influx (Cooper, 1991). The release of calcium from intracellular stores may therefore activate specific components of the calcium-signalling pathway (Figure 7). The transcription factor, the cAMP response element binding protein (CREB), is phosphorylated by Ca2+/CaM-dependent protein kinase PKII. The phosphatases PP-2A and -2B (calcineurin) dephosphorylate the phosphatase inhibitor (PI-1), which in turn inhibits the phosphatase PP-1. The inactivation of PI1 by PP-2A or PP-2B may allow the phosphatase PP-1 to dephosphorylate CREB, thus rendering the latter inactive. Calcineurin is reported to have an affinity for CaM two to three magnitudes greater than that of PKII. Therefore, low levels of intracellular calcium, such as those resulting from its release from intracellular stores, might preferentially activate calcineurin.
FIGURE 6 The differential regulation of S100A4 expression by calcium influx into cells as compared with the release of Ca2+ from intracellular stores. Calcium influx up-regulates S100A4. Verapamil, which blocks calcium influx, down-regulates its expression. In sharp contrast, thapsigargin, which raises intracellular calcium levels by releasing Ca2+ from intracellular stores, down-regulates S100A4 expression. This suggests that calcium released from intracellular stores may be functionally differentiated from influxed calcium and may be activating different components of the calcium signalling system. (Based on Parker and Sherbet, 1992). cAMP cyclic AMP; MSH, melanocyte-stimulating hormone.
24
Calcium Signalling in Cancer
FIGURE 7 Summary of cAMP and Ca2+/CaM-mediated regulation of “immediate early” gene expression. cAMP, cyclic AMP; CREBP, cyclic AMP response element binding protein; PI-1, phosphatase inhibitor l; PKA, protein kinase A; PKII protein kinase II; PP-1, protein phosphatase 1; PP2B, calcineurin.
Several extracellular agents are known to activate the cAMP- and Ca2+-signalling pathway. There are also instances where the calcium-signalling pathway is independent of an upstream event of cAMP activation. cAMP and calcium signalling mediate the biological responses of several hormones. Adrenocorticotropic hormone (ACTH) stimulates uptake of Ca2+ and elevates cAMP levels in lymphocytes. Splenic lymphocytes that possess ACTH receptors show ACTH-dependent calcium uptake, but thymocytes, which lack these receptors, do not show enhanced calcium uptake (Clarke et al. 1994). In adrenocortical cells maintained in culture, ACTH exerts a biphasic effect, inhibiting cell proliferation in the initial phase followed by a stimulatory phase of cell differentiation, and synthesis and secretion of corticosterone and 18-OH-deoxycorticosterone. cAMP and 8-bromo-cAMP can induce adrenocortical cells to differentiate and to secrete steroid hormones, but they do not inhibit cell proliferation. This suggests that although cAMP mediates the mitogenic, differentiative, and steroid stimulatory signals of ACTH, it is not involved in the process of inhibition of cell proliferation by ACTH (Arola et al. 1993). Similarly, although the stimulation of bone resorption in foetal limb bud bones by tumour necrosis factor (TNF) appears to involve cAMP, the latter may not be directly associated with TNF signalling (Shankar and Stern, 1993). Calcitonin and calcitonin-like substances induce cell proliferation in prostate cells in culture and possibly also in the genesis of carcinoma of the prostate. Calcitonin induces a dose-dependent enhancement of cAMP and intracellular levels
The Calcium Signalling Pathway
25
of Ca2+ (Shah et al. 1994). The alterations in intracellular calcium levels in Sertoli cells induced by follicle-stimulating hormone (FSH) involve the generation of endogenous cAMP in response to this hormone treatment (Gorczynska et al. 1994). Hypothalamic neurohormones that control a variety of normal biological processes, such as cell proliferation and differentiation as well as hyperplasia and neoplastic processes, transduce their signals by the cAMP/Ca2+ pathway (Spada et al. 1997). The expression of cytokines in T lymphocytes is a highly regulated feature, involving cAMP. Benbernou et al. (1997) treated activated Jurkat cells with dibutyryl cAMP or pentoxifylline and found that IFN-γ mRNA expression was inhibited but that of IL-10 was unaffected. Cholera toxin and prostaglandin E (PGE)-2 also inhibited IFN-γ but greatly enhanced IL-10 mRNA expression. Using immunofluorescence techniques to detect intracellular cytokines, these authors confirmed the inhibition of IFN-γ by dibutyryl cAMP and the enhancement of expression of IL-10 by PGE2. This clearly shows that a differential control is exerted by cAMP at both the transcriptional and the protein levels. Downstream events such as the induction of class II major histocompatibility complex (MHC) genes by IFN-γ, on the other hand, can be inhibited by agents that trigger the cAMP signal transduction pathway (Ivashkiv et al. 1994). The endpoint of the pathway is obviously the activation of responsive genes. There are certain regulatory regions called cAMP response elements (CREs) that interact with CREB. Besides CREB, the transcription factor known as ATF1 also mediates the transcription of responsive genes upon transduction of the extracellular signal via the cAMP/Ca2+-signalling pathway. Both these transcription factors are phosphorylated by the mediation of cAMP. CREB and ATF may integrate the signals flowing from the cAMP/Ca2+ pathway. As stated before, cAMP activation can either inhibit or enhance biological responses. This has been suggested to be a consequence of blocking or activation of CREB. P.Q. Sun et al. (1994) showed by transient transfection studies with the Ca/CaM-dependent protein kinases CAMKIV and CAMKII that the former is a more potent activator of CREB than the latter. This they found was due to the nature of CREB phosphorylation. CAMKIV phosphorylated CREB at serine residue 133, but CAMKII phosphorylated serine 142 in addition to serine 133. The studies also showed that whilst phosphorylation of serine 133 activated CREB, phosphorylation of serine 142 inhibited CREB activation. In ATF1, CAMKII phosphorylates the positive regulatory serine 63, corresponding to serine 133 of CREB, but not serine 72, which corresponds to the negative regulatory serine 144 of CREB (Shimomura et al. 1996). Thus, although CREB and ATF share substantial sequence homology, it may be that these two transcription factors may differentially transactivate the responsive gene (Figure 8).
ARCHITECTURAL ASPECTS OF THE SIGNAL TRANSDUCTION MACHINERY THE ROLE
OF
CAVEOLAE
IN
SIGNAL TRANSDUCTION
The signal transduction machinery contains several elements along which information flows. A wide variety of signals are imparted to the cell and these need to be
26
Calcium Signalling in Cancer
FIGURE 8 Phosphorylation of the transcription factors CREB (cyclic AMP response element binding protein) and ATF in the negative and positive regulation of genetic activity. The Ca2+/CaM-activated protein kinases CAMKIV and CAMKII phosphorylate specific positive and negative regulatory serine residues of the transcription factors, which therefore differentially transactivate the responsive genes.
targeted and conveyed to specific subcellular compartments for eliciting cellular responses. This inevitably means that there should be an optimal organisation of the various elements to achieve a coordinated functioning of signal transduction. Certain invaginations involving specialised microdomains of the plasma membrane called caveolae were identified in epithelial and endothelial cells many years ago (Simionescu, 1993; Anderson, 1998). Caveolae do occur in many cell types. They have been identified with the endocytosis of macromolecules and in signal transduction and calcium homeostasis. The status of caveolae as a dynamic structural component of signal transduction is underlined by the presence within these membrane microdomains of a variety of signal transduction molecules. They contain G-protein-coupled receptors, ras family proteins, receptor tyrosine kinases (RTKs), and isoforms of PKC (Shaul and Anderson, 1998). Also identified with them are adenylyl cyclase and CBPs such as CaM and annexin. Caveolin, a cholesterol and lipid-binding protein (Murata et al. 1995; Trigatti et al. 1999), of which a number of isoforms are now known, is an integral membrane protein of caveolae. The caveolins are synthesised in the ER and are transported to the plasma membrane. Specific domains of the molecule take part in the movement of caveolins from the ER to the cell surface (Machleidt et al. 2000). The N-terminal cytoplasmic domains of caveolin-1 interact with G-proteins (S. Li et al. 1995), RTKs (Couet et al. 1997), and endothelial nitric oxide synthase (eNOS) (Okamoto et al. 1998).
The Calcium Signalling Pathway
27
eNOS is also a Ca2+/CaM-dependent enzyme. The increases in intracellular calcium levels induced by extracellular signals and the binding of Ca2+/CaM complex with eNOS seem to lead to its activation. eNOS also appears to be negatively regulated by caveolin-1. The interaction between eNOS and caveolin seems to reduce nitric oxide production (Shah et al. 1999). The vascular endothelial growth factor (VEGF) increases endothelial cell permeability as well as endothelial cell (EC) migration and proliferation. The VEGF signal appears to involve the production of nitric oxide by eNOS (Yiyu et al. 1999), and this mediated by the Flt-1 receptor (Ahmed et al. 1997). The up-regulation could be attributed also to posttranscriptional changes leading to the stability of eNOS mRNA (Bouloumie et al. 1999). In any event, the serine/threonine kinase Akt phosphorylates the serine residue 1179 of eNOS and activates the enzyme (Fulton et al. 1999). The nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) inhibits VEGF-mediated EC migration and proliferation (Shizukuda et al. 1999). Nitric oxide is able to inhibit focal adhesion and spreading of endothelial cells and affects the formation of stress fibres (Goligorsky et al. 1999). Human tumour cells have been transfected with the NOS gene. The transfectant cells have shown enhanced invasive ability, growth rate, and vascular density, with parallel constitutive expression of NOS (Thomsen and Miles, 1998). The mechanisms involved in the nitric oxide–mediated increase in invasive and proliferative capacity have not yet been addressed, but there are suggestions that nitric oxide might up-regulate matrix metalloproteinases and block their endogenous inhibitors (Lala and Orucevic, 1998). IFN-γ and lipopolysaccharide (LPS) induce nitric oxide synthesis in C3-L5 murine adenocarcinoma cells as well as enhance their invasive ability in vitro. This is also accompanied by an upregulation of matrix metalloproteinase (MMP)-2. Furthermore, endogenous nitric oxide seems to down-regulate TIMP-2 and TIMP-3 (tissue inhibitors of metalloproteinases). This has led to the suggestion that nitric oxide alters the balance between MMPs and their inhibitors (Orucevi et al. 1999). VEGF is a potent inducer of angiogenesis. This angiogenic signal also involves nitric oxide production. L-NAME inhibits angiogenesis in vitro (Pipili-Synetos et al. 1995) as well as tumour-induced angiogenesis in vivo (Jadeski and Lala, 1999). Norrby (1998) supports the view that nitric oxide suppresses angiogenesis, but states that L-NAME did not suppress VEGF-induced angiogenesis. Nitric oxide synthase is also inducible. The inducible form (INOS) is found in large quantities in malignant prostate epithelium and in bladder cancer epithelium, but normal epithelial cells are only weakly positive. eNOS is expressed in the endothelial cells of tumour stroma, but not in stroma of normal bladder tissue (Klotz et al. 1998, 1999). In breast and gastric cancers also INOS occurs predominantly in the stromal component (Thomsen and Miles, 1998). This suggests a possible functional differentiation between INOS and eNOS. A marked up-regulation of NOS isoforms has also been reported in non–small cell lung cancers in relation to their progression (Ambs et al. 1998). Also of much interest is the finding by Gallo et al. (1998) that NOS activity in head and neck tumours with lymph node metastasis was higher than in tumours that had shown no metastatic spread. This has received some further support from Thomsen and Miles (1998) who state that NOS activity correlates with tumour grade in breast cancer.
28
Calcium Signalling in Cancer
It is possible that VEGF might follow two different pathways to increase endothelial permeability, endothelial cell migration, and proliferation, and induce angiogenesis. Whereas nitric oxide production is essential for effecting an increase in endothelial permeability, it appears to negatively regulate the angiogenic signal. This is partly borne out by the demonstration that VEGF reduces the activity of PKC isoforms, especially PKC-δ, and this could be blocked by pretreatment with LNAME (Shizukuda et al. 1999). Overall, it seems that there is a switching mechanism operating here, which apparently is distinct from the transduction pathway involving eNOS activation. This is likely to be a very rewarding area of investigation in the context of cancer spread and metastasis. The presence of IP3-like receptors (Patel et al. 1999; Fujimoto et al. 1995) and Ca2+-ATPase (Fujimoto, 1993) amply testifies to the participation of caveolae in calcium homeostasis. Caveolae seem to sequester extracellular calcium into the vesicles and release it into intracellular locations, presumably by the mediation of IP3 and Ca2+-ATPase. Furthermore, with possible lateral mobility of caveolae one can envisage a regulation of entry and release of calcium to appropriate cellular compartments.
CAVEOLIN EXPRESSION
IN
CANCER
On account of the highly significant participation of caveolae in signal transduction, the expression of caveolin has been the focus of some investigation in cancer progression. Caveolin expression appears to decrease with tumour progression, which is compatible with the view that there is a serious deregulation of signal transduction in neoplasms. Caveolin-1 and -2 genes, which occur at chromosome 7q31, are frequently deleted in tumours (Fra et al. 1999; Hurlstone et al. 1999). Caveolin expression is lower in breast cancer cell lines as compared with normal epithelial cells of the breast. Furthermore, caveolin expression seems to be inhibitory of growth (S.W. Lee et al. 1998). S.W. Lee et al. (1998) also transfected caveolin cDNA into breast cancer cells that normally show no detectable caveolin and showed that its overexpression in the transfectants resulted in a 50% reduction in growth rate and colony forming ability. Pflug et al. (1999) grew LNCaP prostate cancer cells in androgen-depleted culture medium, and from these they derived tumorigenic androgen-independent cell clones. These clones also showed greatly reduced levels of caveolin expression. In contrast, benign prostate epithelial cells express caveolin at high levels. On the face of it, caveolin seems to function as a tumour suppressor. However, metastatic tumours also overexpress caveolin (Thompson, 1998). It would seem therefore that although its overexpression can lead to androgen resistance, its association with metastatic progression could be a secondary event. Caveolin-3, which is believed to be a muscle-specific isoform, is often mutated in patients with limb girdle muscular dystrophy, and the mutations have been suggested to be associated with the pathogenesis of the disease (McNally et al. 1998a; Minetti et al. 1998).
3
Calcium Binding Proteins and their Natural Classification
Calcium-binding proteins comprise a large family of proteins that can be subdivided into two subfamilies based on their molecular organisation. A large number of these proteins have been identified and characterised, and their physiological functions have been investigated (Tables 2 and 3). The subfamily of CBPs, referred to here as non-EF-hand CBPs, binds to certain phospholipids in a calcium-dependent fashion (Heizmann and Hunziker, 1990). They do not possess the characteristic feature of the other subfamily, popularly described as the EF-hand CBPs. The EF-hand protein subfamily in turn can be divided into two groups (Da Silva and Reinach, 1991). The members of one group function as Ca2+ sensor proteins. These are inactive at calcium concentrations in the low range of 10–7 to 10–8 M. They are activated into playing their regulatory role when the Ca2+ concentration increases to around 10–5 to 10–6 M. The second group comprises EF-hand proteins that are mainly concerned with calcium buffering and transport. Calcium ions function as second messengers par excellence in many pathways of cellular response. The translation of the calcium signal into biological function is mediated by CBPs that occur ubiquitously in intracellular locations as well as in the extracellular matrix. In order to be able to mediate the transduction of calcium signalling into cellular responses, CBPs need to recognise and interact with downstream target proteins. The binding of Ca2+ to CBPs produces conformational changes in these molecules and these changes appear to endow the CBPs with the ability to recognise and interact with their target molecules. This is discussed in greater detail in a later section. Both EF-hand and non-EF-hand CBPs participate in a host of normal physiological functions and consequently they are also associated with an array of pathological conditions (Tables 2 and 3). Although many EF-hand proteins have been studied for their involvement in normal and aberrant physiology and in pathogenesis, only a small number of them have been studied extensively. Consequently, the information currently available about some EF-hand proteins has tended to be somewhat fragmentary. Nonetheless, there is an indisputable theme that underlies the molecular features of CBPs as associated with their function in normal physiology and in pathogenesis. Their functions appear to be linked closely with the molecular organisation of the EF-hands, and furthermore, to the characteristic conformational changes that they undergo and the new molecular configuration that they assume upon Ca2+ binding.
29
30
Calcium Signalling in Cancer
TABLE 2 Non-EF-Hand Calcium Binding Proteins Non-EF-Hand CBP Annexins (individual annexins also known as chromobindin, endonexin, lipocortin, etc.)
Gelsolin family proteins Gelsolin
Severin Villin
Function Membrane-related functions; adhesion; fusion; exocytosis; possible cell-cycle-related expression; morphogenesis; differentiation
Martin and Creutz (1987, 1990); Hamman et al. (1988); Martin et al. (1989); Creutz et al. (1992, 1994); further references cited in text
Cytoskeletal dynamics; severing and capping of actin filaments; cell migration, cancer progression; amyloidosis Sequence homology with gelsolin in actin-interacting domains Regarded as a marker of differentiation; occurs in intestinal and brush border epithelia, and in Barrett’s metaplasia and adenocarcinoma
Cited in text
Cap G Fragmin Calreticulin
Calsequestrin Osteocalcin
Regucalcin [senescence marker protein-30 (SMP-30)]a
Ref.
ER-associated CBP; molecular chaperone; intracellular calcium storage; cell adhesion; proliferation; autoimmune diseases Muscle homologue of calretinin, intracellular calcium storage Extracellular matrix (ECM) protein; bone metabolism; cell proliferation; differentiation; cancer invasion; osteotropism of cancer metastasis Implicated putatively in cell proliferation; regulation activity of protein phosphatases and Ca2+/CaM-dependent kinases; adenosine triphosphate (ATP)dependent transport of calcium across the plasma membrane
Cited in text Cited in text
Mishra et al. (1994) Van Ginkel et al. (1998) Constantin et al. (1998) Khanna et al. (1987); Smith et al. (1989); Milner et al. (1991); Heilmann et al. (1993); N. Liu et al. (1993) Cited in text Cited in text
Fujita (1999); M. Yamaguchi (1998); M. Yamaguchi et al. (1996, 1997); T. Murata et al. (1997); Murata and Yamaguchi (1998); Kurota and Yamaguchi (1997); Hanahisa and Yamaguchi (1998); H. Takahashi and Yamaguchi (1997), M. Yamaguchi and Kanayama (1996)
Calcium Binding Proteins and their Natural Classification
31
TABLE 2 (CONTINUED) Non-EF-Hand Calcium Binding Proteins Non-EF-Hand CBP Calelectrin Calcimedin
a
Function
Ref. Morse and Moore (1988) Moore and Dedman (1984); Moore et al. (1984); Morse and Moore (1988)
A large body of literature about regucalcin, mostly from the laboratory of M. Yamaguchi, has appeared in the past few years. The references cited indicate that it is a non-EF-hand CBP that shows tissuespecific expression mainly in the liver and to a lesser extent in the kidney. It is also found in hepatoma cell lines. The mouse regucalcin gene is described as spanning 18 kbp of the genome and containing seven exons and six introns. The human regucalcin gene has been provisionally mapped to chromosome Xp11.3–q11.2.
32
Calcium Signalling in Cancer
TABLE 3 Functional Grouping of Major EF-Hand Proteins and Their Involvement in Normal and Aberrant Physiology EF-Hand Protein
S100 family members
Calmodulin
Function Regulatory Proteins Modulation of enzyme function; cytoskeletal dynamics; binds to various cellular target proteins; control of cell cycle traverse and cell proliferation; apoptosis; intercellular communication, signal transduction modulation of cell shape; motility and invasion; metastasis; ageing; Alzheimer’s disease Regulation of enzyme activity; inhibition of transcription; cell proliferation; invasion
Troponin C
Muscle contraction
Myosin light chains Recoverin
Muscle contraction Activation of guanylate cyclase; phototransduction Calcium buffering and transport; neuronal function; motor coordination; neuroprotective action
Calbindins, 9 and 28 kDa
Calretinin
Guanylate cyclase (GC)-activating protein Centrin (caltractin)
Calnuc (nucleobindin) Reticulocalbin family (reticulocalbin, calumenin, ERC-55, Cab-45) DAG kinases α, β, and γ
Calpains
Calcium buffering and transport; phosphorylation; cell proliferation and differentiation; tumour marker Photoreceptor-specific CBP
Ref.
Cited in text
James et al. (1995); Corneliussen et al. (1994) J.D. Potter and Johnson (1982); Wnuk (1988) Stryer (1991); Gorczyca et al. (1995) Bronner et al. (1986); Chard et al. (1993); further references cited in text Rogers (1987); further references cited in text Cited in text
Microtubule dynamics; cell polarity; cell motility; duplication of microtubule organising centre; cell proliferation; response to environmental signals Associated with luminal surface of Golgi membrane ER-associated proteins; membrane trafficking of macromolecules DNA supercoiling (?)
Cited in text
Phosphorylation of DAG and activation of PKCs
Cited in text; Sakane et al. (1990); Sakane and Kanoh (1997); Yamada et al. (1997) Cited in text
Keratin filament aggregation (proteolytic processing of profilaggrin)
P. Lin et al. (1998, 1999) Cited in text
Calcium Binding Proteins and their Natural Classification
33
TABLE 3 (CONTINUED) Functional Grouping of Major EF-Hand Proteins and Their Involvement in Normal and Aberrant Physiology EF-Hand Protein Osteonectin
Calcineurin B Calmyrin
β-Parvalbumin (oncomodulin) α-Parvalbumin
Calbindins, 9 and 28 kDa Calretinin
Function Embryonic development and differentiation; extracellular matrix (ECM) remodelling; modulation of cell adhesion; cell shape; angiogenesis; tumour development and progression Protein phosphatase B regulatory subunit Calcineurin B- and CaM-related 191 amino acids; two C-terminal EF-hands; binds to cytoplasmic domain of platelet integrin αII bβ3; putative regulation of the integrin function Buffer Proteins Lymphocyte maturation Muscle contraction; electrophysiology of neurones
Calcium buffering and transport Calcium buffering and transport; phosphorylation
Ref. Cited in text
Cited in text Naik et al. (1997)
Brewer et al. (1990) Heizmann (1984); Heizmann and Berchtold (1987); Heizmann and Braun (1990) Bronner et al. (1986); Chard et al. (1993) Rogers (1987)
Note: The S100 protein family is separately listed in Table 17. Calretinin has been advisedly included as both a regulatory and buffer protein, for although it was regarded preeminently as a buffer protein, its participation in cell proliferation and differentiation and utility as a tumour marker were considered as providing a strong basis for classifying it with other calcium-binding regulatory proteins. EF-hand proteins have also been identified in prokaryotes. An example of this is the Escherichia coli lytic transglycosylase Slt 35. The EF-hand domain of this enzyme binds Ca2+ as well as Na+, albeit in different molecular configurations. Ca2+ ions are bound preferentially, and this appears to be conducive to the stability of the enzyme (Van Asselt and Dijkstra, 1999). Source: Based on B.W. Schafer and Heizmann (1996) and references cited in the text in the course of discussions relating to their respective physiologic functions.
4
Non-EF-Hand Calcium Binding Proteins
Several non-EF-hand calcium-binding proteins have been studied in the past few years with regard to their participation in normal physiological processes and their apparent ability to modulate biological behaviour of cells (see Table 2). Of these, annexins, gelsolin, calreticulin, and osteocalcin have been extensively investigated. Although they are grouped together here as non-EF-hand CBPs, the pathways of their approach to the modulation of cell physiology and function are distinctively different. Annexins are calcium-dependent membrane binding proteins that participate in membranerelated processes of fusion, adhesion, exocytosis, and the remodelling of the plasma membrane. Calreticulin also subserves a membrane-associated function (e.g., the intracellular storage of calcium). Osteocalcin is an extracellular matrix protein and is involved in bone metabolism. It is apparently also significantly implicated in invasive behaviour of cancers, their proliferation, and osteotropic metastasis. In contrast, gelsolin activity is mainly targeted on the cytoskeletal dynamics.
ANNEXINS STRUCTURE Several non-EF-hand CBPs have been identified and sequenced. Of these, annexins have been studied extensively. Annexins form a family of structurally related and highly conserved proteins that bind phospholipids in a Ca2+-dependent manner. Several annexins have been identified and some of these have been well characterised, e.g., annexins I, IV, V, and XII. A 40-kDa annexin, distinct from annexin XII, has been reported from Hydra vulgaris (Schlaepfer et al. 1992a). Although basically annexins are intracellular proteins, it has been postulated that these proteins may be inserted into the phospholipid bilayer of the plasma membrane. Integration of the molecules into the plasma membrane is essential for their postulated functions of membrane trafficking, fusion, and the formation of ion channels. The crystal structure of annexins is characterised by a common fold that consists of four domains. Each domain has five helices with a short interconnecting loop. The loops between helices A and B (domain 3) and helices D and E (domain 2) are attributed with the ability to bind phosphatidyl serine in a Ca2+-dependent manner. It has been suggested that annexin XII forms a trimer on the surface of the membrane (Luecke et al. 1995). Furthermore, it appears that an intramolecular Ca2+-binding site participates in the formation of the trimer, and this is quite distinct from the Ca2+ site involved in interaction with phospholipid (Mailliard et al. 1997). Langen et al. (1998) have postulated that, at low pH, annexin is inserted into the membrane as a continuous transmembrane helix that is formed, in a reversible manner, from
35
36
Calcium Signalling in Cancer
the helix–loop–helix configuration. They regard this latter configuration as being conducive to ion channel formation. Tyrosine phosphorylation of the tetramer may occur following the interaction of the tetramer with phospholipid. This is suggested by the stimulation of pp60src RTK following the binding of the annexin II tetramer to plasma membrane or phosphatidyl serine vesicles (Bellagamba et al. 1997).
BIOLOGICAL FUNCTIONS Annexins are regarded generally, although not exclusively, as intracellular proteins with predominantly intracellular functions. Several biological functions have been attributed to annexins, (e.g., membrane fusion, calcium-channel formation, etc.) that involve cAMP as the second messenger in signal transduction. Thus membranebound annexins could be subserving a different class of function. Annexin II, for instance, can be found in both soluble and membrane-bound states. It has been identified on the cell surface, and in this location it could be functioning as a receptor for extracellular signalling ligands (Siever and Erickson, 1997). This argument is further reinforced by the apparent interaction of annexin V with the actin cytoskeleton. Membrane preparations of activated platelets indicate the presence of an 85kDa complex, which contains annexin V. Besides, this complex also contains actin (Tzima et al. 1999). This suggests the presence of a link between the plasma membrane and the actin cytoskeleton, which is potentially of considerable significance in defining the function of annexins as an early link in the transmembrane signal transduction machinery. Annexins also show a major involvement down-stream in the flow of information in PKC-mediated transduction of growth factor signals. It has been demonstrated that annexin V is able to inhibit PKC and this in turn results in the inhibition of phosphorylation of annexin I (Schlaepfer et al. 1992b, 1992c). Annexin I has phosphorylation sites in the hinge region, which is believed to be important for cell proliferation and differentiation. Annexin XII is also a high-affinity substrate for phosphorylation by PKC (Schlaepfer et al. 1992b). This could be a reason why they show cell proliferation related expression (Schlaepfer and Haigler, 1990). Another aspect of PKC-mediated regulation of annexin function is the phosphorylation of certain amino acid residues that are involved in the interaction with EF-hand proteins of the S100 family. Annexin II is known to interact with S100A10 (p11) protein. There is a serine residue in the N-terminal region of annexin. If this residue is phosphorylated by PKC, annexin II interaction with S100A10 appears to be inhibited. Other amino acid residues have been implicated in similar interactions between annexin I and S100A11 (S100C) (Seemann et al. 1996). Annexin XI-A has been shown to bind to S100A6 (calcyclin) by means of specific hydrophobic residues on the surface of its α-helix (Sudo and Hidaka, 1999). It seems, however, that annexin V does not inhibit the phosphorylation of annexin XII by the epidermal growth factor RTK (Schlaepfer et al. 1992c). On the other hand, annexin II, which is also involved with cell proliferation is a substrate for RTKs. Hubaishy et al. (1995) demonstrated that the phosphorylation of annexin II is effected by RTKs. They reported that phosphorylation negatively regulates annexin
Non-EF-Hand Calcium Binding Proteins
37
II function, because it inhibited the binding of annexin II to and the formation of F-actin bundles. The annexins show a definable pattern of intracellular distribution. Barwise and Walker (1996) studied the distribution of annexins I, II, IV, V, and VI in human foreskin fibroblasts. Annexins IV and V were predominantly located in the cytoplasm and annexin VI was partly associated with the endoplasmic reticulum, whereas annexins I and II were associated with the plasma membrane. Furthermore, annexins I, IV, and V occurred in the nucleus at higher concentrations than in the cytoplasm. When the cells were treated with calcium ionophores and C2+[i] was raised, a marked relocation of the annexins occurred. Annexins II, IV, and V translocate from the nucleoplasm to the nuclear membrane. In MG-63 cells a relocation of intranuclear annexins IV and V to the nuclear membrane occurs within 40 s after treatment (Mohiti et al. 1995). Annexins located in the cytoplasm may be translocated to the plasma membrane. Human osteosarcoma MG-63 cells grown under normal serum conditions show high levels of annexin V in the nucleus. Upon serum starvation, however, the cells lose 72% of the nuclear annexin. When serum levels are restored nuclear annexin levels are also restored (Mohiti et al. 1997). These authors also observed that annexin phosphorylation is essential for the relocation of annexins. The translocation of annexin V appears to be inhibited when tyrosine kinase activity is blocked. Whether PKC-mediated phosphorylation plays any part in the translocation is unclear. PKC itself shows intracellular translocation upon being activated. It would have been of considerable interest also to determine PKC translocation, especially in light of the role PKC plays in the regulation of annexin function. A different pattern of annexin II and V translocation has been described in human neuroblastoma SH-SY5Y cells. Blanchard et al. (1996) found that both annexins were associated with membranes. Annexin II showed a uniform association before elevation of intracellular calcium levels, but upon treatment with calcium ionophores, it was relocated to discrete patches. Annexins take part in the process of calcium-dependent aggregation of liposomes. Annexins I through IV, but not V or VI, seem to mediate liposome aggregation (L. Liu et al. 1996). From this functional viewpoint, there is evidence of cAMP involvement in calcium-dependent aggregation of phosphatidyl serine liposomes and bovine chromaffin granules and in calcium channel activity (Cohen et al. 1995). Blanchard et al. (1996) showed that membrane-associated annexin II is reorganised into discrete patches. It seems preferentially to partition into cholesterol-rich domains of the plasma membrane. Furthermore, the transmembrane adhesive glycoprotein CD44 also partitions into the same type of domain, with the result that CD44 clusters at the external membrane surface and annexin II at the cytoplasmic surface (Oliferenko et al. 1999). Whether this seemingly fortuitous partitioning of annexin II has a functional provision in CD44-mediated cell adhesion is unclear at present. Nevertheless, with the demonstration by Tzima et al. (1999) that annexin II might be coupled with the actin cytoskeleton, this is highly suggestive of its involvement in membrane-mediated functions of intercellular adhesion and cell fusion. Several mammalian annexins positively influence the process of exocytosis (Creutz et al. 1992). Such a function seems to be strengthened by the observation by Oliferenko et al. (1999) that the redistribution of CD44 and annexin II was accompanied by changes in the cytoskeletal organisation. CD44 patching is induced
38
Calcium Signalling in Cancer
by overexpression of the S100A4 protein, and this appears to relate to the ability of S100A4 to depolymerise cytoskeletal elements (Lakshmi et al. 1993, 1997). Therefore, there is the distinct possibility that annexins and S100A4 might cooperate in generating the membrane-mediated behavioural changes of cells. The intracellular translocation of annexins in the human osteosarcoma cell line MG-63 has been found to be phosphorylation dependent. Serum depletion results in a reduction of nuclear annexin V levels. With serum stimulation these levels increase. Inhibition of tyrosine kinases has been found to reduce nuclear translocation of the annexin (Mohiti et al. 1997), which suggests that the relocation of annexins requires tyrosine phosphorylation.
ANNEXINS
IN
CANCER GROWTH
AND
PROGRESSION
The influence of annexins on cell growth was recognised some years ago. The expression of annexin VII has been reported to inhibit the growth and viability of some secretory mutants of Saccharomyces cerevisiae at semipermissive temperatures. In contrast, annexin IV mitigated the growth defect of the sec2 secretory mutant (Creutz et al. 1992). Recent studies have in fact elucidated in some detail the significant part that annexins play in cell proliferation. Raynal et al. (1997) demonstrated convincingly that annexins exhibit a cell cycle-related expression. Apparently, annexins II, V, and VI are, on the whole, uniformly expressed at a low level at all phases of the cell cycle. Annexin IV, on the other hand, showed a 50% increase in the S-phase of the cycle. Annexins I and V decreased by 40% in early G2M phase, although the corresponding gene expression did not vary. These observations show that there are specific patterns of occurrence of annexins and the expression may be regulated at the transcriptional level. The apparent cell cycle-related expression of annexins and the deregulation of PKC-mediated signal transduction with consequent deregulation of proliferation has prompted the investigation of annexins in relation to the proliferative state and progression of human cancers. Masaki et al. (1996) found that annexin I levels were greatly increased, at both the transcriptional and the protein levels, in human hepatocellular carcinomas as compared with normal liver tissue. Annexin II was reported to be overexpressed in human pancreatic carcinomas compared with normal pancreatic tissue (Vishwanatha et al. 1993). Furthermore, these authors found that the expression of annexin II was associated with proliferating ductal adenocarcinomas and especially that its expression colocalised with that of proliferating cell nuclear antigen (PCNA). Roseman et al. (1994) also found some association between levels of annexin II and the BrDU (bromo-deoxyuridine) proliferation index. Compatible with this is the reported histological grade-related expression of annexin II in gliomas (Roseman et al. 1994). They found that annexin II levels were greater in glioblastoma multiforme than in anaplastic astrocytomas, which in turn showed higher levels than did astrocytomas. With variations of annexin levels seemingly in consonance with growth deregulation in human cancers, there has been some effort directed at examining whether variations in expression might relate to the stage of progression of cancers. As stated before, annexin levels have been found to correlate with histological grade of gliomas
Non-EF-Hand Calcium Binding Proteins
39
(Roseman et al. 1994). Annexin I does not occur in ductal luminal cells of normal breast tissue, but it is expressed in a range of breast cancers including noninvasive ductal carcinomas as well as invasive and metastatic breast cancer (Ahn et al. 1997). Annexin VI, in contrast, has been shown previously to inhibit cell proliferation. Theobald et al. (1994) transfected A431 cells with annexin VI. The growth of these cells, in normal serum concentration, was only moderately inhibited by the expression of annexin VI. When grown in low serum, their doubling time seemed to increase. However, Theobald et al. (1994) found that annexin VI-expressing cells grown in low serum conditions showed arrest at the G1 phase of the cell cycle. Furthermore, annexin VI expression inhibited the growth of A431 cells injected subcutaneously into nude mice (Theobald et al. 1995). It appears that the inhibitory effect is exerted only by the larger of the two splice variants of annexin VI. Fleet et al. (1999) found that the larger splice variant inhibited the Ca2+ mobilisation and cell proliferation induced by EGF. The shorter splice variant of annexin VI was not capable of such inhibition. Francia et al. (1996) identified several mRNAs that are differentially expressed in the murine melanoma cells B16F-10 and an immortalised melanocyte cell line called Melan A. Among these was an mRNA that was found to be identical to the 3′ region of murine annexin VI. The expression of this mRNA was reduced in B16F-10 melanoma cells. Melan A may not be a proper control cell line with which to compare the mRNA profile of B16 melanomas, and the low metastasis variant B16F1 might have been a more appropriate control cell line. Nonetheless, Francia et al. (1996) followed this up with a study of the expression of annexin VI in human melanomas. In these tumours also a reduced or loss of annexin expression was encountered during progression. The expression of annexin V has been found to be markedly suppressed in carcinomas of the uterine cervix and the endometrium (Karube et al. 1995). Thus, most of the annexins studied to date have related directly, however indecisively, to cell proliferation and progression; however, annexin VI seems to differ from the rest. If confirmed, the reported tumour suppressor function of annexin VI does add a new dimension to the biology of annexins. But clearly, more work needs to be done to examine whether the putative suppressor function is associated with the larger splice variant and whether the second shorter variant of the annexin might possess some compensatory and antagonistic function. Overall, in spite of the cell cycle-related expression of some of the annexins, no clear relationship has emerged between their expression and the neoplastic disease process. Annexin II, which seems to relate to histological grade and differentiation of gliomas, tends to be expressed uniformly in the cell cycle. The expression of annexins I and V seems to change in opposite directions in the context of the cell cycle. Both are down-regulated in their expression at the G2M point in the cell cycle. Perhaps such comparisons are unhelpful because of the differences in the biology and histogenesis of the tumours studied.
ANNEXINS
IN
MORPHOGENESIS
AND
DIFFERENTIATION
The expression patterns of annexins have been studied with respect to cell differentiation. Rahman et al. (1997) reported that annexins V and VI are not detectable in
40
Calcium Signalling in Cancer
undifferentiated mesenchymal cells of foetal rat limb buds. The progenitor cells of skeletal muscle, which appear in the limb bud on day 14, express annexin VI on the cell surface upon differentiation from myogenic cells into myotubules. Annexins V and VI also are associated with the differentiation of chondrocytes. King et al. (1997) have confirmed that annexin V is required for the formation of the pericellular matrix of chondrocytes.
THE GELSOLIN FAMILY OF CALCIUM-BINDING PROTEINS Actin-binding proteins constitute a large family of proteins that actively participate in actin bundling, nucleation, actin capping, and severing. Gelsolin, severin, and villin are three important proteins of the gelsolin family of actin-binding proteins that will be discussed here, for they possess the remarkable property of rapidly reorganising the cytoskeleton and also rapidly modulating, in a Ca2+-dependent manner, cell shape, substrate adhesion, and cell locomotion.
GELSOLIN
IN
SEVERING
AND
CAPPING
OF
ACTIN FILAMENTS
Gelsolin was identified as an 82-kDa actin-binding protein that is involved in Ca2+dependent severing of actin filament and capping of filaments. The kinetics of polymerisation of actin filaments, namely, the association and dissociation of monomeric subunits, essentially involves F-actin elongation by the association of ATPbound monomers with the barbed end of the filament and a slower loss of ADPactin from the pointed end (Sheterline and Sparrow, 1994). Actin polymerisation is altered by the sequestration of monomeric elements and by filament capping, which prevents the addition of subunits. The exchange of subunits at the filament ends is controlled by gelsolin and gelsolin-related proteins. They bind to the filaments and inhibit the addition of actin subunits. Several proteins that participate in the regulation of cytoskeletal organisation have been identified (A. Schafer and Cooper, 1995). A large number (>60) of actin-binding proteins are known (Pollard et al. 1994) and the new ones are continually being identified and reported. A group of proteins composed of the gelsolin family and of tensin, and profilin bind to barbed ends. Others bind to pointed filament ends, whereas some proteins bind alongside the filament and yet successfully influence filament assembly. Certain isoforms of tropomyosin have been found to protect actin filaments from gelsolin-mediated severing. This protective function may be further enhanced by caldesmon (Ishikawa et al. 1989a). Tropomyosins appear to be able to anneal the actin fragments and again caldesmon is said to accentuate this process (Ishikawa et al. 1989b). The Drosophila flightless-I gene and the homologous human FLII gene encode gelsolin-like actin-binding proteins (H.D. Campbell et al. 1997). Constantin et al. (1998) have isolated a gelsolin-like protein from Physarum polycephalum that affects cytoskeletal integrity when introduced into mammalian cells. Tropomodulin and spectrin bind to pointed filament ends. Two isoforms of gelsolin had been identified: a cytoplasmic form and a secreted isoform called plasma gelsolin. A third isoform has now been reported; all three isoforms arise by alternative splicing of the gelsolin
Non-EF-Hand Calcium Binding Proteins
41
transcript (Vouyiouklis and Brophy, 1997). The FLII maps to chromosome 17p11.2 (Chen et al. 1995), in the region that is consistently deleted, and is associated with Smith-Magenis Syndrome (SMS). Cytoplasmic-free calcium and inositol 4,5-bisphosphate regulate the function of gelsolin family proteins. Gelsolin binding to PIP2 has been found to be modulated by Ca2+ (K.M. Lin et al. 1997). Several functional domains that regulate actin filament length have been identified in the gelsolin molecule. The N-terminal domain (S1) is able to inhibit actin polymerisation. The inhibitory activity has been attributed to a small peptide sequence. The interaction of the C-terminal domains (S4–6) with actin filaments occurring during the severing process has been localised with residues 112 to 120 of actin subdomain 1 (Feinberg et al. 1997a, 1997b). By deletion mutagenesis, residues close to the S2 domain have also been implicated in actin filament binding, capping and as well as interaction with phosphoinositides (H.Q. Sun et al. 1994). Cofilin is another protein that binds actin and promotes its depolymerisation. There are important sequence homologies between cofilin and gelsolin. The actin-binding peptide of cofilin has been found to compete with gelsolin segment S2 for binding to actin, suggesting that they share a binding site on the actin filament (Van Troys et al. 1997). Interaction with gelsolin induces conformational changes in actin, and nucleation of actin polymerisation may be promoted by these conformational changes (Khaitlina and Hinssen, 1997).
GELSOLIN
IN
EMBRYONIC DEVELOPMENT
AND
MORPHOGENESIS
Gelsolin and related proteins have been shown to be actively involved in normal embryonic development and morphogenesis as well as in pathogenesis of diseases such as amyloidosis and cancer. The gelsolin gene has been mapped to the chromosome 17p11.2 region, which is a critical region deleted in SMS which encompasses short stature, brachydactyly, dysmorphic features, retarded development, and behavioural problems. Gelsolin may also participate in the process of programmed cell death or apoptosis. Gelsolin shows a definable pattern of expression in the developing CNS. It is found predominantly in oligodendrocytes and Schwann cells. It is also found in the myelin sheath. In oligodendrocytes, gelsolin is found in the soma and in cultured cells it is detectable in the branched cell processes (Lena et al. 1994). The protein is detectable in the brain of newborn rats. The expression of gelsolin gradually increases at 8 to 10 days after birth, reaching a maximum at 20 to 30 days when myelin formation is actively occurring. However, subsequently, its levels decrease even though myelin basic protein levels continue to rise until 6 months after birth. In Schwann cells gelsolin is found in the cytoplasm and in compact myelin (J. Tanaka and Sobue, 1994). It would appear therefore that gelsolin may be involved in the wrapping of myelin sheaths around the axons by promoting a process of motility generated by means of its effects on the cytoskeleton (J. Tanaka and Sobue, 1994; Lena et al. 1994). The gelsolin-like protein, fragmin, which has been isolated from Physarum, has been shown to interact with actin in a Ca2+-dependent fashion, when introduced into PtK2, CV1, and NIH3T3 cells. This has been reported to cause cytoskeletal disruption and bring about changes in cellular morphology (Constantin
42
Calcium Signalling in Cancer
et al. 1998). Fibroblast migration has been found to be dependent on the actinsevering activity of gelsolin (P.D. Arora and McCulloch, 1996). Furthermore, gelsolin has been implicated in cytoskeleton-mediated transduction of EGF signal and EGF-induced cell motility (P. Chen et al. 1996). The Drosophila melanogaster flightless-I gene product is a gelsolin-like protein that is also involved in embryonic development and in the structural organisation of the indirect flight muscle. However, it should be pointed out that gelsolin-null transgenic mice appear to develop normally, albeit associated with certain abnormalities such as prolongation of bleeding time caused by abnormalities of platelet shape, and also inhibition of neutrophil migration. The transgenic mice also show increased stress fibre formation in dermal fibroblasts together with reduced motility and increased contractility (Witke et al. 1995).
GELSOLIN EXPRESSION
IN
AMYLOIDOSIS
The strong association of gelsolin with CNS components has initiated studies of possible alterations in its expression in CNS-associated abnormalities. CNS abnormalities in patients with familial amyloidosis may conceivably be related to gelsolin expression (Kiura et al. 1995). Paunio et al. (1997) recently measured the mRNA levels of both intracellular and secreted gelsolin isoforms in tissues of human subjects. Intracellular gelsolin mRNA has been found to be a major component in all tissues. Most adult tissues can show mRNAs of both isoforms, with muscle and skin tissues showing especially high levels of expression. The high levels of skin gelsolin may be related to skin amyloidosis. The levels of expression may differ between adult and infant tissues. Patients with gelsolin-related amyloidosis had higher serum levels of gelsolin but did not show increased gene expression.
GELSOLIN
IN
CANCER
A major feature of cancer development is the perceived derangement of the cell signalling system and the inappropriate acquisition of cell motility. The process of actin filament severing and capping brings in its wake alterations in cellular motility. The involvement of gelsolin in the remodelling of the cytoskeleton has naturally led to the investigation of the expression and possible involvement of gelsolin and related proteins in cancer development and progression. Neoplastic transformation alters cell behaviour, morphology, and pattern of growth. These changes are indeed attributable to the loss of stress fibres and focal adhesion. Accompanying cell transformation, modulation of the expression of cytoskeleton-associated proteins is observed, and among them is gelsolin. Van de Kerckhove et al. (1990) showed some time ago that gelsolin expression is down-regulated in transformed human fibroblasts and epithelial cells. Transformed cells also show a down-regulation of tropomyosin. Upon restoration of tropomyosin status, cells return to the normal modes of spreading and organisation of stress fibres. These events are far from being coincidental, for the higher molecular weight forms of tropomyosin appear to protect actin filaments from the severing activity of gelsolin (Matsumura et al. 1985; Ishikawa et al. 1989a).
Non-EF-Hand Calcium Binding Proteins
43
Although only a few studies have been carried out to date, gelsolin appears to be consistently down-regulated in cancers. Moriya et al. (1994) found that gelsolin expression was down-regulated in several tissue culture cell lines derived from human gastric carcinomas. Gelsolin levels were found to be markedly reduced in human breast cancer cell lines as compared with normal breast epithelial cells and cell lines derived from benign breast diseases. Gelsolin loss was also found in 70% of 30 sporadic invasive breast carcinomas as well as in all chemically induced murine and rat mammary tumours (Asch et al. 1996). In human transitional cell bladder carcinoma cell lines as well as tumour tissues (14 out of 18 samples) gelsolin was not detectable or detectable only at low levels compared with normal bladder epithelium (M. Tanaka et al. 1995). M. Tanaka et al. (1995) also transfected gelsolin cDNA into the human bladder cancer cell line UMUC-2. The transfectants showed a greatly reduced colony forming ability as well as tumorigenicity. One can see from these studies the emergence of the concept of tumour suppression by gelsolin. However, it is paradoxical that gelsolin on the one hand can enhance cellular motility and on the other suppress tumorigenicity. Tumorigenicity and cellular motility can be dissociated temporally, and therefore one can envisage a situation where the loss of gelsolin could lead to tumour development and be involved in a positive way at a later stage of tumour progression by conferring invasive properties on tumour cells by altering cytoskeletal dynamics. There is little doubt that this is a fruitful avenue to explore. One needs to investigate the pattern of gelsolin alteration at various stages of tumour progression. The colon carcinoma model immediately comes to mind. The progression of colon carcinoma has been described in clearly identifiable phenotypic phases, and there is considerable evidence that different genetic changes are associated with the different phases of progression and that the development of carcinoma is a cumulative effect of these genetic alterations (Sherbet and Lakshmi, 1997b). It would be interesting to see whether alterations of gelsolin or related gene alterations have a place in this picture. There is also the need to glean more information about the intracellular localisation of these proteins in the context of the alterations in cytoskeletal dynamics occurring in proliferating and transformed cells. Other questions can be raised. For example, are gelsolin and related proteins associated with cell proliferation and apoptosis? We have noted earlier that EGFinduced cell motility involves gelsolin. The alteration of cytoskeletal dynamics is an essential ingredient of cell proliferation. There is compelling evidence that other Ca2+-binding proteins such as the S100A4 (18A2/mts1), which also causes perturbation of cytoskeletal dynamics (Lakshmi et al. 1993), can control cell cycle progression by interfering with G1S and G2M checkpoint control exerted by the p53 suppressor gene and stathmin (Parker et al. 1994a, 1994b; Cajone and Sherbet, 2000). Therefore, if the gelsolin story is to be comprehended it is of the utmost importance to determine whether gelsolin is associated with cell proliferation. There are indications that gelsolin may indeed influence cell population dynamics by inhibiting apoptotic death of cells (Ohtsu et al. 1997).
44
Calcium Signalling in Cancer
SEVERIN
AND
CYTOSKELETAL REORGANISATION
Severin is a 40-kDa Ca2+-activated actin-binding protein that was isolated from the amoeba Dictyostelium discoideum, and of this, mammalian homologues have also been identified. Severin severs F-actin, nucleates actin assembly, and caps actin filaments. It is a gelsolin-related protein and shares sequence homology with gelsolin and profilin in certain conserved functional domains that are involved with actin interaction (Schnuchel et al. 1995). Severin possesses two actin-binding sites located next to each other, and these participate in both severing and nucleation functions. The third actinbinding site, situated near the N-terminus, suffices for the filament capping function (Eichinger et al. 1991). Eichinger et al. (1998) recovered a protein kinase from cytosolic extracts of D. discoideum. This kinase phosphorylates severin, but phosphorylation is reduced in the presence of calcium. Eichinger et al. (1998) have therefore suggested that phosphorylation might be another regulatory mechanism. Severin is known to alter rapidly the organisation of the cytoskeleton and as a consequence influence cell adhesion to the substratum, pseudopodial activity, and cell motility. Early work had suggested that mutants deficient in severin did not affect the motility of Dictyostelium (Andre et al. 1989). But Schindl et al. (1995), who studied mutants that were deficient in severin, found the protrusion of pseudopodia was slower and the pseudopodia were shorter in the mutants. As noted in the previous section, the loss of gelsolin has been associated by some with cell motility, especially in neoplastic transformation. Folger et al. (1999) have reported that severin replaces gelsolin in murine Lewis lung carcinoma (LL2) cells. No severin is detected in normal epithelial lung tissue, but gelsolin is expressed at high levels. Folger et al. (1999) suggested tentatively that severin takes over from gelsolin the function of actin fragmentation in transformed cells. In light of the paradoxical effects of gelsolin of suppressing tumorigenicity on the one hand, and stimulating invasive behaviour on the other, further work on the expression of gelsolin and severin in a temporal relationship to tumour progression seems warranted.
VILLIN
IN
DIFFERENTIATION
AND
NEOPLASIA
Villin is another actin-binding protein that shows sequence homology with gelsolin with respect to certain conserved sites involved in actin-binding. It occurs in intestinal and kidney brush border epithelia. Villin is known to take part in actin bundling, nucleation, filament capping, and severing in a Ca2+-dependent manner, in vitro. Villin cDNA has been transfected into cells that do not synthesise the protein, and it has been found that this induces the growth of microvilli and the reorganisation of the submembranous actin cytoskeleton of the transfectant cells. This process is inhibited by cytochalasin (Friederich et al. 1993). Friederich et al. (1999) have provided further experimental evidence for the involvement of villin in actin bundling. Villin not only induces the growth of microvilli, but also in parallel induces actin bundling. This actin bundling ability seems to depend on the KKEK motif
Non-EF-Hand Calcium Binding Proteins
45
occurring at the C-terminal end of the F-actin-binding site. However, some uncertainty about these events has arisen with the report by Ferrary et al. (1999) that in villin-null mice there is no disruption or disorganisation of microvilli, nor are there any changes noticed in the localisation of actin-binding and membrane proteins of the intestinal brush border in these null animals. Nevertheless, because the expression of villin appears to be a marker of differentiation, it has been investigated as a potential marker of tumour progression. Villin has been employed as a means of differentiating between primary pulmonary adenocarcinomas and pulmonary metastases of neoplasms of the bronchial or digestive tract. Nambu et al. (1998) examined 57 primary pulmonary adenocarcinomas for villin expression and found that 31% of the cancers expressed villin. Of the positives, 10.5% showed a diffuse cytoplasmic distribution of villin and 21% showed cytoplasmic distribution with minor brush border staining for villin. In contrast, metastatic lung tumours showed mainly primary brush border localisation that is characteristic of villin. The findings of J.Y. Tan et al. (1998) are similar. These authors found that villin, together with cytokeratin 7 and 20, is useful in differentiating between primary pulmonary adenocarcinomas and pulmonary metastases of colon carcinomas. Villin is expressed in Barrett’s metaplasia as well as in Barrett’s adenocarcinoma. According to Regalado et al. (1998), all metaplasias and 93% (30) of adenocarcinomas were villin positive. Furthermore, Northern analyses revealed the presence of both 3.5- and 2.7-kb villin mRNAs. Thus, overall, villin seems to be expressed in most adenocarcinomas, metaplasias, as well as other oesophageal tumours. Villin also has been investigated as a possible marker of neuroendocrine tumours of the gastrointestinal tract and also of hepatic tumours (P.J. Zhang et al. 1997; Velazquez et al. 1998), but definitive reports of these studies have not been published. Another actin-regulatory protein called Cap G, which belongs to the gelsolin family, has been investigated somewhat superficially. Cap G is an actin-capping but not -severing protein. The Cap G gene is located on the short arm of chromosome 2 and consists of ten exons and nine introns. The open reading frame has nine exons and eight introns (Mishra et al. 1994). Van Ginkel et al. (1998) found that this gene is differentially expressed between normal uveal melanocytes and uveal melanomas and cell lines derived from these tumours. In summary, there seems to be ample evidence that villin gene function is involved in the organisation of the brush border cytoskeletal assembly and in the formation of microvilli. Therefore, the use of this protein as an indicator of brush border differentiation, with an implicit relationship to neoplastic transformation, seems fully justified. However, as a marker, villin will need to perform more stringently and with greater specificity than merely providing a means of differentiating between primary tumour of the lung and tumours metastatic to the lung. There is much scope for combining villin expression with other proteins such as ezrin and moesin, which link the plasma membrane with the cytoskeleton. These proteins not only localise with the actin cytoskeleton, but they are also specifically associated with the formation of microvilli and membrane ruffles.
46
Calcium Signalling in Cancer
CALRETICULIN AND ITS FUNCTIONAL DIVERSITY STRUCTURE
AND
MOLECULAR FEATURES
OF
CALRETICULIN
Two types of CBPs are associated with the endoplasmic reticulum (ER), namely reticulocalbin (an EF-hand CBP whose localisation and function are discussed in Chapter 12 and calreticulin). Calreticulin is a non-EF-hand CBP that is ubiquitously associated with the ER of a variety of tissues. It is regarded as the nonmuscle equivalent of calsequestrin, which is associated with the sarcoplasmic reticulum (SR). Calreticulin, which was identified as a CBP and isolated from SR (Ostwald and MacLennan, 1974), is believed to be a homologue of calnexin, which is a 64kDa transmembrane protein (Hammond and Helenius, 1995). It is a highly conserved protein. Calreticulin obtained from rat liver has a molecular size of 60 kDa. In some cell-free systems a 62-kDa protein has been detected, which is probably processed into 60-kDa calreticulin (Denning et al. 1997). Hershberger and Tuan (1998) have cloned a full-length cDNA for calreticulin from mouse trophoblast coding for a 57kDa protein showing a high degree of sequence homology to calreticulin. Yamamoto and Nakamura (1996) isolated and sequenced the ER-associated calnexin from Rana rugosa, which shared 77% sequence homology with calreticulin. Two distinct isoforms of calretinin have been isolated from spinach leaves and from the pollen of Liriodendron tulipifera L. and Ginkgo biloba L. (Navazio et al. 1995, 1998; Nardi et al. 1998). These are reported to show very low sequence homology with animal calreticulin. However, maize calreticulin is said to be a 48-kDa protein (as deduced from its cDNA sequence), highly acidic in nature, sharing 77 to 92% sequence homology with other plant calreticulins, and have approximately 50% homology with animal calreticulin (Dresselhaus et al. 1996). Calreticulin consists of 400 amino acid residues. It has three distinct domains: an N-terminal domain containing 180 amino acid residues, a C-terminal domain with acidic residues and lysines, and a middle domain (P-domain) that is composed of three repeats of a 17 amino acid motif. The C-domain binds calcium with high capacity but low affinity. In contrast, the P-domain binds calcium with low capacity but high affinity. Overall, calreticulin may be seen as a high-capacity but low-affinity CBP. The mouse calreticulin gene spans 4.2 kbp of genomic DNA and contains nine exons and eight introns (Waser et al. 1997). In the mouse the gene is located on chromosome 8 (Rooke et al. 1997). It should be pointed out here that P. Lin et al. (1998) state that nucleobindin, a mammalian protein showing a high degree of homology to calreticulin, is an EF-hand CBP. This protein is found in the cytosol and is associated with membranes, in the latter case mainly with the luminal surface of Golgi membranes.
REGULATION
OF
CALRETICULIN EXPRESSION
The expression of calreticulin appears to be regulated by intracellular calcium levels. The promoter region of the calreticulin gene contains elements responsive to the calcium ionophore A23187 and to agents such as thapsigargin, which can raise intracellular calcium levels by releasing calcium from intracellular stores. Both A23187 and thapsigargin have been shown to increase transcription of the calreticulin gene. It is not
Non-EF-Hand Calcium Binding Proteins
47
affected by changes in extracellular or cytoplasmic levels of calcium. This has led to the suggestion that loss of calcium levels in the intracellular stores could induce gene transcription (Waser et al. 1997). Calreticulin gene expression is also up-regulated by other stimuli such as heat shock and heavy metals like zinc and cadmium (Nguyen et al. 1996; Szewczenko-Pawlikowski et al. 1997). A number of heavy metal ions, e.g., Ni2+, Zn2+, Cu2+, and La3+, stimulate the release of calcium from intracellular stores (McNulty and Taylor, 1999). Hyperthermia also raises intracellular calcium levels by calcium mobilisation from intracellular stores as well as by simulating its influx into the cell (Itagaki et al. 1998). Therefore, the up-regulation of calreticulin gene expression might, again, be mediated by the stress response of depletion of calcium held in the intracellular stores. This is in sharp contrast with the effects of hyperthermia and thapsigargin on the expression of S100A4. Both treatments have been shown to downregulate S100A4 expression (Parker and Sherbet, 1992; Albertazzi et al. 1998a). This might suggest a different mode of regulation from that of calreticulin. The thesis that the calreticulin gene is regulated by androgen has been advocated vigorously by N. Zhu et al. (1998). This is based on the finding that androgen ablation down-regulates and its restoration up-regulates both calreticulin mRNA and protein expression in the prostate. Calreticulin is expressed at higher levels in the prostate than in the seminal vesicle and other organs and muscle. The regulation by androgen occurs only in the prostate and seminal vesicles. In vitro, the induction of calreticulin by androgen is not inhibited by inhibitors of protein synthesis, hence the suggestion that the calreticulin gene might be regulated by androgen. Furthermore, in androgen-sensitive LNCaP prostate cancer cell lines, androgen is able to block apoptosis induced by the calcium ionophore A23187. This effect of androgen can be negated by antisense calreticulin oligonucleotides (N. Zhu et al. 1999).
PHOSPHORYLATION
OF
CALRETICULIN
Calreticulin phosphorylation occurs under different physiological conditions. However, it is unclear at present whether this is a physiological mechanism by which calreticulin activity is regulated. A phosphorylated form of calreticulin is detectable in cells infected with rubella virus (RV). It has been reported that the binding of phosphorylated calreticulin to the 3′-end of RV genomic RNA is necessary for initiating RNA replication (Singh et al. 1994). Phosphorylation is a requirement also in the binding of calreticulin to Leischmania donovani RNA (Joshi et al. 1996). Calreticulin from spinach leaves is phosphorylated by protein kinase (casein kinase) CK2, but those of animal origin are not substrates for this kinase. It appears that this is due to structural differences between the two types of calreticulin (Baldan et al. 1996). CK2 was identified as an ER-associated kinase involved in the phosphorylation of calreticulin (Ou et al. 1992). CK2 might be localised in the lumen of the ER (N.G. Chen et al. 1996). The in vitro phosphorylation of calreticulin and other proteins in plasma membrane-enriched fractions has been attributed also to other protein kinases susceptible to inhibition by the PKC inhibitor staurosporine (Droillard et al. 1997). CK2 also phosphorylates calnexin in vitro as well as in vivo. Serine residues that occur in the C-terminal half of the cytosolic domain of calnexin were exclusively phosphorylated (Wong et al. 1998). Sphingosine-dependent kinases
48
Calcium Signalling in Cancer
(SDKs) are another kinase variety that have been shown recently to phosphorylate calreticulin. SDK1 has been found specifically to phosphorylate calreticulin and protein disulphide isomerase (PDI) (Megidish et al. 1999). Heat shock proteins are also substrates of SDKs. Calreticulin, heat shock proteins, and PDI have a common function as molecular chaperones. Furthermore, calreticulin and PDI both occur in the ER. Therefore, these observations might be the closest researchers have come to suggesting a relationship between calreticulin function and phosphorylation. In spite of these various findings, how phosphorylation of these molecules regulates their participation in their apparently diverse physiological functions is yet to be elucidated. At present, no changes in the state of calreticulin phosphorylation have been found to correlate with a specific function. Furthermore, it has been suggested that calreticulin could occur in a constitutively phosphorylated form (Cala, 1999). This would deny the process of phosphorylation any regulatory control over calreticulin function. Nevertheless, the induction of apoptosis of HL-60 cells by geranylgeraniol has been shown to be accompanied by a decrease in calreticulin as well as a decrease in the phosphorylation of another protein of 36 kDa molecular size. These reductions occur prior to DNA fragmentation (Nakajo et al. 1996). The occurrence of these events in parallel suggests that calreticulin may influence the phosphorylation of the 36-kDa protein.
INTRACELLULAR DISTRIBUTION
OF
CALRETICULIN
As stated earlier, calreticulin shows a predominant association with the intracellular membrane system, the ER. The molecule contains KDEL/HDEL sequence at the Cterminal, which is the targeting signal for its localisation at the ER. Calreticulin occurs also in the SR and membranes of the Golgi bodies. In protoplasts of plants, it is localised in the ER (Opas et al. 1996b). In animal as well as in some plant cells, calreticulin is found in the lumen of the ER, nucleus, and nuclear membrane, on the surface of the cells, and in the cytoplasm (Opas et al. 1991; Dedhar, 1994; White et al. 1995; Dresselhaus et al. 1996).
CALRETICULIN
IN INTRACELLULAR
CALCIUM STORAGE
Calreticulin is prominently associated with the endoplasmic reticulum, as its nomenclature implies. Over the past few years, it has been found to participate in several biological phenomena. With its occurrence in the ER, calreticulin has been linked empirically with the cellular faculty of intracellular storage of calcium. This role has been confirmed by a variety of experimental data. There are several lines of evidence on this score. Using reporter gene constructs carrying the promoter of calreticulin gene, Waser et al. (1997) showed that the promoter can be transactivated by agents such as bradykinin and thapsigargin, which are known to release calcium held in intracellular stores. They have identified two regions of the promoter that are responsive to thapsigargin as well as the calcium ionophore A23187. Furthermore, both these agents have been shown to be able to enhance the transcription of calreticulin gene in NIH3T3 cells.
Non-EF-Hand Calcium Binding Proteins
49
Mery et al. (1996) transfected a mouse fibroblast cell line with an expression vector carrying a calreticulin cDNA insert. In the transfectant cells, a 1.6-fold overexpression of calreticulin was found, and concurrently, intracellular calcium levels rose to nearly two-fold. Furthermore, most of this calcium originated from intracellular stores, as indicated by thapsigargin sensitivity. A study of the intracellular distribution of calreticulin in motor neurones of rat spinal cord has revealed that it is localised not only in the ER but also in “coated” vesicles (Copray et al. 1996). Copray et al. (1996) suggested that these vesicles may be counterparts of calciosomes, which are calcium storage vesicles found in liver cells and in cerebellar Purkinje cells. It ought to be pointed out, nonetheless, that Coppolino et al. (1996) found that the intracellular calcium stores were unaffected in cells in which the calreticulin gene had been knocked out.
CALRETICULIN
AND
CALNEXIN
AS
MOLECULAR CHAPERONES
A second function attributed to calreticulin is that of a molecular chaperone. The assembly of the T-cell antigen receptor (TCR) complex involves several genes, including calreticulin. Calnexin, which shares considerable sequence homology with calreticulin, is known to be involved with the chaperoning of newly synthesised TCR proteins. Similarly, calreticulin seems to be involved in the chaperoning of nascent TCR-α and -β proteins (Van Leeuwen and Kearse, 1996). Indeed, on the one hand, both calnexin and calreticulin seem to bind to and promote correct folding of proteins. They prevent aggregation, delay oligomerisation, and suppress degradation (Herbert et al. 1996). On the other hand, they possess the ability to bind to glycoproteins of the ER. Calnexin was shown to interact with and be involved in the assembly of class I MHC (major histocompatibility complex) molecules (Degen and Williams, 1991). Calreticulin has also been shown to interact with class I MHC molecules and probably with greater specificity than calnexin (Zhang and Salter, 1998; Harris et al. 1998). Both calnexin and calreticulin are lectin-like proteins and are able to interact with newly synthesised glycoproteins that have been partially trimmed of the N-linked oligosaccharides and assist in their folding and assembly (Helenius et al. 1997; Zhang and Salter, 1998). Receptors for insulin and insulinlike growth factor (IGF)-1 are receptor tyrosine kinases that have to dimerise before they are exported to the ER. The receptor monomers form dimers through disulphide bonding, when the newly synthesised monomers are associated with calreticulin or calnexin (Bass et al. 1998). Some of these studies implicate oligosaccharide-dependent binding to calnexin and calreticulin in a direct way in protein folding, assembly, and secretion. However, there are instances in which a lack of binding to these proteins has been of little consequence. It is possible that the chaperoning function of calreticulin might have implications for gene function. Calreticulin-deficient cells show an inability to import transcription factors belonging to the NF-AT (nuclear factor of activated T cells) family into the nucleus (Mesaeli et al. 1999). This could be a reflection of the part played by calreticulin-mediated chaperoning of the transcription factors. The NFAT transcription factors are substrates for calcineurin, and thus calreticulin might indirectly influence the expression of genes regulated by these factors. (See Figure
50
Calcium Signalling in Cancer
19.) This view is compatible with the intracellular distribution of calreticulin. An overall increase in the levels of calreticulin has often been associated with cancers. Yoon et al. (2000) have reported that the total calreticulin content of hepatocellular carcinomas is similar to that of corresponding normal tissues, but carcinomas differ from normal tissues in their intracellular distribution. Calreticulin occurs more abundantly in the nuclear matrix of hepatocellular carcinomas as compared with controls. Whether this might reflect an enhanced transport of substances such as transcription factors into the nucleus of cancer cells is an interesting subject for speculation. Such altered chaperoning of materials into the nucleus could greatly alter the pattern of gene expression.
CALRETICULIN
IN
CELL PROLIFERATION
AND
DIFFERENTIATION
There is very little evidence at present that calreticulin is involved in cell proliferation and differentiation. A retinoblastoma susceptibility (rb) regulatory element has been identified in the promoter region of the calreticulin gene (Valente et al. 1996). The rb gene is a negative regulator of cell cycle progression (see Sherbet and Lakshmi, 1997b). This observation provides some basis for implicating the calreticulin gene in cell proliferation. Dresselhaus et al. (1996) found an enhancement in the expression of calreticulin cDNA in the maize zygote during cell division. It has also been reported that calreticulin reduces intimal hyperplasia following arterial injury (Dai et al. 1997). There is considerably more information with regard to the involvement of calreticulin in cell adhesion and morphology, which, by implication, may be deemed to support the view that it might influence also cell proliferation. However, its expression has been related to differentiation in NG108-15 neuroblastoma/glioma hybrid cells (N. Liu et al. 1996; Johnson et al. 1998). Higher levels of calreticulin expression were observed in these cells, when induced to differentiate by exposure to dibutyryl cAMP (db-cAMP). Although there could be a true effect on cell proliferation, calreticulin, in general, does not seem to affect the proliferative capacity of the cell. However, cell numbers might increase merely by the ability of calreticulin to protect cells from apoptosis (see below).
CALRETICULIN
IN
CELL ADHESION
Two other examples of the physiological involvement of calreticulin are in the process of cell adhesion and cell spreading and in disease states engendered by autoimmune conditions. The influence exerted by calreticulin on cell adhesion to substratum was appreciated from early experiments of White et al. (1995). They demonstrated that anticalreticulin antibodies inhibited the binding of murine B16 melanoma cells to a substratum covered with laminin. They also showed the antibodies bound to the cell surface. The interaction of cells with the substratum also appeared to involve mannoside residues. Further, cell spreading could be inhibited by adding purified calreticulin to the medium, which presumably competed with cell surface calreticulin and denied the cells interactive binding with the substratum. Incidentally, this also confirms the lectin-like properties of calreticulin.
Non-EF-Hand Calcium Binding Proteins
51
An exciting avenue has opened in the continued search for potential functions of calreticulin. It seems to possess the ability to influence cell adhesion mediated by integrins. The walk along this avenue is exciting because integrins are a class of transmembrane heterodimeric glycoproteins that function as receptors for adhesion mediating macromolecules. The integrin family of cell surface receptors has been extensively studied and it has been established that their mediation of signal transduction as well as cell adhesion is accomplished by linking up with the cytoskeletal machinery. Vinculin, α-actinin, and talin provide the linkage to the actin cytoskeleton. This involves a specific interlinking of the three proteins as follows: integrin/talin/vinculin:α-actinin/actin. There is considerable evidence that adhesiondependent phenomena such as invasion and metastatic deposition are modulated by macromolecules that make up the extracellular matrix (Sherbet, 1982, 1987; Sherbet and Lakshmi, 1997b). In the first place, there is much evidence that implicates integrins in the modulation of cell adhesion by calreticulin. Embryonic stem (ES) cells from calreticulin knock-out mice, which are deficient in calreticulin, and fibroblasts derived from calretinin mutant mice have been reported to show severe reductions in integrinmediated cell adhesion. Transfecting ES cells with calreticulin cDNA restored this faculty (Coppolino et al. 1997). The cytoplasmic domain of the α subunit of integrins contains the amino acid sequence KXGFFKR to which calreticulin is known to bind (Shago et al. 1997). Cell adhesion is modulated by a mechanism in which the expression of the linking proteins is regulated. Overexpression of calreticulin in Lfibroblasts is accompanied by increased cell–substratum and cell–cell adhesion, and this overexpression also enhances cell spreading and decreases motility. Fibroblast cells overexpressing calreticulin also overexpress vinculin protein as well as its mRNA, and reduced levels of vinculin correlate with a down-regulation of calreticulin expression (Opas et al. 1996a). It is intriguing to note that another link in the system, namely talin, is unaffected by calreticulin overexpression. Nevertheless, calreticulin does not seem to affect the expression of α-catenin. The latter reputedly links other CBPs such as cadherin to the cytoskeleton (Sherbet and Lakshmi, 1997a, 1997b). Shago et al. (1997) have shown that calreticulin can interfere with signal transduction mediated by retinoic acid receptors that contain an amino acid sequence similar to that found in the α subunit of integrins. Retinoids are known to be able to inhibit invasive ability (Fazely and Ledinko, 1990). Furthermore, they can influence the flow of information from ligand binding to integrins. Therefore, this possible complication of the perceived events should be borne in mind when interpreting the effects of calreticulin overexpression on cell adhesion.
CALRETICULIN
IN
NEOPLASIA
Although the above discussion indicates a significant involvement of calreticulin in cell adhesion and possibly also in cell proliferation, only a few studies have dealt with its occurrence in tumours. Of the multiple functions attributed to calreticulin, its perceived effects on cell proliferation are the most relevant in relation to cancer. Calreticulin is one of several peptides of human breast cancers studied by Franzen et al. (1997). They state that it is expressed at higher levels in carcinomas than in
52
Calcium Signalling in Cancer
nonmalignant conditions of the breast, confirming an earlier study in which calreticulin expression in ductal carcinomas of the breast was compared with normal breast tissue (Bini et al. 1997). In the latter study, the enhancement of expression of calreticulin, and a number of other peptides, appeared to be specific for epithelial neoplasms. It would be premature to speculate on the nature of these correlative observations, but it has been suggested that calreticulin might control tumour progression by initiating a loss of apoptotic potential in tumours (Bruchovsky et al. 1996). Calreticulin levels increased in NG 108-15 neuroblastoma/glioma hybrid cells when induced to differentiate by treatment with db-cAMP (Johnson et al. 1998). Interestingly, however, antisense oligonucleotides for calreticulin do induce cell death in undifferentiated cells but not in differentiated cells. When the apoptotic pathway is experimentally induced in HL-69 cells by exposing them to geranylgeraniol, the expression of calreticulin is inhibited (Nakajo et al. 1996). Similarly, antisense calreticulin oligonucleotides seem to protect prostate cancer cell lines from calcium ionophore A23187-induced apoptosis. In this experimental system both androgen and calreticulin seem to be involved in the control of apoptotic events. A23187 induces apoptosis in both LNCaP and PC-3 cells. However, androgen is able to block apoptosis only in the androgen-sensitive LNCaP cells and not in the androgeninsensitive PC-3 cells. Furthermore, the inhibition of apoptosis of LNCaP cells by androgen is reversible by antisense calreticulin oligonucleotides (Zhu and Wang, 1999). One should recall here that in experimentally induced apoptosis of HL-60 cells, changes were also found in another protein species together with a downregulation of calreticulin expression (Nakajo et al. 1996). There was a decrease in the phosphorylation of a 36-kDa protein species. Thus it might be premature to link loss of calreticulin expression exclusively with apoptosis. Nevertheless, these observations suggest that calreticulin might protect cells against apoptosis. It is possible that deregulation of apoptosis is involved in both the growth of primary tumours as well as their metastatic deposits. Deregulation of growth control as well as inhibition of apoptosis can lead to cell population expansion in tumours. The phenomenon of metastatic dormancy may imply that cell mass is maintained by apoptosis-mediated regulation. Protection of cells from apoptotic death may lead to the appearance of overt metastasis. Most of these arguments are speculative. It would be interesting to see how the apoptosis regulating genes are affected by calreticulin expression.
IMMUNOLOGICAL IMPLICATIONS
OF
CALRETICULIN FUNCTION
Calreticulin has been implicated in the pathogenesis of some autoimmune disease conditions. In systemic lupus erythematosus (SLE), calreticulin might support the formation of the Ro/SS-A autoantigen complex (reviewed by Eggleton et al. 1997), and this could be related to its response to heat shock and stress factors. An interesting aspect of calreticulin in autoimmune diseases that has recently come to light is the amino acid sequence identity between calreticulin and the C1q receptor (Malhotra et al. 1993). C1q is a subunit of the first component of complement C1. C1q recognises and binds to circulating immune complexes (N.R. Cooper, 1985). A consequence of this binding is that C1q is released from the complex (Sim
Non-EF-Hand Calcium Binding Proteins
53
et al. 1979). It can now interact with the surface receptors on the various types of blood cells and endothelial cells (Tenner and Cooper, 1981; Malhotra and Sim, 1989; Peerschke and Ghebrehiwet, 1987; Peerschke et al. 1993). The binding of C1q to the receptor elicits a variety of immunological responses. The binding site of C1q to the C1q receptor or calreticulin has been identified (Stuart et al. 1996). Calreticulin occurs predominantly in association with immune complexes and C1q in sera of patients with SLE (Kishore et al. 1997). Kishore et al. (1997) suggest that inflammatory episodes occurring in autoimmune conditions could be attributed to the release of calreticulin from leukocytes, leading to an antigenic reaction, and further by virtue of its identity with C1q receptor, to an interference with C1q-mediated inflammatory effects. It is unclear at present why calreticulin should function as an autoantigen, but one reason could be that some parasitic organisms contain proteins that possess partial sequence homology with calreticulin. The inhibition of expression of steroid hormone-regulated genes is one of the postulated functions of calreticulin. As Coppolino and Dedhar (1998) have stated, it is truly remarkable that a single protein can have such a diversity of function. Clearly more work needs to be done on the multiple functions attributed to this CBP. Calreticulin has been highly conserved in the evolutionary process. Its conservation in a structural sense is probably less stringent than its functional conservation in signal transduction involving Ca2+ as a second messenger. Also it should be pointed out that calreticulin may not be the only CBP with multiple functions. The S100 family protein S100A4 has been described to participate in a wide spectrum of functions (Sherbet and Lakshmi, 1997b, 1998).
CALSEQUESTRIN AND INTRACELLULAR CALCIUM STORAGE Calsequestrin is a high-capacity, low-affinity CBP and is the muscle equivalent of calreticulin. Like calreticulin, calsequestrin is associated with specialised regions of the SR and participates in intracellular calcium homeostasis. Its major function seems to be intraluminal calcium storage. When intracellular calcium channels are activated, calcium is released from the intracellular pools leading to increases in cytosolic calcium levels, and this is an important ingredient of sustained muscle contraction. The release of calcium requires the activation of ryanodine receptor/Ca2+ channels of SR (Berridge, 1993). These ion channels are formed by tetrameric complexes consisting of 565-kDa monomers of the ryanodine receptor (Sutko and Airey, 1996). Three isoforms of ryanodine receptor are known. The type I isoform is restricted to skeletal muscle and is involved in voltage-gated Ca2+ release. The distribution of types II and III is less restricted. Type II is the main mediator of Ca2+induced Ca2+ release in cardiac cells (Lai et al. 1988; Gianini et al. 1992). Ryanodine receptors resemble IP3 receptors, which are another mediator of Ca2+ release, both in respect of their structure and function (Sutko and Airey, 1996). The calsequestrin molecule binds to and releases 4 to 50 calcium ions. Calsequestrin must be linked with the ryanodine receptor/calcium release channel, and indeed a close physical relationship does exist between them (B.E. Murray and
54
Calcium Signalling in Cancer
Ohlendieck, 1998). The anchoring of calsequestrin to the SR has been found to involve a family of transmembrane proteins. One such transmembrane protein is triadin. Triadin seems to anchor calsequestrin to junctional regions of SR and couples it with the ryanodine receptor/Ca2+ release channel (W. Guo and Campbell, 1995). A 26-kDa protein identified by Mitchell et al. (1988) as a calsequestrin binding protein was purified and characterised by L.R. Jones et al. (1995). This protein, now called junctin, bears significant sequence homology to triadin and aspartyl β-hydroxylase. Junctin contains a transmembrane domain and a short N-terminal portion extending into the cytoplasm. But a major portion of this molecule extends into the lumen of the SR (L.R. Jones et al. 1995). Junctin is distributed with ryanodine receptors and calsequestrin in the SR, which suggests that it may also be involved in calcium release from intracellular stores. The binding interactions are attributed to specific amino acid motifs that occur in the luminal portion of both triadin and junctin. L. Zhang et al. (1997) have suggested that calsequestrin, junctin, and triadin might form a quaternary complex with the ryanodine receptor to achieve calcium release. It seems possible that calsequestrin might regulate the calcium release mechanism. This is suggested by the finding that in transgenic mice overexpressing calsequestrin, the expression of junctin, triadin, and ryanodine receptor is downregulated (L.R. Jones et al. 1998). Very little is known about the involvement of calsequestrin in pathogenesis. In a recent report the sera of some patients with ocular myesthenia gravis showed the presence of antibodies that react against calsequestrin (Gunji et al. 1998). This suggests that an autoimmune mechanism might be operating in the pathogenesis of this disease.
OSTEOCALCIN IN BONE METABOLISM AND OSTEOTROPISM OF CANCER THE BIOLOGY
OF
OSTEOCALCIN
Osteocalcin is a noncollagenous protein. It is the most abundant matrix protein of bone and dentine (Price, 1992). It is regarded as a marker of bone turnover and metabolism, where bone resorption and formation are coupled. Osteocalcin is synthesised exclusively by osteoblasts and secreted into the extracellular matrix (ECM) during bone mineralisation. It is released also during osteoclastic degradation. Therefore, it is considered to be a marker of bone formation when formation and resorption of bone are uncoupled (J.P. Brown et al. 1984; Delmas et al. 1985, 1986; R.H. Christenson, 1997). Osteocalcin expression in developing chick and rat embryos coincides with the onset of mineralisation of the bone and hence it is considered to play a role in this process (Hauschka et al. 1989). Osteocalcin functions as a chemoattractant for osteoblast progenitor cells (Mundy and Poser, 1983). Also, bone resorption is poor under conditions of osteocalcin deficiency (Lian et al. 1984). These observations have supported a role for osteocalcin in bone resorption. Metastatic spread to the bone might activate bone metabolism, and therefore osteocalcin has been investigated as a potential marker of metastatic progression in certain forms of cancer, such as breast cancer and carcinoma of the prostate, which tend to show osteotropic secondary spread. Osteocalcin has turned out to be a good marker for
Non-EF-Hand Calcium Binding Proteins
55
bone turnover in osteoporosis (Delmas et al. 1983; Eastell et al. 1993). Mutations of the gla protein, a member of the osteocalcin family of proteins, have been suggested as a causal factor in the autosomal recessive Keutel syndrome, which is characterised by abnormal calcification of the cartilage (Munroe et al. 1999).
CALCIUM-BINDING PROPERTIES
OF
OSTEOCALCIN
Osteocalcin is a non-EF-hand CBP and binds 10 Ca2+ per mole protein at pH 7.5. The binding is virtually halved when pH is lowered to 5.0 (Kobayashi et al. 1998). Kobayashi et al. (1998) produced, by proteolysis, peptides of less than 8 amino acids from the N- and C-terminal ends of osteocalcin. The middle fragment bound 4 to 5 Ca2+ per mole protein. A proline-rich segment and three γ-carboxyglutamic acid residues are believed to participate in calcium binding (Heizmann, 1996).
OSTEOCALCIN GENE STRUCTURE
AND
FUNCTION
The osteocalcin gene has been mapped to human chromosome 1q25–q31 (Barille et al. 1996). The gene is regulated developmentally and in a tissue-specific manner. The tissue-specific expression seems to be due to the fact that the osteocalcin promoter functions only in cells of the osteoblastic lineage. This is suggested by the work of Ko et al. (1996), who constructed a virus vector carrying the thymidine kinase (TK) gene under the control of osteocalcin promoter. When this vector was introduced into osteoblastic cells TK gene was expressed, but no expression was detected in NIH3T3 or in a cell line derived from a transitional cell carcinoma of the bladder. The regulation of the osteocalcin gene is mediated by several transcription factors. Sequences that can bind the general transcriptional promoter AP1 have been identified in the promoter region of the osteocalcin gene (Goldberg et al. 1996; Lian et al. 1996). Lian et al. (1996) have also described two highly conserved regulatory motifs, which are, somewhat surprisingly, reported to relate to the cell type-specific expression of osteocalcin, albeit being functional in osteoblastic as well as nonosteoblastic cell lines. The modulation of expression of osteocalcin from the proliferative state to the differentiated state accompanying mineralisation of the ECM involves the function of a silencer element. An osteonectin silencer element (OSE) has been identified in the human osteocalcin gene, constituting a 7-bp (+29 to +35) sequence TGGCCT of the first exon of the osteocalcin gene (Y.P. Li et al. 1995). In proliferating cells, OSE is activated by the binding of an OSE-binding protein (OSE-bp) and consequently osteocalcin is either not expressed or is found in very low levels. When OSE-bp expression is downregulated OSE is inactivated, which leads to enhanced osteocalcin expression and the onset of ECM mineralisation. A silencer element also occurs in the first intron of the rat osteocalcin gene. Mutation of this suppressor element seems to inactivate the suppressor function (Goto et al. 1996). Other genes such as Dix-5 and MsX-2 have been shown to regulate the expression of osteocalcin during osteoblast differentiation. Dix-5 is believed to repress osteocalcin gene transcription (Ryoo et al. 1997). Interestingly, there is an increase in the expression of Dix-5 with osteoblast differentiation, which suggests an important regulatory role for this gene in the control of ECM mineralisation.
56
Calcium Signalling in Cancer
Among other regulatory elements that have been identified is a short motif called the OSCARE-2. OSCARE-2 is reported to bind a number of proteins including AP1. Furthermore, this element appears to be able to bind also nuclear proteins that are induced by vitamin D3 (VD3; 1α, 25-dihydroxyvitamin D3) (Goldberg et al. 1996). As described below, VD3 receptor response elements have also been identified in the osteocalcin promoter region. This provides a molecular basis for the cooperation of VD3 and osteocalcin in the regulation of several processes such as calcium homeostasis, osteoblast differentiation, and cell proliferation and apoptosis.
REGULATION
OF
OSTEOCALCIN
BY
VITAMIN D3
Vitamin D3 (VD3) is an important regulator of calcium homeostasis. It plays a major role in bone mineralisation of type I collagen matrix, the transport of calcium and phosphate. VD3 influences several important biological processes such as cell differentiation, apoptosis, inhibition of cell proliferation, and cell signalling. It is known to suppress proliferation of T cells and their ability to produce cytokines. The function of VD3 is mediated by the VD3 receptor (VDR). VDR is a phosphoprotein transcription factor that functions in the form of a heterodimer with the retinoid X receptor (RXR). VD3 induces the formation of a heterodimeric complex between VDR and RXR (Carlsberg and Polly, 1998). VDR has a number of identifiable domains that participate in DNA binding, binding of the ligand, receptor dimerisation, and gene transactivation, as well as the C-terminal activation function (AF-2) domain required for co-factor interaction (reviewed by Issa et al. 1998). RXR seems to enhance the DNA-binding affinity of VDR as well as its specificity. VDR/RXR transcription factor regulates transcription of target genes by zinc finger-mediated DNA binding and protein–protein interaction. However, the RXR ligand 9-cis retinoic acid (RA) prevents RXR from forming heterodimers with VDR and promotes the formation of RXR–RXR homodimers. This effectively negates the transcription of VDR responsive genes. On the other hand, once VDR–RXR is generated, these seem to block the formation of RXR homodimers (Haussler et al. 1997). The genes that encode the major bone matrix proteins, namely, osteocalcin, osteopontin, and β3-integrin, are among the target genes activated by VDR. A VD response element (VDRE), which consists of hexanucleotide repeats with intervening trinucleotide spacers, has been identified in the promoter regions of these genes. VD3 induces the synthesis of osteocalcin by osteoblast cells in both in vitro and in vivo conditions (Price and Baukol, 1980). VD3 not only increases the transcription of the osteocalcin gene but also seems to increase the half-life of osteocalcin mRNA (Mosavin and Mellon, 1996). However, species differences might exist in VD3-induced osteocalcin expression. Transgenic mice carrying human osteocalcin gene do respond to VD3 and show increased serum levels of human osteocalcin, but there is no increase in the endogenous mouse osteocalcin. These species-specific differences are believed to be due to possible differences in the regulatory sequences of the mouse and human osteocalcin genes (Clemens et al. 1997; Sims et al. 1997).
Non-EF-Hand Calcium Binding Proteins
OSTEOCALCIN
IN
CELL PROLIFERATION
AND
57
DIFFERENTIATION
The osteocalcin gene is expressed in consonance with the inhibition of cell proliferation and the onset of cell differentiation and ECM mineralisation (Y.P. Li et al. 1995). VD3, as discussed above, induces osteocalcin expression, but on the other hand, it inhibits cell proliferation, apparently with the mediation of cdk inhibitors. M.J. Campbell et al. (1997) synthesised a number of VD3 analogues and demonstrated that these were capable of inhibiting proliferation of the prostate cancer cell lines LNCaP, PC-3, and DU145. The inhibition of cell proliferation was accompanied by an up-regulation of the expression of the cdk inhibitors p21waf1 and p27kip1. An up-regulation of p21waf1 expression has also been encountered in VD3-induced differentiation of human MG-63 osteosarcoma cells, and this has been shown to be independent of p53 function (Matsumoto et al. 1998). Therefore, these observations seem to define a direct and novel pathway of inhibition of cell cycle progression by VD3. Other hormones, such as thyroid hormones, that regulate the differentiation of osteoblasts also seem to function through the mediation of osteocalcin. Triiodothyronine (T3) has been found to inhibit the proliferation of the osteoblast-type MC3T3E1 cells and, in parallel, induce the expression of osteocalcin mRNA and protein and alkaline phosphatase activity (Varga et al. 1997; Luegmayr et al. 1998). Oestrogen has been reported to increase cell proliferation in the early stages of in vitro culture of osteoblasts derived from mouse bone marrow. The effects of oestrogen seem to involve the osteoblast-specific transcription factor osf2 (cbfa1) (SasakiIwaoka et al. 1999). Oestrogen increases the expression of osteocalcin, alkaline phosphatase, osteopontin, and transforming growth factor (TGF)β-1 as well as collagen type 1. Furthermore, exposure to oestrogen also increased the formation of bone nodules. Anti-oestrogens (Qu et al. 1998) blocked all these effects. Postmenopausal breast cancer patients treated with the anti-oestrogen tamoxifen have reduced (22%) levels of osteocalcin in serum (Marttunen et al. 1998). Fibronectin (FN) is a component of the ECM that has been implicated in several biological activities. Thus FN influences cell adhesion to substratum, spreading, and modulation of cell shape. It influences membrane ruffling and cell motility and also is associated with cell differentiation (Sherbet, 1987). The pattern of FN expression in osteoblast differentiation has attracted some attention. Although there is very little information about its role in vivo, there seems to be some correlation between the expression of FN and osteocalcin, in relation to the state of proliferation and differentiation in vitro. In the initial period of growth of osteoblasts, derived from foetal rat calvaria, on a collagen-coated substratum, a 50 to 70% reduction of FN occurs, but the expression of osteocalcin, osteonectin, and osteopontin is up-regulated severalfold (Lynch et al. 1995). Similarly, in chicken osteoblast cell cultures at 6 to 18 days, FN is associated with the cell membrane, but subsequently it remains associated with the ECM in a fibrillary form. Overall, FN increases in the early periods of cell culture and its levels are then maintained. In contrast, the major bone matrix ECM markers show increased expression with the onset of differentiation (Winnard et al. 1995). There is no suggestion, however, that these events are necessarily related,
58
Calcium Signalling in Cancer
beyond the recognition that collagen type I could be involved in the signal transduction pathway. Possibly, in the initial stages where it is bound to the membrane, FN could be mediating extracellular signals through the occupancy of its specific integrin receptors. The subsequent association with ECM in a fibrillary form is clearly a postsignalling event. This suggestion seems to be upheld by the experiments described by Moursi et al. (1996). These authors found that anti-FN antibodies inhibited the formation of bone-like nodules and the expression of osteocalcin and alkaline phosphatase genes. Generally compatible with this is the ability of VD3 to regulate FN expression at the transcriptional level. A VDRE has been identified in the FN gene (Polly et al. 1996). Interestingly, osteoblast differentiation requires more than the RGD domain of FN that is functional in cell adhesion. Certainly, the experiments of Moursi et al. (1996) indicate that FN regulates the differentiation of osteoblasts. There is now general acceptance that integrin receptors form an important link in the transduction of signals generated by ECM components (Sherbet and Lakshmi, 1997a). Integrin receptors are actively involved in the recognition of and interaction with ECM ligands occurring in the process of osteoblast differentiation (Uemura et al. 1997). The integrin α5β1 has been identified as the critical component in FN interaction with osteoblasts (Moursi et al. 1997). The murine MC 3T3 cell line responds to ascorbic acid treatment by synthesising a collagen matrix, and collagen type 1 ligand seems to be essential for the subsequent expression of osteoblast markers as well as the activation of the osteocalcin promoter element, OSE2. OSE2 is recognised by the osteoblast-specific transcription factor osf2 (also known as cbfa1, AML3, PEBP2, and alpha A). The latter is expressed only in osteoblastic cell lines, such as MG63, ROS 17/2.8, and MC3T3-E1, but not in cell lines of nonosteoblastic origin (Sasaki-Iwaoka et al. 1999). When the collagen type 1 receptor α2subunit is blocked, the binding of osf2 to OSE2 is also blocked, with consequent inhibition of transcription of the osteocalcin gene (Xiao et al. 1998). These experiments indicate the importance of the interaction between collagen type 1 and its integrin receptor for transduction of the signal that can elicit osteocalcin gene activation. Much effort needs to be directed toward a dissection of the pathway of signal transduction in order to provide the crucial evidence that can link these events in a coherent fashion. Intracellular adhesion as well as cell–substratum adhesion is determined by the components of the ECM. Their temporal and spatial expression is invariably associated with the alterations in the adhesive interactions, as well as changes in cell motility or migration on a substratum or invasive behaviour of cancers. The faculty of migration could be an important feature in bone resorption. Osteoclast precursors, for example, need to target sites of bone resorption and they do possess the ability of diapedesis across capillary endothelia. The modulation of certain ECM components such as FN, in conjunction with osteoblast differentiation and osteocalcin expression, has inevitably led to investigations of a potential association of osteocalcin with cell migration. Stringa et al. (1995) set up osteoblast cultures from 7day-old rat tibia fragments. They found that when the cells were exposed to parathyroid hormone they synthesised and secreted large amounts of osteocalcin
Non-EF-Hand Calcium Binding Proteins
59
together with collagen type III. The conditioned medium from these cultures stimulated the migration of EA HY-926 endothelial cells in vitro. Osteoblast cells obtained from rat calvaria adhere and show migratory behaviour upon plating on three-dimensional matrices. These migrating cells expressed osteocalcin as indicated by immunohistochemical staining (Attawia et al. 1995). TGFβ-1 mRNA expression in regenerating tissue in distraction osteogenesis is said to coincide with osteoblast migration and ECM mineralisation (Mehrara et al. 1999). However, there is also much evidence that TGFβ-1 can inhibit osteonectin expression. Hence, it is conceivable that, in this experimental model, this promotion of migration by TGFβ-1 could be an effect mediated by means other than involving osteocalcin. TGFβ-1 is a highly versatile cytokine that can elicit a wide-ranging cellular response. Not least among these is that it can induce the expression of S100A4 protein (Okada et al. 1997), which has itself been implicated in the induction of cell motility. The identity of the ECM component that might be instrumental in osteoblast migration is uncertain at present. The two major adhesion mediating glycoproteins FN and laminin both regulate adhesive interactions involving osteoblasts. As seen earlier, FN expression does vary with the state of cell proliferation and differentiation, but it has not been directly implicated in the motile behaviour of osteoblasts. Laminin, on the other hand, does seem to mediate the adhesion to substratum as well as migration of osteoclasts. There is also a suggestion that there might be some form of cooperative functioning of laminin and FN in osteoblast migration. It has been suggested, for instance, that FN might be secreted in response to laminin-2mediated adhesion (Colucci et al. 1996). This postulate needs to be tested further. There are a number of possibilities that can be tested, e.g., whether there is de novo synthesis of FN, whether there is a deletion of FN into the medium, whether there is a modulation in the expression of FN receptors, etc. But Colucci et al. (1996) have shown that osteocalcin induces the migration of osteoclasts on laminin-2- but not collagen-coated substratum. One could concede easily that osteocalcin can promote migration involving ECM components and their particular integrin receptors. However, it is unclear at present how one can envisage a physical mechanism that transduces the osteocalcin signal to the cytoskeletal machinery to bring about cell locomotion. Also relevant in this context is the question of whether other biological macromolecules, such as the cadherins, might be involved too. Cadherin has been studied extensively for its ability to suppress invasion by cancer cells and, indeed, it has often been described as an invasion suppressor gene. Now there is evidence that VD3 analogues up-regulate the expression of E-cadherin in prostate cancer cell lines (H.D. Campbell et al.1997). In osteoblastic cell lines, VD3 analogues up-regulate osteocalcin expression. It would be of much interest to examine the status of cadherin expression in osteoblasts and determine what effects VD3 exerts on cadherin. Besides its effects on cell motility, TGFβ is also a powerful modulator of growth and differentiation. TGFβ peptides are known to inhibit proliferation of a number of cell types. More than coincidental is that the mechanism by which TGFβ brings about growth inhibition involves cdk inhibitors, e.g., p27kip1 (see Sherbet and Lakshmi, 1997b for references). TGFβ isoforms subserve many functions, including bone turnover. Banerjee et al. (1996) found that TGFβ-1 down-regulated osteocalcin
60
Calcium Signalling in Cancer
expression in ROS 17/2.8 osteosarcoma cells. Similar effects have also been described in foetal mouse long bone cultures (Staal et al. 1998). Thus, although it would appear that TGFβ could be regulating bone metabolism by inhibiting osteocalcin expression, its effects on cell proliferation are achieved by a different route involving cyclin/cdks (Figure 9). This conclusion is supported by the suggestion made by J.H. Liu et al. (1999) that TGFβ might be inhibiting G1-S arrest partly by inactivating cyclin B/cdc2 kinase. TGFβ treatment results in the phosphorylation of the cdc2 component in the TGFβ receptor II–cyclin B2–cdc2 complex and downregulates its kinase activity. Despite this, it should be recognised that there is much obvious coordination in the functioning of osteocalcin, VD3, and TGFβ in the inhibition of cell proliferation and induction of cell differentiation.
FIGURE 9 A graphical illustration of how some of the functions of osteocalcin, VD3, and TGFβ overlap, and of the putative mechanisms involved. AP1, jun/fos transcription factor; cdk, cyclin-dependent protein kinase; FN; fibronectin; RA, retinoic acid; RXR, retinoid X receptor; TGFβ; transforming growth factor β; VD3; vitamin D3; VDR; VD3 receptor; VDRE; VD response element. (Based on references cited in the text.)
OSTEOTROPISM
OF
METASTATIC DISSEMINATION
Metastatic spread of cancer is a nonrandom process. The perceived organ specificity of metastasis can be attributed to a variety of factors intrinsic to the cancer cell as well as to the target organs (see Sherbet, 1982 for review). Metastatic spread to the bone is a common occurrence in certain forms of cancer. It has been argued often that bone metastases can activate the processes of bone metabolism. For that reason
Non-EF-Hand Calcium Binding Proteins
61
osteocalcin has been regarded as a potential surrogate method for detecting metastatic spread as well as for the purpose of monitoring the outcome of therapy on metastatic bone lesions. Several markers of bone metabolism have been employed in studies of this kind. Among those employed are osteocalcin, C-terminal peptide of type I procollagen (PICP), N-terminal peptide of type III procollagen (PIIINP), pyridinoline crosslinked C-terminal peptide of procollagen I (ICTP), and bone-specific alkaline phosphatase (BA-1p). Bloomqvist et al. (1996) found that ICTP and PICP levels correlated with that of osteocalcin, but not with urinary or serum calcium. All three markers correlated with the number of metastases detected by bone scans. The aminobisphosphonate ibandronate has marked osteoclast inhibitory activity and has been investigated as a treatment modality for metastatic bone disease and cancer-induced hypercalcemia. In combination with taxol/taxotere, ibandronate appears to be able to inhibit invasion of the bone by the human breast cancer cells MDA-MB231 (Magnetto et al. 1999) and the development of bone lesions in animals injected with myeloma cells (Dallas et al. 1999). Ibandronate markedly affects bone resorption in metastatic bone disease (Coleman et al. 1999). Osteocalcin, PICP, and BA-1p have been found to be reliable dose-dependent markers in a phase II clinical trial with ibandronate treatment of metastatic breast cancer. They were also found to be suitable for monitoring the effects of treatment of osteoporosis (Schlosser and Scigalla, 1997). However, Bombardieri et al. (1997) seem to disagree that any of these markers can replace bone scans. So far as prostate cancer is concerned, ICTP has been reported to reflect bone metastasis more accurately than other markers, including PSA (prostate-specific antigen). Osteocalcin showed no correlation with metastatic spread (Maeda et al. 1997). In another study, PICP and BA-1p were found to increase with progression as indicated by bone scans. A slight increase in osteocalcin was also reported in patients with remission of metastatic bone lesions, but not related to progression (Koizumi et al. 1995). Obviously more clinical trials are needed to arrive at any firm conclusions. This need is underlined by laboratory work on the differentiation of osteoblastic cells, using conditioned media of the human prostatic carcinoma PC-3 cells and cell extracts. The effects of the conditioned medium have been studied on two osteoblastic cell lines, namely, a primary cell line derived from foetal rat calvaria and a rat osteosarcoma cell line ROS 17/2.8. The conditioned medium inhibited bone nodule formation in both cell lines without affecting cell proliferation. The conditioned medium also inhibited osteocalcin mRNA but not that of osteopontin (Kido et al. 1997). These data suggest there might be other factors involved in the formation of bone metastasis. A development with much promise is the use of toxic gene therapy for cancer, with osteocalcin promoter for targeting the expression of the toxic gene in the treatment of tumours of osteoblastic lineage and metastatic tumours. Ko (1996) made an adenovirus construct with the TK gene under the control of an osteocalcin promoter (Ad-OC/TK). When this viral construct was introduced into cells of osteoblastic lineage, e.g., murine ROS cells and human MG-63 cells, the TK gene was expressed. In contrast, no TK expression occurred in nonosteoblastic cell lines. The addition of acyclovir (ACV) caused cell death in vitro. Similar growth inhibition
62
Calcium Signalling in Cancer
and cytotoxicity were encountered in vivo when the adenovirus construct was injected into murine ROS osteosarcoma followed by intraperitoneal injection of ACV. (Cheon et al. 1997) has extended its findings and has reported that the administration of the Ad-OC/TK construct coupled with methotrexate was highly efficacious in the treatment of osteosarcoma. Shirakawa et al. (1998) adopted this strategy in another experimental tumour model. They introduced ROS rat osteosarcoma cells into nude mice by intravenous route. These cells formed tumour nodules in the lung. They then injected the Ad-OC/TK construct into the tail vein with subsequent intraperitoneal ACV treatment. This treatment markedly reduced the number of tumour nodules in the lungs and significantly enhanced survival. Furthermore, the cell-type specificity of the functioning of this construct was also demonstrated by Shirakawa et al. (1998). They constructed the adenovirus vector with RSV (Rous sarcoma virus) promoter, rather than by osteocalcin promoter, and placed the E. coli β-galactosidase gene under its control. When this construct was used, there was no osteoblast-specific expression of the β-galactosidase gene, but it was expressed nonspecifically in lung parenchyma. This constitutes a rather elegant demonstration of cell-type-specific targeting of gene therapy coupled with cytotoxic drugs and certainly deserves further testing using experimental models of spontaneous metastasis.
5
The EF-Hand Calcium Binding Proteins
MOLECULAR ORGANISATION OF CALCIUM-BINDING EF-HAND PROTEINS The members of the EF-hand CBPs share a general structural feature of possessing variable numbers of domains that bind to Ca2+ with high specificity and affinity. The EF-hand structural motif was first reported from the crystal structure of carp parvalbumin (Kretsinger and Kockolds, 1973; Kretsinger, 1980). Specific structural features have been defined as being necessary for calcium binding. The EFhand consists of a consensus sequence of 12 amino acid residues in a helix–loop– helix configuration that can ligate Ca2+ (Linse and Forsen, 1995). The Kretsinger principle states that calcium binding is coordinated by five oxygen-containing amino acid residues and a conserved glycine residue, which causes the bending of the loop. The calcium-binding affinities of these proteins range from Kd 10–4 to 10–9 M, and this is dependent on the amino acid sequence of the EF-hand loop. EF-hand loops occur as a pair with antiparallel β-sheet interaction between the two loops. A high degree of cooperativity exists between calcium-binding loops (M. Zhang et al. 1995; Ames et al. 1995). The regulatory (sensor) and calcium buffer functions of EF-hand CBPs are closely related to the conformational reorganisation that occurs as a consequence of calcium binding. Conformational changes are essential for the regulatory function of EF-hand proteins, whereas for their calcium buffer function only a small conformational change appears to suffice (Ikura, 1996). A pair of EF-hands may form a globular domain and the domains within a protein may be functionally different, i.e., they may be either a regulatory domain or a buffer domain. Thus calmodulin has a regulatory domain at the Nand C-terminal regions of the protein. Troponin C and recoverin have an N-terminal regulatory domain and a C-terminal buffer or structural domain. In contrast, 9kDa calbindin has only one buffer domain at the N-terminal end. The regulatory domains undergo conformational changes upon binding to calcium and participate in the activation of target proteins (Ikura, 1996). The remarkable similarity in the genetic organisation of the genes coding for the EF-hand proteins has led to the formulation of an evolutionary profile of the EFhand protein family. As shown in Table 4, three classes of EF-hand proteins can be identified. Type I proteins include calmodulin, myosin light chains (MLCs), and spec I. The coding sequences of these are interrupted by five introns, of which four occur at identical sites. The type II proteins, the S100 and related proteins typically possess two EF-hands and the corresponding genes have two introns, one of them
63
64
Calcium Signalling in Cancer
TABLE 4 EF-Hand Calcium Binding Proteins and Their Genetic Characteristics Protein Class
Name
Number of EF Domains
Type I
Parvalbumin
3
Type II
Calmodulin Myosin light chains Centrin (caltractin) Spec I (sea urchin) S100 proteins
4 4 4 4 2
Type III
Calcyclin S100A8 (MRP-8, myeloidrelated protein) S100A9 (MRP-14) Calbindin, 9 kDa
2
Calbindin, 28 kDa
6
Calretinin
6
Genetic Organisation 5 introns interrupting EF-hand coding sequences
2 introns: one in the 5′ untranslated region and the other between the two EF-hand domains In S100A8/A9, one EF-hand occurs at each terminal region 2.5 kbp; 3 exons and 2 introns; exons 2 and 3 coding for EF-hand domains 10 introns; 7 within the EF-hand coding domains 8 introns; distribution coinciding with their distribution found in calbindin
Source: Based on Heizmann and Hunziker (1990) and Ikura (1996) and other references cited in the text.
in the 5′ untranslated region and the second separating the two coding domains. Type III proteins, such as the 28-kDa calbindin and calretinin, have six EF-hands. The corresponding genes have ten introns that occur with the EF-hand coding domain and they occur at identical sites in the 28-kDa calbindin and calretinin genes (see Heizmann and Hunziker, 1990 for a full review) (see Table 4). Kawasaki et al. (1998) have proposed a more elaborate classification of EF-hand CBPs based on the congruence of EF-hand domains. They have identified as many as 43 subfamilies on this basis. Of these, a group composed of 13 subfamilies is thought to have evolved and diversified, by gene duplication and fusion, from a progenitor domain. The remaining subfamilies do not show this probable evolutionary relationship and, indeed, some EF-hand CBPs do not appear to lend themselves to forming natural groups of subfamilies. The evolutionary relationship of EF-hand CBPs is also highlighted by the similarity that odd and even numbered domains of one protein show to the corresponding odd-and even-domains of another protein. Nonetheless, the framework for discussion adopted in the present work is based on the functional, rather than structural, homology of the CBPs.
The EF-Hand Calcium Binding Proteins
65
CALCIUM BINDING AND THE MOLECULAR CONFIGURATION OF CALCIUM-BINDING PROTEINS A characteristic feature of the binding of Ca2+ to CBPs is the conformational changes that these proteins undergo as a result. These changes in their molecular configuration have a significant impact on their function. The calcium-induced switch between active and inactive forms of target proteins is often a consequence of changes in molecular conformation. Ca2+ can induce conformational changes in both non-EFhand and EF-hand CBPs. Calcium-mediated modulation of conformational changes in actin figures prominently in actin dynamics. For instance, following calcium binding, actin seems to take a conformation that is conducive to strong binding with MLC (Avrova et al. 1998). The gelsolin family proteins are regulated by calcium, interact with actin, and induce conformational changes. These conformational changes seem to be essential in actin dynamics. Cross-linking of actin is mediated by actin-binding proteins such as fimbrin. The function of fimbrin itself is regulated by conformational changes induced by the binding of calcium ions to fimbrin. The EF-hand CBPs contain one to six EF-hand calcium-binding domains. The EF domain consists of a loop of 12 amino acid residues flanked by α-helical domains. Calcium binding to these domains brings about changes in the conformation of these domains, the major changes being the relative orientation of EF-hands. The EFhands open upon Ca2+ binding and assume a closed conformation state in the absence of Ca2+ (M.R. Nelson and Chazin, 1998). The open configuration is conducive to interaction with target proteins. However, CBPs might differ in the assumption of the closed position of EF-hands in the absence of Ca2+. Thus the C-terminal EFhand of CaM shows a closed position, whereas the C-terminal EF-hand of MLC would show a semi-open position. This would in effect mean a differential response of these proteins to the presence of calcium. In other words, the interaction of some CBPs with their target molecules might not be calcium sensitive. Sastry et al. (1998) have studied the three-dimensional structure of calcyclin and other EF-hand proteins such as calbindin D-9K (CBD9K) and reported the occurrence of major differences in the calcium-induced changes between these proteins. The flexibility and dynamics of the EF-hand are very much dependent on the amino acid sequence of the entire EF-hand (Malmendal et al. 1998). The degree as well as the nature of the various changes are probably characteristic of individual EF-hand proteins, as in the case of S100 proteins. Furthermore, a combination of changes might endow individual S100 proteins with specific functional properties. Conformational changes can affect protein function in many ways. For instance, the activation of calpains, which possess protease activity, seems to be a consequence of conformational changes in the molecule that result in the re-orientation of the protease domain to produce a functional active site of the enzyme (Hosfield et al. 1999). A classical example of the effects of another facet of molecular configuration is provided by CaM. The changes undergone by CaM seem to enable the protein to bind to a wide spectrum of target proteins and bring about their activation. Guanylate cyclase-activating protein (GCAP), on the other hand, seems to be inactivated by calcium binding to EF-hands 3 and 4. Mutations of EF-hand 3 suffice to inactivate
66
Calcium Signalling in Cancer
GCAP. Possibly, this suggests that calcium binding to EF-hand 4 is a secondary, albeit important, event. An intriguing example would be a CBP that at least putatively contains domains that are involved in diametrically opposed functions. Osteonectin is a prime example of this. Two subdomains have been identified in the osteonectin molecule, of which one is involved in the inhibition of endothelial cell proliferation and the other stimulates endothelial cell proliferation in vitro. In a similar fashion, osteonectin is able to exert differential effects on cell adhesion and spreading. Possibly, all these effects are regulated in a tissue-specific manner. The process of regulation could involve a mechanism in which molecular conformation might conceivably play a prominent part. One could postulate that changes in molecular configuration might change the relative orientation of one functional domain to the other. One can cite another example taken from the signal transduction system. As suggested in relation to osteonectin, conformational changes occurring upon Ca2+ binding might be linked closely with function. Only nonmuscle and cytoskeletal isoforms of α-actinin are capable of binding Ca2+, and only these isoforms are functional in the interaction with the cytoskeleton. This interaction is essential for successful signal transduction. Posttranslational changes of CBPs can influence calcium binding and in this way also influence molecular configuration and function. Several S100 proteins are modified at the posttranslational level. S100A8 and S100A9 are often found in the phosphorylated form. Phosphorylation can affect the functions of these proteins and can be a positive or negative regulator. It can influence the binding of Ca2+ and other ions and the configuration that molecules undergo as a consequence. These changes in molecular configuration are an essential feature of the process of target protein recognition. Phosphorylation can also target S100 proteins to specific subcompartments of the cell. For instance, S100A8 and S100A9 translocate to the cell membrane, following their phosphorylation (Guignard et al. 1996). Recoverin is myristoylated at its N-terminus. It has been suggested that this modification induces cooperative calcium binding. More precisely, calcium binding to EF-hand 3 of RCN is believed to produce reorientation of the molecule to enable EF-hand 2 to bind calcium. The myristoylation of recoverin might be involved functionally in the targeting of the molecule to the appropriate cellular compartment. Some CBPs might influence molecular changes in other CBPs merely by altering intracellular calcium homeostasis. It has been shown, for instance, that calretinin deficiency markedly alters intracellular calcium levels in calretinin-null Purkinje cells. As a result, calbindin D-28K (CBD) is saturated with calcium and undergoes conformational changes. Obviously, in this case calretinin functions as a calcium buffer and thereby influences or controls the molecular configuration and function of another CBP. Calcium binding also alters the quaternary structure and consequent oligomerisation of these molecules. Oligomerisation is essential for the binding of heat shock proteins to their targets and their oligomerisation is also known to be regulated by calcium. Such changes could alter the pattern of target recognition and in this way confer on S100 proteins the ability to interact with diverse target molecules and thus define the specificity of their function. Besides calcium, the biological functions of CBPs might be regulated by other divalent cations such as Zn2+ and Cu2+ (Heizmann
The EF-Hand Calcium Binding Proteins
67
and Cox, 1998). EF-hand proteins can bind other divalent ions such as Mg2+ and Zn2+. Indeed, a subgroup of S100 proteins that binds Zn2+ with high affinity has been identified. These bind two to four Zn2+ ions per protein monomer (Fohr et al. 1995; Fritz et al. 1998). As with Ca2+ binding, Zn2+ ion binding also occurs with much cooperativity. In S100A3, for instance, the binding of the first Zn2+ ion facilitates the binding of the second Zn2+ ion. This cooperative binding appears to be associated with and, indeed, requires structural reorganisation of the molecule (Fritz et al. 1998). Whether these conformational changes also have functional significance is still unclear. S100 proteins are known to form dimers readily in both intracellular and extracellular environments. Both homo- and heterodimers are formed by means of disulphide linkage, or the monomers may be held together by ionic bonds, depending on the environment and conditions. The relevance of the formation of dimers or tetrameric complexes to their function is yet uncertain, except probably in the case of S100A8 and S100A9. These are translocated from the cytosol to the plasma membrane. They seem to be able to form tetrameric complexes (A82/A92). Some recent work has brought to light the possibility that, at least in some CBPs, both Ca2+ and Zn2+ ions might be involved in the regulation of their function. For instance, the heterodimeric complexes of S100A8 and S100A9 bind arachidonic acid and transport it to its target site where it is metabolised. Kerkhoff et al. (1999c) have found that Ca2+ induces the binding of arachidonic acid by the S100A8/A9 complex, but this is reversed by Zn2+. This is an interesting joint functional involvement of these divalent cations, which contrasts with the demonstrations hitherto that they act on their own in bringing about changes in molecular configuration in the context of their function. Precise knowledge of the changes in conformation occurring here is still lacking. It would appear that S100A8 and S100A9 can form heterodimers in the absence of Ca2+. Possibly, Ca2+ induces a primary change in the molecular configuration of the constituent monomer to expose Zn2+-binding sites. In the wake of binding of the zinc ions a secondary molecular reorganisation could be occurring, which is incompatible, by reason of spatial constraint, with the continued association of arachidonic acid with the S100A8/A9 complex. It would be essential, therefore, to know the disposition of Zn2+-binding sites relative to the terminal calcium-binding EF-hand domains. Fritz et al. (1998) pointed out that Zn2+-binding cysteine residues are clustered in the C-terminal part of the S100A3 molecule that is said to be involved in the recognition of target proteins. Transcription factors recognise and bind to specific sequences in the promoter regions of genes, which initiates gene transcription. The binding of transcription factors to the DNA has been attributed to specific structural motifs that are present in the transcription factors. Many transcription factors possess Zn2+-binding domains in the form of protrusions and these are described as zinc fingers. The zinc finger motif binds to specific elements in the promoter. Zinc fingers, first identified in the transcription factor TFIIIA derived from Xenopus, are known to be present in a large family of proteins that includes the thyroid hormone receptor, vitamin D3 receptor, and retinoic acid receptors, among others. Four types of zinc finger motifs have been identified. The TFIIIA zinc finger is regarded as the classical type or the prototype, which binds one Zn2+ atom via two cysteine and two histidine
68
Calcium Signalling in Cancer
conserved residues and to DNA as a monomer with high affinity. The zinc atoms seem to stabilise the structure of the zinc finger (Miller et al. 1985; Berg, 1990). The TFIIIA shows dual specificity in that it binds to DNA (5S RNA gene) as well as to 5S RNA (Pelham and Brown, 1980). The second type of zinc finger motif occurs in the steroid/nuclear receptor. Here the zinc finger binds two Zn2+ atoms binding to four cysteine residues each, and these receptors bind to the DNA as a dimer (Hard et al. 1990; Schwabe and Rhodes, 1991). The third type of motif is found in retroviral proteins and is characterised by 2 cysteine, a histidine, and a cysteine residues (Summers et al. 1990). The GAL4-type zinc finger from yeast binds two Zn2+ atoms, with six cysteine ligands to each Zn2+ (Keegan et al. 1986; Tao and Coleman, 1990; Pan and Coleman, 1991). Fritz et al. (1998) found that S100A3 binds two Zn2+ atoms. Of these, one zinc atom bound four cysteines and the second one bound four cysteines and one histidine residue. There is therefore some similarity between S100A3 and the zinc finger organisation of GAL4 transcription factor. These observations underline the potential importance of Zn2+ binding and the related changes in the molecular configuration in the function of S100A3. Gribenko and Makhatadze (1998) have proposed an attractive model in which molecular properties are postulated to change dependent upon relative the concentrations of Ca2+ and Mg2+. Calcium binding may not produce conformational changes in some proteins. S100A7 (psoriasin) has been reported to show very little change in its conformation upon calcium binding (Brodersen et al. 1998), but there were earlier reports of significant changes in conformation of S100A7 upon binding of Ca2+, Zn2+, and Mg2+ (Vorum et al. 1996). It is possible that in this particular case Ca2+-mediated changes may not be functionally relevant.
THE STRUCTURE AND ORGANISATION OF S100 FAMILY GENES The members of the S100 gene family have a shared intron–exon organisation. S100β has three exons and two introns. The first exon codes for the 5′ untranslated region and the second and third exons each code for an EF-hand (Allore et al. 1990). Similarly, the S100A4 gene (h-mts1) has three exons interspersed with two introns. The first exon is a noncoding exon and exons 2 and 3 contain the coding sequences for the mts1 protein (Ambartsumian et al. 1995).
ALTERNATIVELY SPLICED VARIANTS OF S100A4 Ambartsumian et al. (1995) also reported the occurrence of a splice variant of the h-mts1 cDNA. In the generation of this variant, alternative splicing seems to have occurred within the 5′ untranslated region of the original cDNA transcript, and a second noncoding exon is inserted in the variant form. This insertion, nonetheless, retains the main open reading frame (ORF), without creating a new longer ORF. In a recent study of the expression of S100A4 (h-mts1) in carcinomas of the breast, Albertazzi et al. (1998c) discovered the presence of another variant form, which has been designated as h-mts1v. This variant is a shorter version of the original h-mts1
The EF-Hand Calcium Binding Proteins
69
message. They have deduced the molecular organisation of the h-mts1v by reverse transcriptase polymerase chain reaction (RT-PCR). These studies have suggested that a loss of exon 1 (1a as well as 1b) sequences corresponding to one or more primers used for PCR may have occurred in the variant cDNA. The organisation of the h-mts1 gene and that of the variant cDNA is presented in Figure 10. The only and striking difference is the loss of exon 1 (1a as well as 1b) in the shorter splice variant, which is present in the larger variant reported by Ambartsumian et al. (1995).
FIGURE 10 Molecular organisation of the h-mts1 (S100A4) and that of the variant h-mts1v cDNA. Exon 1 (1a and 1b) of h-mts1 is not translated. This is spliced out in h-mts1v. Exons 2 and 3 encode the protein. (From Albertazzi et al. 1998c.) Reprinted by permission of the publisher Mary Ann Liebert Inc.
FUNCTIONAL SIGNIFICANCE OF ALTERNATIVELY SPLICED ISOFORMS Alternative splicing of pre-mRNAs is a ubiquitous phenomenon in higher eukaryotes. However, the significance of the occurrence of splice variants is poorly understood. Alternative splicing has been regarded as a mechanism of regulation of gene function. Splice variants may have different functions and different intracellular locations, and may indeed subserve opposing functions (Sherbet and Lakshmi, 1997b). Alternative splicing of pre-mRNA can generate isoforms of biologically active molecules and of membrane receptors for extracellular ligands functioning as biological response modifiers (Gunthert et al. 1991; Kim and Yamada, 1997; Shi et al. 1994). This results in changes in the mode of function. Splicing out of the transmembrane domain of the IL-6 receptor appears to cause its deletion from the cell membrane (Horiuchi et al. 1994). The generation of splice variants of the kinases and phosphatases might be a common mechanism associated with the regulation of cell cycle progression. The PITSLRE protein kinases are members of the p34 (cdc2) kinase family, and are so named on the basis of the amino acid sequence of an important regulatory region. Several splice variant isoforms of the PITSLRE protein kinases have been described
70
Calcium Signalling in Cancer
(Xiang et al. 1994). They may be expressed differentially in different cell types and subserve different functions (Lahti et al. 1995). Similarly, the phosphatase cdc25B, which is involved with the function of the cyclin/cdk complex in cell cycle regulation, occurs in the form of several splice variants, which may be involved together with the wild-type phosphatase in the regulation of the cell cycle (Forrest et al. 1999). Another striking example is provided by the splice variants of annexin VI. Annexin VI has marked effects on cell proliferation. In A431 cells, it inhibits the mobilisation of Ca2+ induced by EGF. But this effect is produced only by the larger isoform. The shorter isoform does not affect Ca2+ mobilisation nor does it influence cell growth (Fleet et al. 1999). Alternative splicing could also generate protein isoforms that may be unable to interact with target proteins or, as in alternatively spliced p53, to bind to DNA (Bayle et al. 1995). Possibly, the 5′ region is most prone to splice modification, and the stability and translation efficiency could be affected in these splice variants (N. Roy et al. 1992; Bingham et al. 1988). There is the further possibility that the 5′ untranslated region may have a role in the regulation of the mRNA translation, as demonstrated for the alternatively spliced variants of the muscle-specific enolase gene (Oliva et al. 1995). On similar lines, the noncoding exons 1 and 2 of the angiotensin II receptor gene have been shown to be able to regulate the translation of the transcripts (Curnow et al. 1995). The 3′-untranslated region seems to inhibit the expression of the cell membrane receptor of luteinising hormone. The inhibition has been attributed to a decrease in the half-life of the receptor mRNA (Nair and Menon, 2000). As stated before, Ambartsumian et al. (1995) reported that the occurrence of the larger splice variant of h-mts1 that contained an additional noncoding exon. It has been argued that splice variants may subserve different, often opposing, functions. If this were the case, one would expect to find a differential expression of splice variants in tissues (Sherbet and Lakshmi, 1997b), which appears to be the case with respect to the h-mts1 splice variants (Ambartsumian et al. 1995). Ambartsumian et al. (1995) have stated that this splice variant showed marked variations in the level of expression in different human tissues. This large isoform was not found in the breast cancers, which Albertazzi et al. (1998b) investigated. However, there are indications that the expression of the h-mts1v isoform described here may have some bearing upon nodal spread of the disease (Albertazzi et al. 1998c), although h-mts1v did not appear to influence nodal spread as decisively as h-mts. It would be premature to speculate on the significance or relevance of h-mts1v expression to the state of the disease, because the deleted exon 1a/1b is not transcribed and exons 2 and 3 that encode the functional protein are intact. It may be argued that the loss of the 5′ untranslated exon could be affecting the secondary structure of the transcript and its stability and translatability as a consequence. Possibly, the integrity of the S100A4 protein and its molecular properties might be affected by the splicing process, and this might impair the ability of S100A4 to promote metastatic spread.
The EF-Hand Calcium Binding Proteins
71
REGULATION OF EXPRESSION OF S100 FAMILY GENES The widespread involvement of S100 genes in diverse physiological function, and the demonstration that abnormal expression of many of these genes is associated with aberrant physiological events and the pathogenesis of several diseases, has inevitably led to the investigation of how the expression of S100 genes is regulated. Two modes of gene regulation have been investigated: transcriptional regulation and epigenetic regulation.
TRANSCRIPTIONAL REGULATION
OF
S100 GENES
The promoter regions of several S100 genes have now been characterised. The functional promoter of S100β has been localised to a region –168 to +697 and contains 168 bp upstream of the transcription start site. The activity of this promoter has been identified in several cell types. Furthermore, there are both positive and negative regulatory elements in the promoter region. There are positive regulatory elements in –788 to –391 and –1012 to –788. Further upstream, in the region –4437 to –1012 and in –1012 to –788, occur negative regulatory elements. The regulatory element in –4437 to –1012 has been found to suppress promoter activity in many cell types (Castets et al. 1997). Several potential regulatory elements, such as the CRE and AP2, have been identified in the promoter region of S100β (Allore et al. 1990). AP1-like binding sites are found also in the promoter region of the calcyclin gene, but the latter shows no binding by transcription factors such as AP-2, AP-3, or NF1 (Bottini et al. 1994). The murine homologue of S100A4 has been investigated by Tulchinsky et al. (1990, 1992), who have found homology between the 5′ region of S100A4 and the promoter regions of rat fibrinogen and human prothrombin, and also with certain enhancer elements of SV40. Tulchinsky et al. (1992) found no cis-acting control elements in the 5′ region of S100A4. Subsequently, a 16-nucleotide cis-acting transcription regulatory element has been identified in the first intron of the gene, and this element has been found to bear a high degree of sequence homology to the enhancer element of the CD delta gene. The S100A4 promoter region also has been reported to contain motifs that bear a high degree of homology to p53 binding negative regulatory elements and AP1-like enhancer elements in the 3′ region (Parker et al. 1994a). Okada et al. (1998) have identified a cis-acting element stretching from –187 to –88, upstream of the first intron, that they believe specifies the transcription of the S100A4 (FSP1) gene in fibroblasts. They have also reported the occurrence of an enhancer element in the first intron. This does not show cell type specificity. Okada et al. (1998) have reported further that a 5-bp domain TTGAT at –177 to –173 interacts specifically with nuclear extracts derived from fibroblasts. This fibroblast-specific expression is not a typical feature of S100A4, which is indeed expressed to a variable degree in a variety of normal and neoplastic tissues. Thus, there are clear suggestions that the function of S100 genes may be controlled by a variety of transcription factors.
72
REGULATION
Calcium Signalling in Cancer OF
GENE EXPRESSION
BY
DNA METHYLATION
DNA methylation is an epigenetic mechanism that regulates gene expression and gene imprinting. The CpG dinucleotide sites or islands that occur within and around genes are the targets of methylation (Ng and Bird, 1999). The process of methylation alters the conformational state of the DNA and it has been suggested therefore that methylation may play a role also in genomic stability. The association of the state of DNA methylation with gene expression has been known for many years (Kass et al. 1997). Hypomethylation is associated with constitutive gene expression. Demethylation of promoter regions of a gene, e.g., by treatment of cells with 5-azacytidine, increases the level of its expression (S. Lu and Davies, 1997). The regulation of tissue-specific expression of a tyrosine hydroxylase gene is dependent on the methylation status of the cytosine bases occurring around the CRE of the promoter (Okuse et al. 1997). Similarly, the expression of the manganese superoxide dismutase gene is suppressed when certain cytosines present in the 5′ flanking region are methylated (Y.H. Huang et al. 1997). Methylation of regulatory elements may interfere with the binding of transcription factors, as shown by Ryhanen et al. (1997). These authors found that AP-1 transcription factor bound to unmethylated response elements with far greater affinity than to methylated ones. The pattern of DNA methylation has been studied extensively. Methylation patterns may be somatically inherited, but probably not through the germ line. Epigenetic DNA methylation may be linked with genetic changes. However, in contrast with the generally held view that DNA methylation is a heritable and stable phenomenon, Ramchandani et al. (1999) have postulated that it is indeed a reversible signal. This postulate makes it easier to appreciate how DNA methylation might be involved in developmental processes as well as in neoplastic progression, both inherently associated with changes in the patterns of gene expression. Wachsman (1997) has argued that DNA damage, e.g., by alkylation of bases, oxidative lesions, etc., can interfere with the methylation of CpG dinucleotides by DNA methyltransferases (DNA-MTases) and alter the distribution of 5-methylcytosine (5-MC). The presence of 5-MC results in an increased risk of mutagenesis. CpG islands are hot spots for mutations with the presence of 5-MC and DNA-MTases. Furthermore, the levels of DNA-MTases correlate with the state of DNA methylation. Quite clearly, epigenetic changes of DNA methylation and mutations are interrelated and also are associated with carcinogenesis.
DNA METHYLATION
IN
CANCER
It has been known for many years that changes in methylation patterns are associated with normal developmental processes (E. Li et al. 1992; Neumann and Barlow, 1996) as well as human cancers (P.A. Jones, 1986; P.A. Jones and Chandler, 1986). Whether abnormal methylation status is associated with neoplastic transformation has been the subject of many investigations. Tumorigenic and non-tumorigenic cell lines differ markedly in their DNA-MTase levels (Kautiainen and Jones, 1986), and human tumours show a range of 5-MC levels (Gamasosa et al. 1983). The expression of DNA-MTase is said to be deregulated in colonic carcinomas, when compared with
The EF-Hand Calcium Binding Proteins
73
normal colonic epithelia and adenomatous lesions. The carcinomas have also been reported to be highly heterogeneous with regard to DNA-MTase expression (De Marzo et al. 1999). However, because cancers tend to be intrinsically heterogeneous, the heterogeneity of DNA-MTase might not be sufficient grounds for postulating an association between possible deregulation of its expression and the process of carcinogenesis. The overexpression of certain oncogenes in animal tumour models has been associated with their demethylation (Wainfan and Poirier, 1992). Indeed, the oncogene ras was reported many years ago to be hypomethylated in human cancers (A.P. Feinberg and Vogelstein, 1983). Using an experimental tumour model, Counts et al. (1997) have demonstrated that hypomethylation of Ha-ras and raf oncogenes is related to tumour promotion, and further that carcinomas were more hypomethylated than adenomas. In breast carcinomas, marked hypomethylation has been reported in the vicinity of the promoter region of the calcitonin gene (Hakkarainen et al. 1996). pS2 is a protein associated with oestrogen-induced breast cancers. The expression of this protein has been found to be associated with hypomethylation of a CCGG site within the promoter/enhancer region of the pS2 gene (V. Martin et al. 1997). In contrast with oncogenes, tumour suppressor genes appear to be hypermethylated and inactivated in association with tumorigenesis (Zingg and Jones, 1997; Denissenko et al. 1997). The suppressor gene p53 is mutated in a large number of human tumours. Not only does a large number of somatic mutations occur at methylated CpG dinucleotide sites, but also these might be preferred targets for mutagenic agents (Denissenko et al. 1997; M.S. Tang et al. 1999). There is a generalised DNA hypermethylation in chronic lymphocytic leukaemia. More specifically, two tumour suppressor genes — cyclin-dependent kinase inhibitor genes CDKN2A and CDKN2B — have been reported to be methylated. Apparently their expression is suppressed thereby in B-cell chronic lymphocytic leukaemia (Martel et al. 1997), and also in many other forms of human cancer, such as carcinoma of the breast, prostate, and kidney (Herman et al. 1995). The candidate suppressor gene HIC1 is relatively unmethylated or hypomethylated in peripheral blood or in acute myelogenous leukaemia as compared with recurrent acute lymphocytic leukaemia and blast crisis chronic myelogenous leukaemia (Issa et al. 1998). The inactivation or silencing of other tumour suppressor genes has also been reported, e.g., the MUC2 gene in colorectal cancer (Hanski et al. 1977) and the Wilms tumour gene (Kleymenova et al. 1998). The promoter region of the E-cadherin gene, which is regarded as a putative tumour and invasion suppressor, often has been found to be hypermethylated in gastric carcinomas. This has been associated with the reduced expression of E-cadherin in these tumours, and it has been suggested that hypermethylation of the promoter might occur as an early event in gastric neoplasia (G. Tamura et al. 2000). In prostate cancer, there is a decreased expression of endothelin receptor as compared with normal prostate epithelium. This appears to be due to methylation of a 5′ CpG island covering the transcriptional regulatory region of the endothelin receptor gene (J.B. Nelson et al. 1997).
74
REGULATION
Calcium Signalling in Cancer OF
S100 GENE TRANSCRIPTION
BY
METHYLATION
The expression of S100 genes may also be regulated by methylation. This has been suggested by Tulchinsky et al. (1995) for S100A4. They have implicated the methylation of the first exon and the first intron in the repression of transcription of S100A4. Subsequently, Tulchinsky et al. (1996) showed that the first intron of this gene contains a methylation-dependent AP1 binding site. They further stated that the transcription of the gene is related to hypomethylation of the first intron in murine adenocarcinoma cells. In human colonic adenocarcinoma cell lines, the expression of S100A4 closely correlates with hypomethylation of the second intron of the gene. Also, where S100A4 expression was low, this could be increased by treating the cells with 5-Aza-2′-deoxycytidine (N. Nakamura and Takenaga, 1998). Indeed, the pattern of methylation of the gene could be a reason why S100A4 often shows a differential pattern of expression (D.S. Chen et al. 1999). S100A2, on the other hand, may be regarded as a tumour suppressor because it is expressed in normal breast tissue but it is down-regulated in the progression of breast cancer. Wicki et al. (1997) demonstrated the presence of an enhancer element 1.2 kb upstream of the transcription start site. Here they identified two AP1-like binding sites. The same enhancer element regulates the expression of S100A2 in normal as well as neoplastic breast epithelia suggesting the involvement of an epigenetic mechanism of methylation. Although their observations are not conclusive, it would appear that an element proximal to the transcription start site shows differential states of methylation in normal cells, tumorigenic cells, and cells derived from a breast tumour biopsy. Nonetheless, they have demonstrated that site-specific in vitro methylation of S100A4 gene in normal cells leads to a down-regulation of its expression. Perhaps it is unhelpful to overemphasise the significance of the regulation of gene expression at the transcriptional level. Ambartsumian et al. (1999) have reported that, in S100A4 transgenic mice, S100A4 mRNA was expressed in all organs. The mRNA was expressed at a higher level in some organs. However, they have made the crucial observation that the S100A4 protein was down-regulated in the organs that did not express the gene in the wild-type animal. It is obvious from this that there must exist a complex mechanism that regulates the expression of the protein at the translational level or regulates the decay of the protein. This is not unique to S100A4, and the expression of other S100 proteins in common with a wide variety of cellular proteins might also be controlled at the posttranscriptional level. For instance, S100α1 protein and its mRNA are differentially expressed in differentiating neuronal and skeletal muscle cells (Zimmer and Landar, 1995).
6
The Calmodulin Family of Calcium Binding Proteins
A number of calcium regulatory proteins may be treated as belonging to the calmodulin family of CBPs. In addition to calmodulin, troponins, calbindins, recoverin, and calretinin can be assigned to this family. The regulatory function of these CBPs in normal as well as aberrant physiology will be discussed in the following pages.
CALMODULIN AND ITS PHYSIOLOGICAL FUNCTION STRUCTURE
AND
MODE
OF
ACTION
OF
CALMODULIN
Calmodulin (CaM) is a 17-kDa CBP. Structurally it may be described as a dumbbellshaped molecule with two lobes each containing two Ca2+-binding domains. The two lobes are joined by an α-helix comprising 28 amino acid residues. A conformational change occurs in the CaM molecule in the presence of calcium and as result CaM can bind to a large number of target molecules. The conformational change involves the exposure of two methionine-rich hydrophobic areas, one in each globular domain, and these take part in the interaction with target proteins and in their activation. CaM can activate a large number of proteins, and this ability has been attributed to the highly conserved methionine residues (Kincaid et al. 1987; Perrino et al. 1992; Milan et al. 1994), the mutation of which might affect activation of target proteins. The α-helix linker also plays a crucial role in this process of activation. Tabernaro et al. (1997) studied a mutant form of CaM in which the amino acid residues Thr 79 and Asp 80 are deleted from the α-helix. This deletion appears to alter the relative orientation of the globular domains, which results in the hydrophobic patches coming closer together and consequently becoming less accessible to interaction with target proteins. The CaM binding domains of target proteins occur in short stretches of 15 to 25 amino acid residues (O’Neill and De Grado, 1990; Ikura et al. 1992; Crivici and Ikura, 1995). CaM appears to recognise certain conserved structural features, which might differ from one target protein to another with respect to their topographical arrangement. CaM orientates its globular domains by virtue of the flexible nature of the linker. An interaction with CaM is essential for the activation of several of the target proteins (Kretsinger, 1992). Specificity of activation of the target enzymes seems to be achieved by the phosphorylation of CaM (Williams et al. 1994; Sacks et al. 1995; Quadroni et al. 1994; Saville and Houslay, 1994). Several kinases phosphorylate 75
76
Calcium Signalling in Cancer
CaM, among them the myosin light chain kinase (MLCK) (Davis et al. 1996); casein kinase II (Sacks et al. 1992), and receptor tyrosine kinases (Graves et al. 1986; San Jose et al. 1992). Ubiquitination of calmodulin also has been suggested as a possible regulatory mechanism (Laub and Jennissen, 1991). The occurrence of numerous target proteins indicates the broad spectrum of physiological function in which CaM participates. CaM mediates the function of enzymes that are involved in cyclic nucleotide metabolism, phosphorylation and dephosphorylation, and smooth muscle contraction (Means, 1988; Harrison et al. 1988; MacNeil et al. 1985; G. Li et al. 1989).
CALMODULIN-MEDIATED SIGNAL TRANSDUCTION There is currently a large body of evidence demonstrating the important role calmodulin plays in the transduction of signals of cell proliferation and growth control, and in cell locomotion and invasion. The signalling pathways that are initiated by the activation of cell membrane receptors, as alluded to earlier, involve the raising of intracellular calcium levels and the subsequent phosphorylation of target proteins. Because Ca2+/CaM interacts with and activates target enzymes, CaM has been deemed as an important component of the signalling pathway by mediating protein phosphorylation via CAMKs. CaM kinases subserve a variety of functions. Several examples can be cited for the purposes of discussion and illustration. Thus T-cell activation, cell migration, and proliferation will serve amply to underline the significance of CaM as a signalling molecule. The activation of the T-cell receptor not only increases intracellular calcium but also activates CaM-dependent kinases, which results in the regulation of phosphatases (Ostergard and Trowbridge, 1991). CAMKs are also involved in cell proliferation. CAMK II has been shown to be involved in the induction of S-phase delay in fibroblasts exposed to γ-irradiation. The exposure to radiation also induces CAMK II activity. This induction does not occur if the cells are pretreated with CAMK II antagonists (Famulski and Paterson, 1999). An outstanding example of CaM-mediated signal transduction is the transduction of angiotensin signals. The hormone angiotensin II, derived from the decapeptide angiotensin I, generates many cellular responses. Angiotensin II possesses cytokinelike activity. It functions as a cardiovascular growth factor and is mitogenic to cardiac fibroblasts. It has also been attributed with the ability to induce angiogenesis. Not surprisingly, therefore, angiotensin signal transduction has many similarities to that of growth factors. Some of the effects of angiotensin are indeed mediated by growth factors such as PDGF, EGF, basic fibroblast growth factor (bFGF), and TGFβ. The transduction of the angiotensin signal involves two types of angiotensin receptors: type 1 (AT-1) and type 2 (AT-2). The binding of angiotensin to AT-1 triggers a cascade of signalling events and the activation of transduction pathways (Thomas, 1999). The C-terminal domain of the AT-1, close to the inner membrane, interacts with CaM in a Ca2+-dependent fashion. This interaction seems to be essential for the transduction of angiotensin binding to AT-1A (Thomas et al. 1999). In cardiac fibroblasts, AT-1-induced signals appear to transactivate epidermal growth
The Calmodulin Family of Calcium Binding Proteins
77
factor receptors (EGFr) and eventually result in DNA synthesis. This effect is inhibited by CAMK inhibitors (Murasawa et al. 1998). Angiotensin is able to induce the synthesis of TGFβ and the type II TGFβ receptor (Wolf et al. 1999). TGFβ and its receptor activity have potentially profound effects on the composition and properties of the ECM. Furthermore, angiotensin and TGFβ can both induce cytoskeletal changes, such as the formation of actin stress fibres and the phosphorylation of focal adhesion proteins (Riedy et al. 1999). There can be little doubt that the cytoskeletal modulations and the remodelling of the ECM will influence cell migration as well as cell proliferation and differentiation. Cell migration is another cellular activity that demonstrably involves CaM in signal transduction. Cell migration is believed by some to involve activation of the pathway that includes members of a family of serine/threonine kinases called extracellular signal-regulated receptor kinases (ERK), which are also known as the MAPK pathway. In PC12 cell, calcium influx activates ERK. This activation is inhibited by the CaM inhibitor W13, which indicates that CaM is involved in this pathway (Egea et al. 1998). Egea et al. (1998) also showed that other receptors, e.g., trk A and EGFr, are not involved in the activation of the ERK pathway. In gastric epithelial cultures also CaM appears to be involved in the transduction of the cell migration signal (Ranta-Knuuttila et al. 1998). Of late, much evidence has emerged that links CaM with G-protein-mediated signal transduction. There is a marked parallelism between angiotensin signal transduction and the transduction of growth factor signals. It has been recognised, therefore, that G-proteins might be involved in angiotensin signal transduction. Angiotensin II has been known to bind to a high-affinity G-protein receptor (T.J. Murphy et al. 1991; Sasaki et al. 1991; Sandberg et al. 1992). Recently, CaM has been reported to enhance the Ca2+-dependent binding of guanosine triphosphate (GTP) to the ras-related protein Ral-A (Wang and Roufogalis, 1999). Fischer et al. (1998) found that the PI3K, an enzyme that functions downstream of G-proteins, possesses high-affinity binding sites for CaM. The association of CaM with G-proteins is not restricted to animal cell systems. CaM appears to be closely involved with G-proteins in pollen germination and the growth of pollen tubes (Ma et al. 1999).
CALMODULIN
AND
CELL PROLIFERATION
As stated earlier, among the targets of CaM are the cytoskeletal proteins MAP-2 and the tau protein. The conclusion is inescapable, therefore, that CaM might be involved in cytoskeletal reorganisation. Both cell proliferation and cell motility have been regarded as the natural foci of CaM involvement. CaM seems to be actively associated with cell proliferation, as amply demonstrated by several investigators. Indeed, it is regarded as an essential ingredient of cell proliferation and the progression of the cell cycle (Means, 1994). The exit of cells from the cell cycle has been reported to be accompanied by a decrease in CaM levels (Christenson and Means, 1993). CaM levels increase as cells progress into the mitotic phase, and there is an elegant demonstration that both Ca2+ and CaM are essential for this process. When either of these is reduced cells undergo G2 arrest (K.P. Lu et al. 1993).
78
Calcium Signalling in Cancer
Some investigators have examined the levels of CaM expression in relation to growth responses. Exaggerated growth responses have been recorded in cardiomyocytes resulting from an overexpression of CaM (Gruver et al. 1993). Recently, however, Prostko et al. (1997) found no effects on growth responses arising from an overexpression of CaM in C6 glioma cells in culture, but reduction of CaM expression was found to inhibit their growth. The antiproliferative effects exerted by CaM inhibitors have also provided a substantial body of evidence that suggests an association of CaM with growth responses. Several CaM inhibitors have been tested to date. Schuller et al. (1991) found that B859-35, which is a dihydropyridine derivative, markedly inhibited proliferation of three human lung cancer cell lines. Hait et al. (1994) reported that several phenothiazine antipsychotic drugs inhibit CaM and also the proliferation of C6 glioma cells. They also found that the antiproliferative effects corresponded with the inhibition of CaM-sensitive phosphodiesterases. Further work from the same laboratory has shown that KS-501 and KS-502 similarly affect cell proliferation, not by direct action on the enzymes but by interfering with their function of activating CaM (Hait et al. 1995). In other words, the failure to activate CaM appears to lead to an inhibition of cell proliferation. Glass-Marmor et al. (1996) and Glass-Marmor and Beitner (1997) have investigated the effects of another class of CaM inhibitors, which reduce intracellular levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, and ATP and also detach glycolytic enzymes bound to the cytoskeleton. Four antagonists tested — thioridazine, CGS 9343B, clotrimazole, and bifonazole — brought about a marked reduction in cell viability (Glass-Marmor et al. 1996). The detachment of glycolytic enzymes associated with the cytoskeleton can also affect the function of the latter in cytokinesis. CaM cDNA has been transfected in sense as well as in the antisense orientation into C6 glioma cells. Transfection with sense-cDNA has been found to produce more clones than transfection with antisense constructs. The DNA content of cells has been reported to correlate with CaM levels (Liu G.X. et al. 1996). This is compatible with the finding that cells experience a delay in DNA synthesis in the presence of CaM inhibitors W7 and W13 and the CaM-dependent protein kinase inhibitor KN-62 (Mirzayans et al. 1995). CaM can influence the transduction of growth factor signals via the receptor kinases by modulating their phosphorylation by means of CaM-dependent protein kinases. Thus one can visualise several ways in which CaM could regulate physiological processes.
CALMODULIN
IN
NEOPLASIA
An enhancement of CaM has been recognised as a feature of cell transformation and of malignant cells. CaM levels of human lung cancer cells are higher than that of benign tumours of the lung or normal lung tissue (Liu G.X. et al. 1996). These authors also describe a correlation between tumour grade and TNM stage and levels of CaM. However, Edelman et al. (1994) have described a CaM-like protein that is apparently restricted to epithelial cells. This CaM-like protein was identical in size and largely homologous to CaM, but, unlike CaM, its expression seems to be significantly lower in malignant cells.
The Calmodulin Family of Calcium Binding Proteins
79
The CaM antagonist J8 inhibits the invasive behaviour of the cutaneous melanoma cell line A-375SM and uveal melanoma cells (Dewhurst et al. 1997). Tamoxifen, its metabolites N-desmethyltamoxifen, and 17β-oestradiol also inhibit invasion in the absence of oestrogen receptors, which suggests that the inhibition produced by these anti-oestrogens was mediated by mechanisms other than receptor binding, e.g., CaM inhibition. A deregulation of intracellular calcium resulting in cell death is produced by tamoxifen at high concentrations where its effects are believed to be not mediated by oestrogen receptors (Jain and Trump, 1997). CaM antagonists could inhibit invasion by starving the cytoskeletal machinery of local ATP generation. Glass-Marmor and Beitner (1997) found that the CaM inhibitors, which they had previously shown to reduce the levels of certain glycolytic enzymes and ATP and cause loss of viability (Glass-Marmor et al. 1996), also detach these enzymes from their association with the cytoskeleton. It is possible that CaM could be influencing cell invasion by altering the expression of ECM-associated enzymes. Some years ago A. Ito et al. (1991) suggested that CaM could be differentially modulating the expression of TIMP and prometalloproteinases 1 and 3 in fibroblasts derived from human cervical carcinoma. The expression of these enzymes is known to markedly alter the invasive behaviour of cancers (Sherbet and Lakshmi, 1997b). Possibly, therefore, modification of the expression of ECM-associated enzymes and the properties of the ECM as a means of modulating cell behaviour, ought to be seriously considered. S100A4 does seem to operate through such a mechanism (Merzak et al. 1994b; Lakshmi et al. 1997). It would seem, therefore, that CaM might involve more than one target enzyme in the modulation of invasive behaviour.
RECOVERIN SUBFAMILY OF NEURAL CALCIUM BINDING PROTEINS AND THEIR FUNCTION Recoverin (RCN) and related proteins belong to a four-EF-hand recoverin family of neural calcium-binding proteins (NCBPs) (Table 5). Two types of NCBP can be distinguished. Type A proteins, e.g., recoverin, have two canonical EF-hands. Type B proteins, e.g., VILIP (visinin-like protein) and NCS-1, possess three regular EFhands. Flaherty et al. (1993) have elucidated the three-dimensional structure of RCN. According to them, the four EF-hands are arranged in a compact array. The tertiary structure and arrangement of the EF-hand may control calcium binding. Although generally described as NCBPs, individual NCBPs do show characteristic differences in their localisation within the neural tissue and the retinal component itself.
THE G-PROTEIN SIGNALLING
PATHWAY
Many extracellular modifiers of biological response transduce their signals via heterotrimeric guanine nucleotide regulatory proteins (G-proteins), which consist of α, β, and γ subunits (Koelle, 1997; Dohlman and Thorner, 1997; Berman and Gilman, 1998). These G-proteins are coupled to cell surface receptors. Several agents, such as epinephrine, norepinephrine, cytokines, and nonsteroid hormones, activate Gprotein receptors (Hein and Kobilka, 1997; Watson et al. 1996). Upon activation
80
Calcium Signalling in Cancer
TABLE 5 Recoverin Family of Neural Calcium Binding Proteins Protein Designation Recoverin (S-modulin) Rem-1 Visinin s26 VILIP NCS-1
Occurrence
Ref.
Photoreceptor cells; mammalian bipolar cells Retinal cells; haematopoietic cells; gut cells Photoreceptor cells Photoreceptor cells (frog retina) Inner retina Photoreceptor inner segments; inner plexiform layer; ganglion cells
De Raad et al. (1995) Kraut et al. (1995)
Kawamura et al. (1996) De Raad et al. (1995) De Raad et al. (1995)
these receptors promote guanine nucleotide exchange of guanosine diphosphate (GDP) to GTP on the Gα. This in turn leads to the dissociation of Gβγ complex from Gα. These then regulate the activity of the target protein, leading eventually to the mobilisation of second messengers. A family of proteins called RGS (regulators of G-protein signalling) can preferentially bind to activated Gα. RGS proteins appear to function as guanosine triphosphatase (GTPase) activating proteins (GAP) (Berman et al. 1996; Watson et al. 1996; Hunt et al. 1996) and attenuate or block the signalling pathway (Popov et al. 1997; Tesmer et al. 1997; Hepler et al. 1997). The G-protein-dependent and calcium-signalling pathways are often closely allied. For example, neurotransmitters inhibit calcium channel current, which seems to be regulated by the photoreceptor G-protein called transducin (Jeong et al. 1999; also, see below). Similarly, dopamine-coupled receptors inhibit voltage-activated calcium channels (Wolfe and Morris, 1999). Dolphin et al. (1999) have identified the calcium channel-protein domains that might be involved in the modulation of calcium channel currents by G-proteins. In the signalling events associated with the acrosome reaction in spermatozoa, G-proteins require calcium together with PLA2 to induce acrosomal reaction (Dominguez et al. 1999).
RECOVERIN
AND ITS
FUNCTION
The transduction of the extracellular sensory signal involves the interaction of activated rhodopsin with the photoreceptor G-protein, transducin. The rhodopsin intermediate meta II activates transducin by catalysing the exchange of GDP to GTP. The RGS protein down-regulates this signalling pathway by promoting Gα GTPase activity and additionally by down-regulating cGMP phosphodiesterase, which effectively enhances GTPase activity. RCN (a homologue of this from the frog is known as S-modulin) is a 23-kDa protein that plays a specific role of phototransduction in mammalian retinal photoreceptors. The transduction of visual signals requires rhodopsin to be activated by phosphorylation. Upon illumination rhodopsin is phosphorylated by rhodopsin kinase at several serine and threonine residues. The activated rhodopsin is dephosphorylated by phosphatases to return it to the basal state.
The Calmodulin Family of Calcium Binding Proteins
81
RCN is involved in the process of light and dark adaptation by rod cells by regulating rhodopsin phosphorylation, thereby controlling photoreceptor light sensitivity, which is Ca2+ dependent. Several mutant forms of RCN, with mutations in EF-hands 2 and 3, and others with mutation of EF-hand 4, have been isolated recently. Of these, EFhand 4 RCN mutants were found to be able to inhibit rhodopsin kinase more effectively than could wild-type RCN (Alekseev et al. 1998). Apparently, a decrease in cytoplasmic calcium levels is necessary for light adaptation (Figure 11). Besides RCN, other calcium-binding proteins are involved in this process. Among them are the photoreceptor-specific GCAP and calmodulin, together with their targets, namely rhodopsin kinase, guanylate cyclase, cGMP-gated channel, and nitric oxide synthase (Koch, 1995; Gorczyca et al. 1995).
FIGURE 11 The pathway of sensory signal transduction involving recoverin and RGS (regulator of G-protein signalling) protein.
The RCN gene has been mapped to human chromosome 17p13.1 (J.F. McGinnis et al. 1995). Interestingly, the autosomal-dominant progressive cone dystrophy (CORD5) gene maps to chromosome 17p12–p13. The genes, coding for retinal guanylyl cyclase and pigment epithelium-derived factor, and the retinitis pigmentosa (RP) genes also occur in the RCN region (Balciuniene et al. 1995). Recoverin occurs predominantly in mammalian photoreceptor cells. It may be found in other retinal cell types and may therefore subserve other functions besides phototransduction (McGinnis et al. 1997). RCN appears to be a highly conserved protein, as suggested by its occurrence in the photoreceptor cells of the lamprey (Dalil-Thiney et al. 1998). Its expression may be developmentally regulated (Yan and Wiechmann, 1997). It is found to be transiently expressed in developing follicular and parafollicular pinealocytes in the developing chick embryo (Bastianelli and Pochet, 1994). Four isoforms of RCN occur and each of these shows N-terminal myristoylation. RCN not only participates in phototransduction, a role suggested by its localisation in photoreceptor cells, but it is also associated with the pathogenesis
82
Calcium Signalling in Cancer
of the autoimmune state of cancer-associated retinopathy and uveoretinitis. However, it is uncertain whether RCN is involved with autosomal recessive RP.
MODE
OF
ACTION
OF
RECOVERIN
Recoverin regulates photoreceptor response by inhibiting rhodopsin phosphorylation. Rhodopsin kinase is active in the absence of RCN (Gorodovikova et al. 1994a). Rhodopsin phosphorylation and consequent cGMP hydrolysis are Ca2+- and ATPdependent processes. When the free Ca2+ level is raised, phosphorylation of rhodopsin is reduced and there is an increase in the lifetime of phosphodiesterase. This Ca2+ effect is negated by anti-RCN antibodies, which has been interpreted as suggesting that the calcium effects observed are a result of the inhibition of rhodopsin kinase (Gorodovikova et al. 1994b). Upon addition of RCN, rhodopsin kinase becomes sensitive to free Ca2+. Calcium-dependent interaction between RCN and rhodopsin kinase is indeed necessary for the inhibition of rhodopsin phosphorylation by RCN (C.K. Chen et al. 1995). All four isoforms of RCN inhibit rhodopsin phosphorylation in the same free calcium range (0.3 to 0.8 µM), but they differ with respect to the magnitude of inhibition achieved, which appears to be related to their hydrophobicity (Sanada et al. 1995).
POST-TRANSLATIONAL MODIFICATION
OF
RECOVERIN
Four isoforms of RCN have been identified; all appear to be posttranslationally modified at the N-terminal glycine residue with myristic acid or related lipids. Myristoylation is believed to be essential for the function of RCN. Senin et al. (1995) compared the inhibitory effect on rhodopsin phosphorylation of myristoylated and nonmyristoylated forms of recombinant RCN. They found that both forms of RCN inhibit rhodopsin kinase in the presence of Ca2+, but myristoylated RCN was more efficient in inhibiting the kinase. However, others believe that myristoylation is not necessary for the kinase inhibitory effect of RCN and that it only induces a cooperative Ca2+ dependence of the process (Kawamura et al. 1994; Calvert et al. 1995). Ames et al. (1994) have suggested, on the basis of the flexibility of the N-terminal helix in myristoylated calcium-free and nonmyristoylated calcium-bound form, that calcium binding to the EF-hand 3 domain induces EF-hand 2 to adopt a conformation that promotes calcium binding to RCN. Covalent attachment of a myristoyl or related N-acyl group to the N-terminal glycine appears to promote the binding of RCN to the optic disc membrane when free Ca2+ is raised. The so-called calcium–myristoylation switch is believed to play an essential role in the targeting of RCN to the cell membrane. The addition of the myristoyl group has been found to reduce the calcium affinity of RCN and induce cooperative calcium binding. Two conformational states have been recognised viz. the T and R states. In the T state the myristoyl group is sequestered inside the protein, whereas in the R state it is exposed, and furthermore, calcium binds to the R state several thousand-fold more strongly than to the T state (Ames et al. 1995). Calcium binding to the myristoylated RCN induces its translocation to the membrane. The
The Calmodulin Family of Calcium Binding Proteins
83
nonmyristoylated RCN is not translocated in this way (Tanaka et al. 1995). It would appear, therefore, that posttranslational modification of RCN is required for targeting to and interaction of RCN with the membrane. The RCN family protein VILIP also shows calcium-dependent targeting to the cell membrane. It has been found to interact with the actin component of the cytoskeleton in its recruitment to the cell membrane (Lenz et al. 1996). Braunewell et al. (1997) have confirmed that myristoylated VILIP can be shown to be associated with membranes, whereas nonmyristoylated VILIP is not. Membrane association may stabilise the RCN–rhodopsin kinase complex, as suggested by experimental demonstration of a preferential association of RCN with cell membrane with concomitant increase in rhodopsin kinase inhibition (Sanada et al. 1996). However, Johnson et al. (1997) found that conformational changes and distribution of RCN in the cell were not influenced greatly by calcium concentration and suggest, therefore, that the calcium–myristoylation switch may not be the only mechanism involved in the targeting of RCN to the cell membrane.
RECOVERIN
AND
CANCER-ASSOCIATED RETINOPATHY
Recoverin and Cancer-Associated Retinopathy in Small Cell Lung Cancer A degeneration of the retina is infrequently associated as a paraneoplastic condition with some forms of cancer. This condition, often described as cancer-associated retinopathy (CAR), is an autoimmune syndrome involving the degeneration of the photoreceptor cells of the eyes. Injection of RCN had previously been shown to induce degeneration of photoreceptor cells of the eyes of Lewis rats, and this was correlated with high titres of RCN antibodies in the circulation (Adamus et al. 1994). There are several reports of incidence of CAR in patients with small cell lung carcinoma (SCLC) (Polans et al. 1995; Matsubara et al. 1996). Polans et al. (1995) showed RCN is expressed in lung tumour biopsies of patients who had CAR but not in tumour samples of patients without CAR. They further identified two regions of RCN that were associated with its immunogenicity. Amino acid residues 64–70 and 48–52 were the major determinants. Immunisation of Lewis rats with peptide 64–70 caused photoreceptor degeneration in the animals. This 64–70 region is in close proximity to the EF-hand 2 calcium-binding domain. The autoimmune reactivity has been found to depend on changes in the conformation of the 64–70 stretch of amino acid residues induced by calcium binding to the EF-hand 2 present in the neighbourhood (Adamus and Amundson, 1996). Murphy et al. (1997) have encountered high titres of antibodies to a 60-kDa retinal protein, as well as high titres of RCN antibodies, in association with SCLC. The titres of both declined with treatment and Murphy et al. (1997) have therefore suggested that the detection of RCN antibodies alone should not be used as the sole criterion for diagnosing CAR. A recent report described a patient with non-SCLC with recoverin antibodies in the serum (Salgia et al. 1998).
84
Calcium Signalling in Cancer
Retinopathy Associated with Other Forms of Human Cancer Retinopathy is associated also with other neoplasms such as breast and cervical tumours (Holz et al. 1997) and metastatic melanoma (Kirati et al. 1997). Again, this has been attributed to autoimmune responses to retinal proteins. RCN is expressed in cell cultures derived from retinoblastoma. Using antibodies raised against recombinant RCN, Weichman (1996) demonstrated that RCN is expressed in the cytoplasm of retinoblastoma cell line Y79. The expression was greatly increased by treating cells with 2 mM butyrate, and to a lesser degree by db-cAMP, together with the formation of neurite-like cellular processes indicating a state of induced differentiation. This possible link-up between RCN expression and differentiation is worthy of further investigation. In the sera of patients with CAR, heat shock protein (HSP) 70 has been detected in addition to recoverin (Ohguro et al. 1999). The involvement of bacterial HSPs in the induction of autoimmunity has been recognised with the demonstration that HSP65 from the tubercle bacillus mycobacterium can induce autoimmune disease in certain animal tumour models. Certain peptides derived from mycobacterial HSP65 and their homologous peptide obtained from patients with Behcet’s uveitis or iridocyclitis induce uveitis in Lewis rats. High antibody titres against these peptides are found in rats that developed uveitis as compared with those that had not (Uchio et al. 1998). This suggests that HSPs do function as autoantigens. Therefore, the detection of HSP70, together with recoverin, might suggest that both these antigens stimulate humoral autoimmunity in the pathogenesis of CAR. This view would be in line with the implication of HSPs in other autoimmune diseases such as rheumatoid arthritis (RA) (Winfield, 1989) and SLE (Minota et al. 1988; Conroy et al. 1994). Antibodies against human HSP60 and E. coli HSP60 have been found in patients with RA and SLE and in Reiter’s syndrome which combines arthritis with conjunctivitis, but the antibody titres are far higher than the titres of antibodies against mycobacterium HSP65 (Handley et al. 1996). This seems to suggest that the immune system recognises certain epitopes of these HSPs (Van der Zee et al. 1998). Although these observations suggest that HSPs might play a role in autoimmune conditions, they do not explain the coexpression of RCN with HSPs. It may be that some other HSP function, such as protein folding, may be involved here. As we have seen above, certain critical conformational changes are required in the proper functioning of RCN. Although, in the realms of speculation, the possibility that HSPs influence RCN conformation in such a way that sequestered autoimmune epitopes might be exposed cannot be excluded. It is unclear whether RCN forms complexes with HSPs. This is an interesting avenue to approach; one can envisage a situation where HSPs regulate RCN function by forming a complex. HSPs are known to form complexes with important biological macromolecules such as p53, rb proteins, and S100A4, and possibly influence their function as regulators of the cell cycle (Sherbet and Lakshmi, 1997b).
The Calmodulin Family of Calcium Binding Proteins
85
Is Recoverin Involved in Retinitis Pigmentosa? Retinitis pigmentosa (RP) is an autosomal-recessive disease involving degeneration of photoreceptor cells. RP has been attributed to mutations in the genes coding for rhodopsin and for the rod cGMP-gated channel. Naturally, therefore, the possibility of RCN implication in RP has received some attention. However, mutations in the RCN gene have been ruled out in 42 Spanish families with autosomal-recessive RP. Furthermore, the study by Parminder et al. (1997) did not encounter any mutations in the RCN gene in RP or allied heritable retinal diseases.
GUANYLATE CYCLASE-ACTIVATING PROTEINS The mammalian retina contains two GCAPs: GCAP1 and GCAP2. They are photoreceptor-specific calcium binding protein. GCAP1 is expressed at a high level in the outer segments of rods and cones. GCAP2 occurs mainly in the cone inner segments and is less intensely expressed in inner retinal neurons. Therefore, whereas GCAP1 has a phototransduction function, GCAP2 may not (Otto-Bruc et al. 1997). Furthermore, the expression of GCAP1 and 2 gene transcripts is substantially reduced in retinal degeneration (rd/rd) mutant chicken. Here, GCAP2 protein seemed to be normal, but the expression of GCAP1 proteins was down-regulated by more than 90% and this seems to be consistent with the loss of phototransduction (SempleRowland et al. 1996). GCAP1 has four EF-hand motifs. When not bound to calcium, GCAP is able to activate GC. Calcium binding inactivates GCAP. This seems to be a consequence of Ca2+ binding by EF-hands 3 and 4 and the conformational changes in the molecule (Rudnicka-Nawrot et al. 1998). The involvement of EF-hand 3 is also indicated by an inactivating mutation A → G in codon 99, exon 2 of the GCAP1 gene (Payne et al. 1998). This mutation is reported to occur in the GCAP1 gene in a family with autosomal-dominant cone dystrophy.
7
The Structure of Contractile Proteins
THE ACTIN COMPONENT OF CONTRACTILE MACHINERY OF THE CELL The physical alterations of the shape of the cell, its structure, motility and contractile ability are an attribute of the structure and organisation of the cytoskeletal machinery, of which the intermediate filaments (IF) (10 nm diameter), actin microfilaments (7 nm diameter), and microtubules are the important components. Actin microfilaments are polymers of F- and G-actin. These filaments are flexible, double-helical polymeric structures made up of F-actin strands. The G-actin subunits participate in binding to the myosin globular heads. G-actin also possesses ATP- or ADP-binding domains. Actin filaments have a defined polarity, which flows from the fact that the monomers themselves show a distinct polarity. In association with actin-binding proteins, the actin filaments form specialised structures. To these organised structures the cell owes its faculty of modulation of shape, motility, and other adhesionmediated phenomena. The reorganisation of actin cytoskeleton is also involved with plant cell division, differentiation, and light-induced plastid migration, among other cellular features (Staiger et al. 1997).
ACTIN ISOFORMS Four actin isoforms have been identified, of which two, the α and γ isoforms, are smooth muscle specific and the other two are the cytoplasmic β isoforms. The transfection of mutated β-actin genes in normal diploid cells alters their morphology and growth characteristics, and at the same time mutated β-actin protein is seen to be incorporated into the cytoskeleton (Leavitt et al. 1987a). Leavitt et al. (1987b) have further shown that the transfectant cells that expressed mutant βactin possessed greater tumorigenic potential than those with lower levels of mutant actin. Cells derived from these tumours had a shorter latency period for tumour formation as compared with the original transfectant cells. None of these interesting studies seem to have been followed up to examine motility, invasiveness, and metastatic potential, which, in retrospect, seems highly desirable in light of the changes in cell morphology and growth features engendered by the expression of mutant actin. A natural extension would be to investigate whether wildtype β-actin possesses tumour suppressor function. The suppressor function of αactin has been demonstrated recently. The rat fibroblast cell line 3Y1 expresses α-actin, but this is down-regulated when the cells are transformed by RSV. In
87
88
Calcium Signalling in Cancer
contrast, transfection of α-actin into RSV-transformed fibroblasts resulted in the reduction of tumour growth and invasiveness (Okamoto-Inoue et al. 1999).
REGULATION
OF
ACTIN DYNAMICS
Actin polymerisation and depolymerisation occurring in the dense actin cytoskeleton at the leading edge of a cell is instrumental in achieving locomotion (Tilney et al. 1983; Zigmon, 1993). The polymerisation of actin provides the protrusive power that allows the formation of lamellipodia or filopodia in the direction of cell movement. There is net polymerisation at the front edge while net depolymerisation occurs at the rear of the lamella. The relative rates of polymerisation and depolymerisation are at the basis of cell motility regulation. Actin dynamics are affected and may, indeed, be regulated by many cellular proteins. The actin-binding proteins regulate cell motility by influencing the rates of actin polymerisation and depolymerisation. Actin-binding proteins such as gelsolin thymosin, and profilin are cytosolic proteins that inhibit the process of actin polymerisation and profoundly influence cell morphology and motility. It follows, therefore, that these proteins could be indirect determinants of the altered cell motility and metastasis that often accompany neoplastic transformation. Among other notable cellular proteins that affect cytoskeletal dynamics is the S100A4 calcium-binding protein. S100A4 has been shown to be closely associated with the invasive and metastatic behaviour of cancer cells, and also to promote depolymerisation of the cytoskeletal structures (Lakshmi et al. 1993, 1997). It would be worthwhile, therefore, to discuss the role played by thymosin, cofilin, profilin, and fimbrin in altering cytoskeletal dynamics and assess their impact on cell behaviour. The currently held view is that the actin-binding proteins alter the ratio of monomeric G-actin and F-actin in cells. G-actin-binding proteins such as thymosin β4 (Tβ4) and profilin sequester G-actin from the cell pool and thereby prevent the process of polymerisation, whereas F-actin-stabilising factors such as myosin subfragment I and phalloidin can promote repolymerisation from the Tβ4/G-actin complex (Ballweber et al. 1994) (Figure 12). In continuous cellular locomotion or inherent invasive ability, the cell has to maintain a net high level of actin polymerisation and a constant F-actin content. Actin subunits derived from depolymerisation occur at the rear of the lamella, are assembled into filaments at the front of the lamella (Y.L. Wang, 1985; Small 1995). It would be of considerable interest to review how the expression of these actin-binding proteins affects cell behaviour and especially if any one of them shows any correlation with the aberrant behavioural properties manifested by neoplastic cells.
COFILIN
IN THE
REGULATION
OF
ACTIN DYNAMICS
Recently it has been shown that the phosphoprotein cofilin, also known as the actin depolymerisation factor, is actively involved with actin depolymerisation and in cellular processes that require cyclical changes in the actin cytoskeleton (Abe et al. 1996; Lappalainen and Drubin, 1997; Theriot, 1995). Cofilin is a 20-kDa protein found in muscle as well as nonmuscle cells. Two isoforms of this protein occur in
The Structure of Contractile Proteins
89
Profilin
Tβ4
G-actin ≈ F-actin
Sequestration of G-actin
Tβ4/G-actin complex
Profilin/G-actin
Myosin Fragment I Phalloidin
Prevention of polymerisation
Repolymerisation FIGURE 12 Schema of the participation of actin-binding proteins in the regulation of actin dynamics Tβ4, thymosin β4.
mammals: the muscle (M) type and nonmuscle (NM) type. M-type cofilin expression is up-regulated in the myogenesis of C2 cells in vitro (Ono et al. 1994). Goode et al. (1998) identified a 37-kDa protein in budding yeast, and they named it twinfilin because it contains two cofilin-like regions. Twinfilin is able to sequester actin monomers, but it does not inhibit actin polymerisation. Homologues of this protein may occur in man, mouse, and Caenorhabditis elegans, as sequence data searches have revealed, and Goode et al. (1998) suggest twinfilin may be highly conserved in evolution. Cofilin regulates actin polymerisation in a pH-dependent manner. Rapid cycles of assembly and disassembly of actin depend on this protein (Lappalainen and Drubin, 1997). Overexpression of cofilin leads to disorganisation of actin filaments (Ono et al. 1996). Its intracellular distribution as well as its interaction with actin are regulated by phosphorylation (Obinata et al. 1997). Cofilin is phosphorylated by LIM kinases (LIMK-1 and -2) (Arber et al. 1998; Yang et al. 1998; Sumi et al. 1999). Phosphorylated cofilin loses its normal function of depolymerising actin filaments. Cellular response in the form of alterations in cellular morphology, membrane ruffling, and neuronal outgrowths results from the growth factors being able to activate cofilin. In the case of neurite extension, the dephosphorylation of cofilin
90
Calcium Signalling in Cancer
has been found to correlate with its translocation to the membrane (Meberg et al. 1998). Actin-binding peptide derived from cofilin has been reported to compete with gelsolin segments 2 and 3 for actin-binding. These binding sites of cofilin and gelsolin have structural homologies and therefore they possibly share the same binding domain on the actin filament (Van Troys et al. 1997). How this structural relationship between cofilin and gelsolin translates in functional terms is yet uncertain. However, Van Troys et al. (1999) seem to have made a beginning by providing a framework based on the structure of the actin-binding modules that occur in actinbinding proteins, the similarities and differences between these binding domains, and how, overall, they might impinge on actin dynamics.
PROFILIN
IN THE
REGULATION
OF
ACTIN DYNAMICS
Profilin is another protein that participates in and regulates actin dynamics in cellular responses to external as well as internal signals (Staiger et al. 1997). It is a 14 to 15-kDa protein that has been found to sequester monomeric actin, to promote nucleotide exchange occurring on actin monomers, and to be capable of inducing actin polymerisation when barbed ends of actin filaments are free. Profilin also binds to poly-l-proline and phosphoinositol lipids. In mammalian cells two isoforms of profilin have been described and these also may be differentially expressed in different tissues (Witke et al. 1998). Profilin forms a high-affinity complex with actin (Di Nubile and Huang, 1997). The importance of this complex formation in the cellular function of actin filaments is demonstrated by the effects of deleting residue proline 96 and threonine 97 that occur near the major actin-binding site. Deletion of these amino acids reduces the ability of profilin to bind to actin and its ability to promote nucleotide exchange on actin monomers. When injected into Swiss 3T3 fibroblasts, the mutant profilin failed to affect microfilament organisation, which the wild-type was capable of achieving (Hajkova et al. 1997). A diminution of profilin expression has been shown to result in abnormalities of cytokinesis and the formation of multinucleate cells (Cao et al. 1997). Profilin is also a strong competitor against Tβ4 in binding to actin (Ballweber et al. 1998; also, see below). It would be reasonable to accept that profilin is directly involved in actin polymerisation and in this way influences morphological features and biological behaviour of cells.
RHO GTPASES
IN
ACTIN DYNAMICS
AND
SIGNAL TRANSDUCTION
The Rho family of GTPases are ras-related GTPases. In the yeast Saccharomyces cerevisiae, certain members of the family are known to control the process of budding and the determination of cell polarity (Johnson and Pringle, 1990). The mammalian Rho proteins have been implicated in cytoskeletal remodelling, and cofilin could be the terminal target that brings this about. Rho proteins also have been associated with the control of microfilament assembly in vitro and the formation of cytoskeletal structures such as filopodia, lamellipodia, adhesion plaques, and intercellular junctions (Ridley and Hall, 1992; Nobes and Hall, 1995, 1999; Peterson et al. 1990; Van Aelst and D’Souza-Schory, 1997). Intercellular adhesion is another cellular faculty in which Rho proteins are involved (Morii et al. 1992; Tominaga et al. 1993). The
The Structure of Contractile Proteins
91
processes of cell spreading and alterations in cell morphology and the transduction of growth factor signals also require the participation of and are regulated by Rho proteins (G.A. Murphy et al. 1999). At the fundamental level in all these cell functions is the contractile ability of the actin cytoskeleton, which has been attributed to the activation of Rho GTPases in response to microtubule depolymerisation (B.P. Liu et al. 1998). The Rho GTPases seem to activate a host of signalling molecules such as tyrosine kinases, serine/threonine kinases, and lipid kinases. These kinases phosphorylate downstream target proteins, directly or indirectly via the phosphorylation of other kinases. Rho and Cdc42 induce the reorganisation of the actin cytoskeleton and promote the formation of stress fibres. This process appears to be related to the activation of LIMK-2. LIMK-2 phosphorylates cofilin and inhibits its normal function of cytoskeleton depolymerisation (Sumi et al. 1999). The Rho-activated serine/threonine kinases (ROCK) seem to be important elements in cancer invasion. Itoh et al. (1999) transfected a dominant active mutant of ROCK cDNA into rat MMI hepatoma cells. These transfectant cells were found to possess greatly enhanced invasive ability, in comparison with cells that had been transfected with a dominant negative ROCK cDNA. The MLCK of endothelial cells is another kinase that seems to be regulated by Rho (Garcia et al. 1999). The possibility that Rho proteins might regulate the contractile apparatus of endothelial cells and alter the permeability of endothelia as a consequence has serious implications for cancer cell dissemination, in which the permeation of the endothelial barrier is an essential event. The induction of membrane ruffles has been attributed to Rac, a GTPase that belongs to the Rho family. Rho GTPases have been implicated in Rho kinasemediated phosphorylation of transmembrane adhesion proteins, such as the CD44 splice variants, and their interaction with the cytoskeletal protein, ankyrin (Bourguignon et al. 1999). This interaction between CD44 and ankyrin is manifested as changes in membrane activity in the form of ruffling. In this particular instance, Rho A GTPase stimulates ROCK, which phosphorylates CD44. This leads to an enhancement of CD44–ankyrin interaction. Bourguignon et al. (1999) also demonstrated that the induction of CD44-associated membrane ruffling can be achieved by injecting the catalytic domain of ROCK and, furthermore, that the membrane activity is inhibited by anti-CD44 antibodies. A more indirect route might be adopted in the Rho-mediated reorganisation of the cytoskeleton involving cofilin. Here ROCK phosphorylates and activates LIMK, which then phosphorylates cofilin (Maekawa et al. 1999). Some members of the S100 protein family are known to be able to modulate and possibly regulate actin dynamics. Among them is S100B, which has recently been shown to bind and activate the serine/threonine kinase Ndr (Millward et al. 1998). The Ndr kinase has structural and possibly also functional similarities with ROCK. It is suggested, therefore, that there might exist a general and common mechanism by which S100 proteins could regulate actin dynamics and the cellular processes and functions upon which the modulation of actin dynamics and cytoskeletal organisation might strongly impinge. A family of proteins called WASP [Wiskott-Aldrich syndrome (WAS) protein] is regarded as the regulators of actin reorganisation. WAS is an X-linked condition
92
Calcium Signalling in Cancer
that affects male children. The syndrome is generally described as including immunodeficiency, thrombocytopenia, and eczema, but the actual phenotype may be variable. The WAS gene is mutated in patients and the type of mutation seems to relate to the phenotype of the disease. WASPs are cytoplasmic proteins. One WASP isoform is found only in the lymphocytes. Another isoform called the N-WASP, which was isolated from neural cells, shows a more ubiquitous distribution. These proteins are known to bind to several cellular proteins and kinases and also to Rho GTPases, such as Cdc42 and Rac. They interact directly or indirectly with the actin cytoskeleton. The haemopoietic cells derived from patients with WAS also have been reported to show abnormalities of the actin cytoskeleton. These observations suggest that WASPs play an important part in the transduction of extracellular signals to the cytoskeleton (O’Sullivan et al. 1999). They are believed to function downstream of Rac. The association of WASP with the induction of membrane activity has been demonstrated recently. Castellano et al. (1999) showed that experimentally induced recruitment of activated Cdc42, or its downstream effector WASP, to the cell surface results in actin polymerisation and the formation of filopodia. Other actin-binding proteins, such as profilin, that are associated with actin dynamics may therefore be expected to enter into this picture of WASP- and Rhomediated regulation and organisation of the actin cytoskeleton. Suetsugu et al. (1998) generated a mutant profilin, H119E, that is defective in actin-binding. This mutant profilin suppressed actin polymerisation induced by N-WASP. Under normal circumstances profilin associates with N-WASP, and is essential for a rapidly polymerising actin by N-WASP; this cannot happen with mutated profilin.
INTERACTION
OF
FORMIN
WITH
PROFILIN
AND
RHO GTPASES
The formin family of proteins constitutes another component of the actin regulatory system. Formin and related proteins, which are expressed ubiquitously in several organisms, seem to knit together profilin and Rho GTPases in their function of regulating cytoskeletal dynamics. Members of the formin family share many structural features such as the coiled-coil molecular organisation, the occurrence of homology sequences known as formin homology (FH) 1 and FH2 domains, the collagen-like domain, nuclear localisation signals, and phosphorylation sites. The formin gene was identified by mutations in the gene associated with recessive limb bud deformity (Maas et al. 1990, 1991; Chan et al. 1995). The gene has 24 exons encompassing 400 kb of genomic DNA (C.C. Wang et al. 1997). The formins are predominantly nuclear proteins participating in cytokinesis and cell polarisation (Zeller et al. 1999). They are essential for the correct orientation and alignment of the cell division spindle (L. Lee et al. 1999). Formin also participates in morphogenesis, e.g., in the yeast budding process. The importance of their role in morphogenesis is also indicated by the fact that mutation in the formin gene leads to disruption of epithelial–mesenchymal interactions, which in turn leads to abnormal limb development. This has suggested the possibility that it may participate in the transduction of morphogenetic signals (Zeller et al. 1999). Formin has several ligands. Prominent among them is profilin (Mittermann et al. 1998). Rho GTPase is a downstream target of formin (Watanabe et al. 1997). It seems, therefore, that
The Structure of Contractile Proteins
93
formin is an important element in profilin/Rho-dependent actin polymerisation of cytoskeletal dynamics and in this way might regulate cytokinesis, cell morphology, and adhesion-dependent processes such as cell motility and invasion.
THE ROLE OF THYMOSIN FAMILY ACTIN-BINDING PROTEINS IN ACTIN DYNAMICS SEQUESTRATION
OF
ACTIN
BY
THYMOSINS
The beta thymosins constitute an important family of actin-binding proteins, which are recognised as major participants in the regulation of actin dynamics. Among its members are Tβ4, Tβ10, and Tβ15, which are the most intensively investigated forms of thymosin. Tβ4 is a 4.5-kDa protein consisting of 43 amino acid residues. Tβ14 is another protein isolated from the sea urchin, that has 40 amino acid residues and a molecular size of 4.53 kDa and bears a high degree of sequence homology to Tβ4 (Stoeva et al. 1997). Tβ15 is a 5.3-kDa protein. Thymosins seem to occur ubiquitously. Actin-binding proteins showing a high degree of homology to mammalian thymosins have been isolated from invertebrates. The thymosins from invertebrates have 40 amino acid residues, but they appear to differ with respect to their affinity for binding to rabbit muscle actin (Safer and Chowrashi, 1997). The thymosins function by sequestering monomeric actin and thereby diminishing actin polymerisation (Safer, 1992). Tβ4 binds to actin monomers by means of its N-terminal 5 to 20 amino acid residue sequence (Van Compernolle et al. 1992; Czisch et al. 1993; Van Troys et al. 1996). In vitro this peptide adopts a folded conformation for achieving high-affinity interactions with actin (Feinberg et al. 1996a). Feinberg et al. (1996b) have discovered homologous short sequences in Tβ4 and gelsolin that bind to the C-terminal region of actin. They have also commented on the ability of these short sequences to form secondary structures and its relationship to their biological function. However, Safer et al. (1997) found that Tβ4 crosslinks to both barbed and pointed ends of actin, and this requires that the C-terminal domain, which participates in the binding, is in an extended conformation.
EFFECTS
OF
THYMOSINS
ON
CELL PROLIFERATION
The ability of Tβ4 to inhibit actin polymerisation is well documented. Also adequately demonstrated is the involvement of thymosins in proliferation, motility, cell differentiation, and angiogenesis, all of them important features of embryonic development and cancer development and progression. Recently, Sanger et al. (1995) experimentally enhanced the intracellular levels of Tβ4 and studied the structural integrity of actin bundles of stress fibres and cytokinetic furrows. They microinjected a viral vector carrying Tβ4 cDNA, transfected the vector into PTK2 cells, or injected purified Tβ4 protein into these cells. Both microinjection and transfection of cDNA produced a disassembly of stress fibres. The effects of injection of the pure protein were even more marked; a disassembly of stress fibres occurred within 10 min after injection, resulting in delayed cytokinesis. However, although Tβ4 reduces actin
94
Calcium Signalling in Cancer
polymerisation by sequestering monomeric G-protein, at higher concentrations its ability to depolymerise F-actin appears to decrease (Carlier et al. 1996). The effects of thymosins on cell proliferation are therefore inevitable. Sanger et al. (1995) demonstrated that an overexpression of Tβ4 delays cell division. The N-terminal part of the protein contains an acetylated tetrapeptide sequence of Ac–N–Ser–Asp–Lys–Pro that is known to inhibit haemopoiesis. This peptide has been shown to inhibit the growth of normal bone marrow progenitor cells. It markedly reduces the growth of granulomacrophagic and erythroid progenitor cells and the size of their S-phase fraction (Bonnet et al. 1996). However, Bonnet et al. (1996) also found that although the inhibitory effect of the Tβ4 is similar to that of the tetrapeptide, Tβ4 from which this sequence is deleted retains the inhibitory effect.
THYMOSINS
AND
CELL MOTILITY
AND
DIFFERENTIATION
Needless to say, the amply confirmed effects of thymosins on the structural integrity of the cytoskeleton are bound to find expression in altered cell motility. Tβ4 has been shown to enhance strongly the migratory behaviour of an established cell line of endothelial cells derived from human umbilical vein (Malinda et al. 1997). Of the primary human cell lines that Malinda et al. (1997) examined, the migration of only human coronary artery cells seemed to respond to Tβ4. They also reported an increase in the production of metalloproteinases upon treatment with the thymosin. These enzymes can remodel the extracellular matrix and aid migration by altering cell adhesion to the substratum. NIH3T3 cells induced to overexpress Tβ4 have been reported to be more adherent than corresponding control cells (Golla et al. 1997). This enhanced adhesion appears to be due to adhesion-mediating proteins such as α-5 integrin as well as the transmembrane proteins such as vinculin that link cell membrane proteins to the cytoskeleton. There are also important implications of thymosin overexpression for cell migration in the context of cancer invasion, because thymosins have been reported to be overexpressed in neoplastic cells (see below). Especially significant are the reported specificity of response by endothelial cells to Tβ4 and the associated overexpression of metalloproteinases. Metalloproteinases have been closely associated with breaching of the endothelium and aiding the diapedesis of cancer cells into the vascular compartment (Sherbet and Lakshmi, 1997b). Tβ4 is reported to be highly expressed in the intrinsically highly motile embryonic mesenchymal cells (Carpintero et al. 1996). The expression of Tβ15 seems to be up-regulated in the highly motile Dunning rat prostate cancer cell lines. Besides, the transfection of antisense constructs of Tβ15 gene apparently alters the motility of these cells (Bao et al. 1996).
EXPRESSION
OF
THYMOSINS
IN
EMBRYONIC DEVELOPMENT
Differential cell adhesion and migration patterns are an integral feature of cell differentiation and morphogenesis. The expression of Tβ4 and Tβ10 shows some relationship to specific developmental stages (Carpintero et al. 1996), although there are as yet no indications that it is developmentally regulated. Carpintero et al. (1996) found a marked increase in Tβ10 mRNA in early postimplantation mouse embryos.
The Structure of Contractile Proteins
95
This mRNA is also found in certain tissues, including mesenchymal tissues and the spinal cord, in 9.5 to 12.5-day old embryos. These authors have also encountered differences in the distribution of Tβ4 and Tβ10 mRNAs, which could conceivably suggest differences in their function in embryonic development. Tβ4 has been detected in early chick embryo cells but not in adult skeletal muscle cells. Cofilin also is associated with muscle development, but its relative contribution may change during muscle development (Nagaoka et al. 1996). These observations are consistent with the notion of development-related expression of thymosins. Gomez-Marquez et al. (1996) showed that Tβ4 mRNA occurs in mouse embryonic stem cells, and further that Tβ4 is able to induce embryonal P19 cells to differentiate into neuronal- and glial-type cells or into cardiac and skeletal muscletype cells. Furthermore, Tβ4 mRNA was demonstrable around blood vessels and in heart tissues.
POTENTIAL ROLE
OF
THYMOSINS
IN
CANCER PROGRESSION
As stated before, the putative association of overexpression of Tβ4 with increased production of metalloproteinases in normal cells together with the relationship between Tβ4 and high invasive ability of the Dunning rat prostate cancer cell lines point to the relevance of thymosins in cancer invasion and metastasis. Both Tβ10 and Tβ15 have been investigated for their possible relationship with cancer progression. Tβ10 protein was reported to occur at high levels in the malignant cell rather than the normal tissue component of human breast cancer, and the level of expression increased with tumour grade (Verghese-Nikolakaki et al. 1996). The expression of Tβ10 gene was higher in five thyroid carcinoma cell lines as compared with normal thyroid-derived primary cells. Expression of the gene was higher in anaplastic tumour tissue (Califano et al. 1998). Tβ15 levels have been examined in several tumour cell lines of various histological origins. An up-regulation of the gene has been found in highly metastatic mouse lung and human breast cancer cell lines. This study also involved an examination of the levels of Tβ15 protein in human breast and prostate cancer tissues. Higher expression of Tβ15 has been correlated with the Gleeson grade in prostate carcinomas (Bao et al. 1996). In breast cancer, higher levels of the protein correlated with greater metastatic potential (Bao et al. 1998). This is in contrast with their earlier studies (Gold et al. 1997). Gold et al. (1997) had encountered higher Tβ15 expression in nonmetastatic breast cancer, which suggested the involvement of thymosins in the early stages of breast cancer development rather than in the late stages of the disease. Although much attention has been focused on β-thymosins, Tsitsilonis et al. (1998) found α-thymosins to be of prognostic value in breast cancer. They determined levels of prothymosin α and parathymosin α in breast carcinoma tissue as well as in tissues from benign breast disease, and found that levels of both are much higher in carcinomas than in benign tumour tissue and normal breast tissue. They also reported that these levels correlated with overall survival of patients. As stated before, Tβ4 expression has been found to be very high in Dunning rat prostate carcinoma cells, which possess high motility. When Tβ4 antisense constructs were transfected into these cells the invasive ability was suppressed,
96
Calcium Signalling in Cancer
suggesting that the high levels of Tβ4 expression might be associated with high invasive ability. Contrary to this, transfection of adenovirus E1A and E1B genes has been carried out in a highly metastatic human melanoma cell line by Van Groningen et al. (1996) who reported that a number of markers for tumour progression were down-regulated as a consequence. Among them was Tβ10. Admittedly, E1A gene products can inhibit oncogene-mediated cell transformation as well as invasion and metastasis in certain animal models. E1A protein is known to be able to induce and stabilise p53 phosphoprotein, which controls the G1-S checkpoint transition of cells, and this is accompanied by apoptic loss of cells. On the other hand, E1B protein can bring p53 levels to normality (Sherbet and Lakshmi, 1997b). However, the raft of changes produced by the transfection of the adenovirus genes makes it a rather inappropriate model for the study of tumour progression. Although the transfected cells may have shown a reduction in tumorigenicity upon implantation into compatible hosts, under these circumstances it would be difficult, even unacceptable, to try to extrapolate as to the significance of the suppression of individual markers in relation to tumorigenicity. Some of the difficulties are inherent in the interpretation of data obtained from experimental studies such as gene transfer in vitro and on tumour tissues from patients. Therefore, it is imperative that further studies be undertaken to assess the potential value of thymosins in determining the state of tumour progression.
THE FIMBRIN FAMILY OF ACTIN-BINDING PROTEINS MOLECULAR FEATURES
OF
FIMBRIN
Fimbrins are EF-hand calcium-binding proteins that actively participate in binding to and bundling of actin. In actin filaments, one molecule of fimbrin might bind eight actin monomers under optimal conditions (Namba et al. 1992). Fimbrins are highly conserved in evolution, with regard to both their structure and function. Fimbrin from diverse origins, e.g., from Dictyostelium discoideum to humans, share structural and biochemical properties. Fimbrin-like proteins have also been isolated from plants, such as wheat (Triticum aestivum) and Arabidopsis thaliana (CruzOrtega et al. 1997). The Dictyostelium fimbrin is a 67-kDa protein containing two EF-hands that are followed by two actin-binding sites (Prassler et al. 1997). The Nterminal actin-binding domain is a highly conserved domain that fimbrin shares with other actin-binding proteins. This N-terminal domain contains two tandem calponin homology (CH) domains which are implicated in the binding of F-actin (Goldsmith et al. 1997). Fimbrin-mediated cross-linking and bundling of actin is regulated by free calcium, which it binds with high affinity and selectivity. However, the optimal concentration for cross-linking of actin was determined to be below 0.15 µM. This process was progressively inhibited at higher free calcium concentrations and halfmaximal inhibition of cross-linking occurred at 1.6 µM Ca2+ concentration (Pacaud and Derancourt, 1993). Pacaud and Derancourt (1993) also noted that calciumbinding of fimbrin, in the concentration range of 0.15 to 1.5 µM, produced conformational changes in the molecule, to which they attribute the calcium-mediated regulation of fimbrin function. It may be that the conformational alterations actuated
The Structure of Contractile Proteins
97
by calcium at different concentrations could render actin cross-linking reversible. A further possibility has arisen from the studies of Hanein et al. (1997a) that fimbrin might induce conformational changes in actin itself. Both types of change will inevitably contribute to cell behaviour. Fimbrins form a large family of proteins. Four genes encode fimbrin in Salmonella (Collinson et al. 1996). Three isoforms of fimbrin have been identified and designated as I-fimbrin, L-fimbrin, and T-fimbrin. I- and L-fimbrin are characteristically associated with intestinal and kidney epithelia, leukocytes, and tumours, whereas T-fimbrin shows a more general distribution in a variety of cells and tissues (Chafel, 1995).
FUNCTION
OF
FIMBRIN
IN
CYTOSKELETAL ORGANISATION
A major function of fimbrin appears to be in the assembly of actin filaments. Fimbrin as well as actin capping protein (CP) are required for proper assembly of these filaments in the yeast Saccharomyces cerevisiae. There is a reduced filament assembly and fimbrin in the CP mutants of the yeast. Actin obtained from CP mutants shows defects in polymerisation as well as in its binding to fimbrin (Karpova et al. 1995). In mammalian cells, Rho GTPases may mediate actin filament assembly and bundling. A constitutive expression of the Rho GTPase Cdc42Hs causes impairment of cytokinesis of HeLa cells. This seems to be a consequence of a reorganisation of F-actin with which, among other actin-binding proteins, T-fimbrin is associated (Dutartre et al. 1996). Functional conservation of fimbrin isoforms has been amply demonstrated by Adams et al. (1995), who found that human T- and L-fimbrin can substitute for the yeast fimbrin called Sac6p. T- and L-fimbrin were both able to complement the temperature-sensitive growth defect that is seen in sac6 null mutants, and they could also restore normal cytoskeletal organisation and cell shape in these mutants. The null mutants show defective sporulation, which is restored by human T- and L-fimbrin (Adams et al. 1995). Fimbrin isoforms show not only a tissue-specific distribution, but the specificity appears also to extend to differentiation and morphogenesis. Fimbrin shows a definable temporal and spatial pattern of expression in the course of the development of the cochlea and may be involved in the formation of the inner and outer stereocilia of the hair cell (Zine et al. 1995). The differentiation of intestinal epithelium is associated with the expression of T-fimbrin in the apical area of the cell and Lfimbrin in the basal area, until 14.5 days of development. Both isoforms are said to be totally down-regulated in expression by day 16.5, but instead, I-fimbrin appears on day 14.5 of development to give the epithelium a brush border-like localisation. These findings, reported by Chafel et al. (1995), suggest possible differences in their function in the course of differentiation. A number of the events occurring in morphogenesis and differentiation require changing patterns of cell adhesion, for which fimbrin seems to be ideally placed. Babb et al. (1997) studied the localisation of fimbrin in mature as well as differentiating osteoclasts. Fimbrin is a component of the osteoclast adhesion complexes called podosomes. During migration podosomes are found at the cell periphery. Microfilament organisation and podosome assembly is important in the rapid modulation of adhesion to the substratum, and
98
Calcium Signalling in Cancer
in the motility of cells. T- and L-fimbrin, but not I-fimbrin occurred as an integral component of the core of the podosomes throughout the process of monocyte-derived osteoclast differentiation. The levels of T-fimbrin increased with and appeared to be related to the formation of podosomes. The involvement of fimbrin in podosomes is compatible with the association of fimbrin with the adhesive organelles called fimbriae that have been described in bacteria. Fimbriae are fibre-like structures that mediate the attachment of bacteria to host cells. These are assembled from fimbrin subunits (Smyth et al. 1996). Frederick et al. (1996) investigated the adhesive interactions between lymphokineactivated killer (LAK) cells and came to the conclusion that fimbrin might be an important factor in intercellular adhesive contacts. They also showed that contact between LAK cells and target tumour cells, namely SK-Mel-1 human melanoma cells and Raji lymphoma cells, leads to the phosphorylation of L-fimbrin of the LAK cells. S.L. Jones et al. (1998) have also suggested that induction of fimbrin phosphorylation is an important step in fimbrin function. However, as discussed below, the question of whether phosphorylation leads to fimbrin activation must be regarded as sub judice at present. Podosomes that participate in cell adhesion and locomotion have been found to contain other cytoskeletal linking proteins such as talin and vinculin, besides fimbrin. L-fimbrin has been shown to regulate integrin-mediated adhesion of leukocytes (S.L. Jones et al. 1998). It is possible that fimbrin is instrumental in the organisation of physical pathways, such as fimbriae and podosomes, by which extracellular signals for intercellular and cell–substratum adhesion are transduced to the cell. Another membrane organelle with which fimbrin might be associated in organising a signal transduction machinery is the caveola. Caveolae are plasma membrane invaginations, of 50 to 100 nm dimension, that occur in many cell types. Caveolae have been attributed with many functions, notably transport of molecules across endothelia and signal transduction (Lisanti et al. 1995). A major component of caveolae is a 21- to 24-kDa protein called caveolin. Caveolin is said to function as a scaffolding protein that organises the signalling molecules in the caveolae. That caveolae contain essential components of the signal transduction machinery may be deemed to be firmly established. Thus caveolin has been shown to interact directly with signal transduction molecules such G-protein α subunits and the ras protein (Lisanti et al. 1995; Song et al. 1996). The receptors for PDGF and EGF are located in caveolin-rich microdomains, and caveolin has been shown to interact directly with the EGF receptor (G.X. Liu et al. 1996; Couet et al. 1997). The interaction of caveolin negatively regulates RTK activities associated with activated EGFr and cerbB2 (Couet et al. 1997), and in mammary tumours expressing c-erbB2, caveolin expression is down-regulated (Engelman et al. 1998). Therefore, this interaction between growth factor receptors and caveolin may deregulate the transduction of the growth factor signals. Compatible with this view are recent reports that overexpression of caveolin results in growth inhibition of tumour cells (S.W. Lee et al. 1998; T. Suzuki et al. 1998). On the other hand, caveolin has been associated with cancer progression. It is reported to be overexpressed in infiltrating ductal carcinoma of the breast and prostate. In prostate cancer, caveolin is expressed in both primary and metastatic tumours (N. Yang et al. 1998). These two sets of data may appear to
The Structure of Contractile Proteins
99
contradict each other, but it is possible to envisage caveolin functioning as a growth inhibitor in the early stages of tumour development. Caveolin might function in later stages of tumour progression merely by virtue of its ability to promote cell–cell and cell–substratum adhesion, which are essential requisites for a successful transition of the cancer cell along the metastatic cascade. In this connection, it would be worthwhile to note that T-cadherin, an adhesion-mediating molecule, also occurs in caveolin-rich plasma membrane microdomains (Philippova et al. 1998). After a seemingly long digression, it should also be noted that fimbrin is a component of the caveolae. Fimbrin occurs together with other proteins, e.g., src and ezrin, in cell membranes that are rich in caveolin (Mirre et al. 1996). The available evidence, albeit circumstantial in nature, may be interpreted as implicating fimbrin in tumorigenesis and tumour progression by deregulating signal transduction pathways and cell adhesion mechanisms.
REGULATION
OF
FIMBRIN EXPRESSION
The apparent tissue-specific distribution of fimbrin isoforms has led inevitably to investigations directed toward understanding the mechanisms of fimbrin expression and whether there is any tissue-specific regulation of its expression. C.S. Lin et al. (1997) have characterised the promoters of human and murine L-fimbrin. They described considerable similarity in the organisation and found that both promoters functioned with equal efficiency in most cell types. Therefore, the apparent tissuespecific and differentiation-related expression of fimbrin could be due to posttranscriptional modification of fimbrin rather than to its regulation at the transcriptional level. Phosphorylation could be a mechanism of regulation of fimbrin function, as demonstrated for L-fimbrin. The serine residues of the head-piece region of L-fimbrin are phosphorylated (Messier et al. 1993), although earlier, Namba et al. (1992) found unphosphorylated L-fimbrin of human T cells to be quite effective in F-actin bundling. Shinomiya et al. (1995) reported that LPS stimulated the phosphorylation of L-fimbrin in macrophages. Phosphorylation occurred on amino acid residues at the N-terminal region close to the first Ca2+-binding domain. Shinomiya et al. (1995) also noticed that the phosphorylated region contained motifs that are phosphorylated by CK II, protein kinase A (PKA), and PKC, but not motifs specific for MAPK. Frederick et al. (1996) also have recently implicated PKC in fimbrin phosphorylation and have confirmed further that only serine, not tyrosine, residue is phosphorylated. The possible linkage of fimbrin function with phosphorylation is indicated by the ability of cytokines and phorbol esters, among other agents, to induce fimbrin phosphorylation. Polymorphonuclear leukocytes (PMN) stimulated by IL-8, IL-1, neutrophil-activating proteins, monocyte-derived neutrophil chemotactic factor, and TNF have been reported to stimulate the phosphorylation of I-fimbrin. Phosphorylation was also influenced by phorbol 12-myristate 13-acetate (PMA) (Shiroo et al. 1988; Shibata et al. 1993a, 1993b). Fimbrin of T cells is phosphorylated in response to IL-2 (Zu et al. 1990). The adhesion of neutrophils to immune complexes induces L-fimbrin phosphorylation. Furthermore, it appears that phosphorylation-mediated regulation may be distinct from calcium-mediated regulation of fimbrin (Jones and Brown, 1996). It seems likely that the transduction of extracellular signals involves
100
Calcium Signalling in Cancer
this important component of the membrane cytoskeleton. However, despite the clear demonstration of a fimbrin phosphorylation response to extracellular signals, there is little direct evidence that these features are functionally related. Messier et al. (1993) provide circumstantial evidence for this. They found phosphorylated fimbrin was mainly associated with the insoluble cytoskeleton. When this is read with their observation that the serine residues of the head piece were specifically phosphorylated, one might be justified in concluding that phosphorylation could regulate the process of actin-binding and bundling by fimbrin. Whether the isoforms have different functions in the regulation of cell morphology is a question that has been addressed, albeit superficially, by Arpin et al. (1994). In CV1 fibroblast-like cells, both T- and L-fimbrin cause change of cell shape and reorganisation of the actin stress fibres, and only L-fimbrin is associated with microfilaments. In epithelial cells such as LLC-PK1 cells, T-fimbrin remains associated with actin filaments of microvilli and produces shape changes in them. Lfimbrin has no effect on these structures. These observations might suggest functional differences between the isoforms. The invasion of Shigella flexneri, a bacterium that causes dysentery in humans, involves the formation of heavy actin polymerisation and actin bundling near the site of host cell contact with the bacterium. These bundles form protrusions with which the bacterium coalesces. Adam et al. (1995) experimentally overexpressed T- and L-fimbrin in HeLa cells and demonstrated that Tfimbrin might be preferentially recruited to the zone of bacterial entry.
IS FIMBRIN INVOLVED
IN
CANCER?
The potential of fimbrin to modulate cell behaviour is obviously quite considerable. There are references in the literature since the early 1980s that fimbrin expression increases with cell transformation, especially in fibroblast cells. However, little incisive investigation seems to have been carried out. More recent investigations have pursued the worthwhile aim of establishing a role for fimbrin in neoplastic transformation and tumour progression. The expression of L-fimbrin has been investigated in cell lines derived from carcinoma of the prostate. L-fimbrin has been found in many carcinoma cell lines, but not in normal epithelial cell lines derived from the prostate. L-fimbrin occurs at higher levels in prostate cancer tissue as compared with normal prostate tissue. Immunohistochemical staining has suggested that the increase of fimbrin occurs predominantly in the glandular epithelial cells of the carcinoma, whereas in normal prostate tissue, it is found mainly in the fibromuscular stroma. It would have been interesting to explore the fimbrin expression pattern of benign prostatic hyperplasia (BPH). Nonetheless, the differences shown to exist between normal prostatic epithelium and carcinomatous glandular epithelium are persuasive enough to accept that fimbrin expression may be related to the carcinomatous changes. Interestingly, fimbrin expression was also reported to be rapidly up-regulated in LNCaP cells by dihydrotestosterone and oestradiol (J.P. Zheng et al. 1997). This observation does not per se contribute much to the argument that fimbrin is involved in the transformation of normal epithelium to carcinoma. Testicular hormones are the major factors that regulate the growth and development of the prostate. It is
The Structure of Contractile Proteins
101
possible that changes in hormonal milieu are responsible for the development of BPH and onward to the development of prostatic carcinoma. Androgen receptors (ARs), oestrogen receptors (ERs), and progesterone receptors (PgR) occur in BPH and in prostate cancer (Srinivasan et al.1995). Indeed, AR occurs in all histological types and all clinical stages of prostate gland cancer. Because androgens are involved in the development of the prostate itself, it would be reasonable to suppose that AR occurs in the developing prostate as well. Therefore, one would expect that the androgen-sensitive cell line LNCaP would respond by an altered level of fimbrin. What is crucially important is to find out whether normal epithelial cells respond differently from carcinomas. Testicular hormones bind to the appropriate receptors and stimulate the transcription of androgen-responsive genes, including those that regulate the growth of prostate cells. It should be borne in mind, further, that the progression of prostate cancer is associated with a change from androgen-dependent to androgen-independent state. The fimbrin gene may be a steroid-regulated gene, and it is important to determine whether this is the case, and whether androgen differentially stimulates fimbrin transcription in normal prostatic epithelium and prostatic carcinoma cells. Another isolated observation, which may, nonetheless, be significant in the context of drug resistance of tumours, is the relationship discovered by Hisano et al. (1996) between cisplatin resistance and fimbrin expression. They observed that cisplatin-resistant cells possessed severalfold greater levels of T-fimbrin compared with sensitive cells. They transfected T-fimbrin antisense cDNA into cisplatin-resistant cells and showed that reduction of fimbrin expression resulted in increased sensitivity to the drug.
MODULATION OF ACTIN DYNAMICS DISSEMINATION
AND
CANCER CELL
Conceptually there can be no difficulties in accepting the proposition that the modulation of actin dynamics should be involved in some way with tumour dissemination. A reasonable body of experimental evidence, in the form of changes in the expression of gelsolin, thymosins, and fimbrin in cancer progression, has been adduced in support of this concept. In this context of actin-interacting proteins, the vasodilator-stimulated phosphoprotein (VASP) deserves a mention. VASP is approximately 45 to 50 kDa in size and occurs in domains of the plasma membrane that are involved in the formation of lamellipodia (Reinhard et al. 1992, 1995b). Together with the Drosophila- and murine-enabled (Ena) proteins, VASP belongs to a family of actin-binding proteins that are actively engaged in the regulation of the actin cytoskeleton. VASP has been shown to interact with actin stress fibres via its Cterminal region (Huttelmaier et al. 1999). VASP as well as Ena can interact with the actin CP profilin (see below) (Reinhard et al. 1995a) and with focal adhesion proteins (Reinhard et al. 1995b, Brindle et al. 1996; Lanier et al. 1999; AhernDjamali et al. 1998). This suggests that the VASP family members might be involved in signal transduction (Huttelmaier et al. 1998). Besides, during in vitro morphogenesis of human umbilical endothelial cells, VASP, profilin, and gelsolin are markedly up-regulated (Salazar et al. 1999). In view of the close association of all three
102
Calcium Signalling in Cancer
proteins in actin dynamics, Salazar et al. (1999) have postulated that reorganisation of the actin cytoskeleton is required for the alignment of the endothelial cells during capillary morphogenesis. The expression of profilin or VASP in neoplastic transformation has not been studied in great detail. NIH3T3 fibroblasts that have been made VASP deficient by experimental manipulation have been reported to be able to form tumours in nude mice. In vitro, these cells show loss of contact inhibition and a deregulation of cell proliferation (Liu K.Y. et al. 1999). With the demonstration that these proteins are associated with capillary morphogenesis, it would be of much interest to see whether VASP and/or profilin are down-regulated in neoplastic transformation. One can envisage that perturbation of the actin cytoskeleton could make the cell membrane malleable and the cell more deformable and in this way aid invasion. Mechanistic perturbations in endothelial cell alignment could generate abnormal fenestration in tumour-associated microvasculature that might serve as ports of entry into the vascular compartment for tumour dissemination. These observations highlight the potential importance of CBPs in cancer invasion, and also provide a fertile ground for extracting information that might be highly relevant in assessing the degree of malignancy of cancers and in cancer management.
α-ACTININ The actin cytoskeleton is regulated by several actin-binding and cross-linking proteins that are themselves regulated by free calcium. α-actinin is an EF-hand protein approximately 110 kDa in size and it forms a major component of the cytoskeleton in many cell types. It forms antiparallel, highly stable homodimers. Actinin isoforms can also form heterodimers, both in vivo and in vitro (Y.M. Chan et al. 1998). Y.M. Chan et al. (1998) suggest the possibility that heterodimers formed by different isoforms could potentially have new functional characteristics. The dimerisation of smooth muscle actinin is believed to be mediated by a segment of the C-terminal region of the molecule (Baron et al. 1987; Imamura et al. 1988; Kahana and Gratzer, 1991; A.P. Gilmore et al. 1994). This segment has two cross-linking sites (A and B), and the actinin molecules form cross-links in an antiparallel fashion by the binding of an A site of one molecule with the B site of the second molecule (Imamura et al. 1988). Several isoforms of α-actinin have been identified from vertebrate cytoskeletal, skeletal, and smooth muscle sources (Duhaiman and Bamburg, 1984; Imamura and Masaki, 1992; Landon et al. 1985; J.P. Bennett et al. 1984). Isoforms also have been isolated from invertebrate sources such as Dictyostelium discoideum (Noegel et al. 1987) and Drosophila melanogaster (Fyrberg et al. 1990). A cDNA has been cloned from the nematode Caenorhabditis elegans. The sequence of this clone predicts that it codes for an α-actinin, which possesses a high degree of sequence homology to actinin from other sources (Barstead et al. 1991).
MOLECULAR STRUCTURE
OF
α-ACTININ
α-actinin is an EF-hand calcium-binding protein. Two EF-hands are located at the Cterminal region of the molecule. An actin-binding domain occurs at the N-terminal
The Structure of Contractile Proteins
103
end, followed by the rod domain, which consists of four spectrin-like repeat elements, followed by the EF-hand to the C-terminus (A. Blanchard et al. 1989; Flood et al. 1995). The rod domain is required for stable dimerisation of the molecule, and dimerisation is reduced markedly if either of terminal repeats 1 and 4 is deleted (Flood et al. 1995). Although all the isoforms possess EF-hands, these have been found to be in a functional state only in the nonmuscle or cytoskeletal isoforms of α-actinin (Burridge and Feramisco, 1981; Duhaiman and Bamburg, 1984). Their significance has been elucidated by introducing point mutations to make them nonfunctional. The first EF-hand seems to regulate the Ca2+-dependent cross-linking activity of α-actinin (Janssen et al. 1996). Nonmuscle isoforms might themselves differ in calcium-binding ability (Imamura et al. 1994). The EF-hands of α-actinin isoforms 2 and 3 of human skeletal muscle are not capable of binding calcium, and therefore the binding of these isoforms to actin might not be calcium sensitive (Beggs et al. 1992). Calcium sensitivity or the lack of it can be viewed from a functional viewpoint. The EF-hands appear to undergo conformational changes from a closed position in the absence of calcium, to an open position when calcium is present (Trave et al. 1995). The open conformation may be conducive to protein–protein interactions, which are required for the transduction of signals via the actin cytoskeleton.
α-ACTININ ISOFORMS Two skeletal isoforms of α-actinin have been designated as α-actinin-2 and -3 and two nonmuscle isoforms as α-actinin-1 and -4 (Millake et al. 1989; Beggs et al. 1992, 1994; Honda et al. 1998). The skeletal muscle isoform α-actinin-2 is found in both human skeletal and cardiac muscle, but α-actinin-3 occurs only in limb skeletal muscle (Beggs et al. 1992). The isoforms α-actinin-1 and -4 occur in the actin microfilament bundles and at the adherens junctions. In skeletal, cardiac, and smooth muscle, α-actinin is localised to the Z-discs and dense bodies, and it participates in the anchoring of the actin thin filaments and giant titin molecules to the Z-disc (Endo and Masaki 1984; Geiger et al. 1990). α-actinin has been shown to interact with an N-terminal domain of titin in vitro (Ohtsuka et al. 1997). In the Zdisc, the assembly of the actinin–titin complex seems to involve two types of interaction between titin and α-actinin. In the other regions of the Z-disc, titin binds by means of a single binding site with the outermost pair of α-actinin molecules, but in the middle of the Z-disc the titin binds several α-actinin molecules through binding sites at their C-terminal region (Young et al. 1998). Thus α-actinin seems to play a major part in anchoring actin thin filaments of the two halves of the sarcomere at the Z-disc (see Figure 15). Abnormal expression of α-actinin and other thin filament-associated proteins are known to interfere with the assembly of Zdiscs, which could lead to the formation of so-called nemaline bodies. Two loci are known to be involved in nemaline myopathy: the tropomyosin-3 locus and the nebulin locus on 2q21.2–q22. Mutations of both genes have been implicated in this form of myopathy (Laing et al. 1995; Pelin et al. 1999). The formation of the complex of tropomyosin, titin, nebulin, α-actinin, and actin can conceivably be affected by these mutations, leading to abnormalities in Z-disc assembly and the formation of nemaline bodies.
104
FUNCTION
Calcium Signalling in Cancer OF
α-ACTININ
α-actinin functions predominantly in F-actin bundling and anchoring of the filaments to specific sites within the cell as well as to the cell membrane and in the linking up of the cytoskeletal machinery to the ECM. α-actinin might form a bridge between the actin cytoskeleton and integrin receptors then function as a receptor for components of the ECM (Burridge et al. 1990; Geiger et al. 1990). The cytoplasmic tail of βintegrins and intercellular adhesion molecule-I (ICAM-I) interact with α-actinin via binding sites occurring in the rod domain. Furthermore, α-actinin appears to link the cytoskeleton to the cell membrane (Baron et al. 1987). Kahana and Gratzer (1991) have identified binding sites for long-chain fatty acids in the spectrin-like repeats of the α-actinin domain rod. Han et al. (1997) recently have shown that bundling of actin filaments occurs if diacylglycerol is present in the membrane. It follows, therefore, that α-actinin would be an important component of the signal transduction pathway as well as an important link in the cytoskeleton-mediated changes in cell shape and motility. Miyamoto et al. (1995) have delineated the pathway of integrin-mediated signal transduction. They reported that integrin aggregation induced the accumulation of several signal transduction molecules, such as Rho A, Rac1, ras, raf, and others, of cytoskeletal components, such as vinculin, talin, and α-actinin. The tyrosine kinase inhibitor genistein inhibits accumulation of both the signal transduction molecules and the cytoskeletal signal transduction components.
ACTININS IN CELL ADHESION, MOTILITY, AND SIGNAL TRANSDUCTION The cross-linking of actin filaments increases filament elasticity and viscosity and may be expected to affect the structural properties of actin filaments. It follows from this that actinin might, in this fashion, change the properties of the cell membrane, such as intercellular and cell–substratum adhesion, which in turn would be reflected in alterations in cell shape and motility. These changes will have serious implications for cancer invasion and secondary spread. Furthermore, there are strong indications that actin cross-linking in endothelial cells might result in metabolite transport and permeability. Although yet to be demonstrated, one would expect that alterations in the organisation of adherens junctions might effectively alter endothelial integrity and lead to enhanced tumour cell diapedesis across the endothelium. Changes in the structural properties of the actin cytoskeleton would impugn the link-up between it and the ECM. Such changes would affect seriously the physical pathway of signal transduction, and effectively lead to its deregulation, and eventually to the deregulation of intercellular adhesion and communication and of cell proliferation and growth.
THE CADHERIN–CATENIN COMPLEX CELL ADHESION
IN
SIGNAL TRANSDUCTION
AND
A signal transduction complex that occurs in the cell membrane, consisting of the transmembrane glycoprotein cadherin and other components such as α-actinin, βcatenin, and the adenomatous polyposis coli (APC) protein, has assumed considerable significance by virtue of its apparent dual function, namely in signal transduction
The Structure of Contractile Proteins
105
and cellular adhesion. Intercellular adhesion mediated by cadherin is dependent on the integrity of the link-up with the actin cytoskeleton (Sherbet and Lakshmi, 1997b) (Figure 13). β-catenin subserves two functions, viz. as a signal transduction molecule and in the formation of adherens-type junctions. Its participation in signal transduction has become apparent with the demonstration that plakoglobin and β-catenin are homologues of the armadillo protein of Drosophila that is involved in segment polarity. N-terminus
2+
Extracellular Ca
binding domains
Plasma membrane β-catenin α-catenin α-actinin Actin filaments
Adherens junction protein APC Protein
FIGURE 13 Schematic representation of the interaction of the transmembrane adhesion protein cadherin with the actin cytoskeleton, via β-catenin, α-catenin, and α-actinin. (Based on van Roy [1992] and Sherbet and Lakshmi [1997b]). Reprinted by permission of the publisher Academic Press, from The Genetics of Cancer, (Sherbet and Lakshmi, 1997b).
The armadillo (arm) protein is a component of the signal transduction pathway of the wg (wingless) molecule (Riggleman et al. 1990). The arm family of proteins, e.g., β-catenin, plakoglobin, and the p120ctn protein, are characterised by a central arm repeat domain (Riggleman et al. 1989). The p120ctn gene potentially can code for a large number of isoforms that are generated by alternative splicing, and these have been regarded as constituting a subfamily of signalling proteins (Keirsebilck et al. 1998b). Jou et al. (1995) have shown that β-catenin binds to a C-terminal 25 amino acid region in the cytoplasmic domain of E-cadherin and to the N-terminal domain of α-catenin. The p120ctn protein, on the other hand, seems to bind to a juxtamembrane domain of the cadherin cytoplasmic tail (Yap et al. 1998). The armadillo and wg proteins exert similar effects on embryonic development (Peifer et al. 1991). A family of wnt proteins has been identified. The wnt protein is a secreted glycoprotein signalling factor. It is a vertebrate homologue of wg and has been shown to be a regulator of morphogenesis of Xenopus (Gumbiner, 1996; Miller and Moon, 1996). In a similar vein, β-catenin and plakoglobin are components of the signal transduction pathway of the wnt gene as well as being involved in the formation of adherens junctions and Ca2+-mediated cell–cell adhesion (Hinck et al. 1994; Peifer, 1995). Cadherin, as a part of this signalling complex, not only regulates intercellular adhesion, but also seems to negatively regulate the signalling function of β-catenin. These two functions can be dissociated. Fagotto et al. (1996) noticed that β-catenin deletion mutants affect cadherin-mediated adhesion but not its signalling function. Sanson et al. (1996) showed that a full length E-cadherin and a
106
Calcium Signalling in Cancer
truncated form of cadherin that have opposite effects on cadherin-dependent adhesion, nonetheless function effectively in wg signalling. Two further elements are involved in the signal transduction complex involving E-cadherin and catenins. One is the APC protein and the other component is axin or conductin. β-Catenin forms complexes with both axin and APC. The APC protein is known to compete with cadherin in its binding to the internal repeats of β-catenin. The β-catenin/APC complex is phosphorylated by the glycogen synthase kinase GSK3β. A consequence of this phosphorylation is that the degradation of β-catenin is greatly enhanced (Munemitsu et al. 1995; Hayashi et al. 1997; Hart et al. 1998). Axin also induces β-catenin degradation and is suggested to function downstream of APC (Behrens et al. 1998). The GSK3β-mediated phosphorylation is inhibited when the wnt signal transduction pathway is active. This results in the accumulation of β-catenin in the cytoplasm (Hinck et al. 1994; Giarre et al. 1998; Papkoff and Aikawa, 1998) and leads to the formation of a complex with the T-cell factor/lymphoid enhancer factor (Tcf/Lef). The binding between them occurs via the arm repeats. This complex functions as a transcription factor in the wnt/wg signalling pathway (Behrens et al. 1996; Van de Wetering et al. 1997). The pathway might be deregulated by inhibition of β-catenin degradation, leading to a constitutive activation of the transcription complex (Figure 14).
Axin/conductin Wnt/Wg
APC/β-catenin
APC-P/β-catenin-P
GSK3b
β-catenin Cell adhesion
β-catenin degradation
β-catenin/Tcf-Lef Transcription complex
FIGURE 14 The wnt signal transduction pathway and cell adhesion signal involving βcatenin, APC, and cadherin. (Based on references cited in the text.)
The deregulation that accompanies neoplastic changes seems to be more frequently due to mutation of β-catenin or APC protein than to inactivating mutations of E-cadherin (Morin et al. 1997; Efstathiou et al. 1999). These mutations seem to stabilise β-catenin. They occur at the phosphorylation sites that are essential in the ubiquitination and degradation of the protein. β-catenin mutations occur in approximately 50% of colorectal tumours. Again, these tend to occur in the serine/threonine phosphorylation sites. They seem to occur more frequently in small adenomas than
The Structure of Contractile Proteins
107
in larger adenomatous lesions. Furthermore, a majority of the mutations have been found in adenomas rather than in carcinomas (Samowitz et al. 1999). A high rate (61% of 31 patients) of somatic mutation of β-catenin has been encountered in human anaplastic thyroid carcinoma (Garcia-Rostan et al. 1999). In a murine hepatocarcinoma model, mutations have been reported to occur in the carcinomas but not in adenomas. These findings suggest that deregulation of signal transduction occurs as an early event in the pathogenesis and progression of tumours. The βcatenin mutations in colorectal tumours reported by Samowitz et al. (1999) were not accompanied by APC mutations. The suggestion has been made, therefore, that mutations of APC and β-catenin might be functionally different. Mutations of APC leading to the loss of its suppressor function have been identified with the familial adenomatous polyposis, and are also closely related to the progression of the disease. Furthermore, mutated APC seems to lack the ability to regulate β-catenin levels. Therefore, APC may be regarded ipso facto as functioning upstream of β-catenin. The adhesion function of β-catenin flows from its linkage to cadherin, which spans across the cell membrane, on the one hand, and to the cytoskeleton, on the other, by means of two other elements, namely α-catenin and α-actinin. In fibroblasts, this linkage has been demonstrated by Knudsen et al. (1995), who also noted that α-actinin specifically immunoprecipitates with β-catenin and cadherin. Niesset et al. (1997) have identified the binding sites involved in the interaction of α-catenin with β-catenin on the one hand and with α-actinin on the other. In normal thyroid epithelial cells, the intercellular adhesion junctions show the presence of cadherin together with the catenins. In contrast, CGTHW-2 cells derived from thyroid carcinoma show a marked alteration in the pattern of distribution of these linking proteins in the foci of intercellular adhesion. Further evidence in support of the importance of the integrity of the cadherin–catenin complex in intercellular adhesion comes from the apparent involvement of the Rho GTPase family in the regulation of cadherin-mediated cell adhesion. IQGAP1, which is an effector of two members of the family, namely Cdc42 and Rad, has been shown to be able to dissociate α-catenin from the cadherin/β-catenin/α-catenin complex. This results in the disruption of intercellular adhesion. Both Cdc42 and Rad counteract this process (Kaibuchi et al. 1999). The inhibition of Rho and Rac (another member of the Rho GTPase family) has been reported to lead to a disruption of E-cadherin localisation at keratinocyte–keratinocyte cell junctions. However, when the GTPases themselves are inhibited, the cadherin-mediated adhesive contacts are reestablished (Braga et al. 1999). Rho protein, when microinjected into four-cell blastomere-stage embryos, disrupts cortical microfilaments and reduces interblastomere adhesion. Cdc42 in the same way also disrupts the cortical cytoskeleton and interblastomere contacts (Clayton et al. 1999). But the modes of involvement of Rho and Cdc42 are clearly distinguishable in NIH3T3 cells transformed by the dbl oncogene, which codes for a supposed exchange factor for RhoA and Cdc42. The transformed cells respond to adhesion to fibronectin substratum by changing cell shape. This involves the activation of RhoA and the associated ROCK and CRIK, but not Cdc42. In nontransformed cells, however, change of cell shape seems to require Cdc42 activation (Olivo et al. 2000). Rho GTPases may also be involved in the regulation of endothelial cell adhesion involving cadherins. Rho
108
Calcium Signalling in Cancer
GTPases are also involved in the regulation of the function of other adhesionmediating glycoproteins such as CD44. Therefore, prima facie there is a reasonable basis for investigating their role in maintaining the integrity of the vascular endothelia and possible implications for metastatic spread of cancer. Other proteins that link the plasma membrane with the actin cytoskeleton may disrupt cadherin-mediated adhesion. The proteins ezrin, radixin, moesin, and merlin subserve such a linking function. Hiscox and Jiang (1999) used antisense nucleotides to inhibit ezrin expression in colon carcinoma cells and noticed that this resulted in a loss of intercellular adhesion and acquisition of motility. They further noticed that ezrin co-precipitated with E-cadherin and β-catenin. In cells treated with antisense ezrin nucleotides, this could result in a reduced interaction between ezrin and the cadherin complex. Such a reduction indeed occurs when ezrin is phosphorylated or when the cells are treated with hepatocyte growth factor. Huang et al. (1998) found no cadherin or γ-catenin at the adhesion junctions, and β- and α-catenins were distributed diffusely in the cytoplasm of most cells. However, β-catenin, when detected at intercellular junctions, was found to colocalise with α-actinin. Huang et al. (1998) have therefore suggested that the loss of intercellular adhesion could be due to an incorrect assembly of the linking components. Implicit also in this is the suggestion that such an incorrect assembly might lead to the acquisition of invasive ability. Although this is an attractive hypothesis, it should be mentioned here that Honda et al. (1998) have reported the occurrence of a novel actinin, namely actinin-4, whose expression is said to be upregulated with enhanced cellular migration. This new isoform is said to occur in the cytoplasm. It is reported to be associated with cytoplasmic extensions and is found in peripheral migrating cells of cell clusters. Actinin-4 appears to be translocated from the cytoplasm to the nucleus, when actin is depolymerised. Honda et al. (1998) have also examined the expression of this novel actinin in breast cancers. It is expressed in infiltrating breast carcinomas, and the expression was found to correlate with poor prognosis. Mamura and Masaki (1996) identified a 115-kDa α-actinin in vascular endothelial cells. This actinin differed from other known actinins of muscle or nonmuscle origin in its sensitivity to calcium. However, this isoform of actinin did occur in heart tissue, the pectoralis muscle, and the gizzard. What could be significant about this actinin in relation to cancer progression is its apparent location in the vascular endothelium. It is well known that several inflammatory agents induce a reversible change in endothelial cell shape that results in the formation of intercellular gaps. If cancer cells can reduce the endothelial integrity in this way, that could form ports of entry into the vascular system for cancer cells. There is a view that invading cancer cells take advantage of naturally occurring fenestration of the endothelium. There is no demonstration to date that they might secrete substances that could induce the formation of ports of entry. From this point of view it would be interesting to see if cancer cells induce any changes in the expression of actinins of the endothelial barrier. A new facet that can be added to the story of actinins in invasion and metastasis is their apparent relationship to the expression of metalloproteinases. It was shown some years ago that the production of these enzymes often paralleled the invasive
The Structure of Contractile Proteins
109
and metastatic abilities of cancers, which has suggested the possibility that metalloproteinases might reconstruct the ECM and provide cancer cells with ECM properties conducive to invasion (Sherbet and Lakshmi, 1997b). Crawford et al. (1999) have made some interesting observations on the expression of matrilysin and βcatenin. They found that β-catenin and matrilysin mRNAs were expressed in parallel in murine intestinal adenomas. A further observation of considerable importance is that β-catenin significantly up-regulated the matrilysin promoter. Because β-catenin is a structural component of signalling pathway and intercellular adhesion machinery, these experiments bring together, in a unique fashion, transduction of an extracellular signal that can putatively remodel the ECM and change the invasive behaviour of cells. Other cell adhesion molecules such as the ICAM similarly require interaction with the actin cytoskeleton. A peptide containing a cytoplasmic sequence of ICAM2 has been shown to interact with α-actinin in vitro. Indeed, interaction occurs between several sites of α-actinin and ICAM-2. Besides, ICAM-2 co-localises with α-actinin (Heiska et al. 1996). The epithelial ICAM (Ep-ICAM), an adhesion molecule regarded as specific for epithelial cell adhesion, has a cytoplasmic domain that regulates the cellular adhesion function. It appears that Ep-ICAM achieves this via α-actinin, with which Ep-ICAM appears to interact directly by means of specific binding sites (Balzar et al. 1998). Shigella flexneri, which causes bacillary dysentery, is known to induce changes in the cytoskeleton of epithelial cells. These changes result in the production of membrane protrusions that engulf the bacterium. The bacterium secretes a protein called IipaA. The cytoskeletal reorganisation, which is essential for this process of bacterial invasion, involves the recruitment by IipaA of the linking protein vinculin as well as α-actinin (Van Nhieu et al. 1997). The effects of the loss of α-actinin on cell shape, aggregation, and motility have been studied in Dictyostelium. Rivero et al. (1996) generated mutants lacking αactinin as well as the “gelation factor” and these mutants presented a rounded shape rather than the typical polarised morphology of aggregating cells. The mutants also showed considerable loss of motility. In rat bladder carcinoma cells, the experimentally induced loss of motility was associated with the reorganisation of F-actin and α-actinin (Morton and Tchao, 1994). The transmembrane integrin α2β1 functions as the receptor for the ECM components collagen and laminin. This integrin as well as α-actinin have been implicated in the invasive ability of melanoma cells in vitro. L.M. Duncan et al. (1996) reported that α-actinin was not detectable in benign melanocytic naevi and in laterally spreading lesions, but it occurred in all nodular melanomas and in metastatic melanomas. It would have been of much interest whether there was an association between α-actinin expression and the vertical growth of melanoma. EGF is known to alter cell morphology as well as promote cell invasion in vitro (Shiozaki et al. 1995). These cellular responses seem to originate from the linkage of the activated EGFr to the cytoskeletal system (Roy et al. 1989, 1991; Van Bergen en Henegouwen et al. 1989). There is some recent evidence that EGFr regulates intercellular adhesion by interfering with the formation of a complex between the invasive suppressor transmembrane protein E-cadherin and the actin cytoskeletal
110
Calcium Signalling in Cancer
elements, including α-actinin and β-catenin (Hazan and Norton, 1998; see also Figure 13). As alluded to earlier, the proliferative signal imparted to the cell by EGF is mediated by PKC. N.R. Murray et al. (1999) generated transgenic mice that express PKC-βII at high levels. The colonic epithelium showed high cell proliferation. Besides, the epithelium was more prone to preneoplastic changes. They found that these effects were also accompanied by increased expression of β-catenin and a reduction in glycogen synthase kinase 3β activity. These studies suggest, therefore, that EGFr-mediated signal follows the wnt/APC pathway of transduction leading to cell proliferation. This pathway also may be utilised in neoplastic changes of epithelia. Overall, these data now provide a physical basis for previous observations that high EGFr expression correlated with poor prognosis, and that EGFr status is a powerful marker of clinical aggressiveness and metastatic potential of tumours (Sherbet and Lakshmi, 1997b).
MYOSIN FILAMENTS Myosin is a filament protein found in association with actin in both muscle and nonmuscle cells. Like actin, myosin is a bipolar protein. It possesses a globular head region (subfragment S1), which interacts with actin, and a fibrous region, which promotes aggregation into filaments. The filaments consist of two myosin heavy chain (MHC) subunits and four myosin light chain (MLC) subunits. The class II skeletal myosin has two heads whereas other myosins have only one head. The N-terminal globular domain comprises the motor domain. The heavy chain subunit possesses the ATPase activity that provides the energy for the contractile force. The process of muscle contraction is driven by a cyclical interaction between actin and myosins. Myosins have been described as mechanoenzymes that catalyse the hydrolysis of ATP and release of energy, which is converted into mechanical force (Hasson and Moosekar, 1995). Energy is transduced by a series of interactions between myosin heads and hydrolytic changes of ATP. This is believed to deform the protein, and this change is transmitted to actin as a mechanical effect. The mechanical displacement and force generated in this way has been measured. The force generated by double-headed myosin is nearly twice as large as that produced by single-headed myosins (Tyska et al. 1999). In the skeletal muscle, the two heads of myosin interact when it is bound to filamentous actin (Rayment et al. 1993). The smooth muscle myosin heads interact in the presence of filament actin and in the absence of ATP (Onishi et al. 1992). Such head–head interaction also is required in the phosphorylation-dependent regulation of smooth muscle myosin (Matsuura and Ikebe, 1995). The processes of muscle contraction and cell motility are usually evaluated by an in vitro technique in which actin filaments are slid over myosin and measured using an electron microscope. Actin sliding as well as actin activation of myosin-ATPase is dependent on phosphorylation when myosin is dimerised, but not while myosin is in the monomeric form. Furthermore, the sliding velocity of the dimer is twice as large as that of the monomer (Sata et al. 1996).
The Structure of Contractile Proteins
111
MYOSIN HEAVY CHAIN (MHC) ISOFORMS A large number of MHC isoforms are known to exist (Table 6). There are preliminary reports that the pattern of their expression is modulated in embryonic development and also in association with certain disease processes. For instance, thyroid hormone is reported to alter the pattern of MHC isoform expression in embryonic development (Maruyama et al. 1995). During metamorphosis of Xenopus tadpoles, thyroid hormone has been reported to down-regulate the expression of embryonic but upregulate adult isoforms (Sachs et al. 1997). Modulations in MHC isoform expression have been reported in the progression of human atherosclerosis (Aikawa et al. 1995). Similar changes have also been described in tumour-associated fibrosis and in neoplastic transformation of breast epithelium (Chiavegato et al. 1995).
TABLE 6 Myosin Heavy Chain (MHC) Isoforms MHC Isoform Myosin I slow MHC 1β, α Myosin II fast MHC II a, b, x MCH 3 II c MHC1, MCH 9 Myosin II SM1 (204 kDa); SM2 (200 kDa) Nonmuscle MIIA, B1, B2 Unconventional myosins V, VI Myosin VIIa
Tissue Skeletal, cardiac, foetal Skeletal Foetal Skeletal, immature fibres Smooth muscle Fibroblasts, endothelial cells, macrophages Intestinal brush border, Va in a variety of cell types Cochlea, retina, testes, lung, kidney
Source: Based on several sources including Kelley and Adelstein (1994); Heintzelman et al. (1994); A. Kimura et al. (1995); Chiavegato et al. (1996); Galler et al. (1997); Hasson et al. (1997); Wu et al. (1998).
The metastasis-associated S100A4 (mts1), which is itself a CBP, has been found to bind to the myosin rod in the light meromyosin region and could be destabilising the myosin filament. Besides, S100A4 binding has been found to inhibit the actinactivated ATPase of myosin (Ford et al. 1997). These interactions could conceivably alter the faculty of motility, which has been associated with cancer invasion, and this is especially associated with high expression of S100A4. It would be of interest to note here that the unconventional myosin V could be involved in the mechanisms associated with filopodial extension of neuronal growth cones. When myosin V is inactivated, cones of dorsal root ganglia show a rapid retraction of the filopodia (F.S. Wang et al. 1996). The distribution of the nonmuscle isoforms of myosin II (A and B) shows a pattern that is compatible with their involvement in cell locomotion. These myosins occur in association with lamellipodia and around the cell nucleus. However, myosin IIA shows a preferential localisation along the leading edge, but
112
Calcium Signalling in Cancer
myosin IIB occurs along the trailing edge of cells in locomotion (Kolega, 1998). It is significant that, when injected into the cells, these isoforms show the same pattern of localisation as the endogenous variety. This has led to the suggestion that their localisation pattern is an intrinsic property of locomoting cells (Kolega, 1998). The apparent specificity of localisation may not be a consequence of their synthesis at specified sites, but could indicate that they are being targeted to those locations. HSPs are believed to behave like molecular chaperones for S100A4. HSPs might target S100A4 to the plasma membrane to be secreted into the ECM, and in this way endow the cells with invasive ability. Therefore, further effort into the possible mechanisms involved in the perceived specificity of myosin IIA and B localisation in the locomoting cell would be eminently worthwhile. Among other myosin-driven biological phenomena that may be cited here is cytokinesis in cell division. The myo2 gene of Schizosaccharomyces pombe encodes a protein called myo2, which shows a high degree of homology to myosin type II heavy chain. A contractile ring composed of actin and myo2 is formed before cytokinesis. Disruption of myo2 reportedly leads to an inhibition of cell proliferation (Kitayama et al. 1997). In Dictyostelium the formation of the contractile ring requires phosphorylation of myosin (Sabry et al. 1997). The unconventional myosin Va has been localised to the microtubule organising centre of interphase cells and to the mitotic apparatus in dividing cells. Using specific antibodies against myosin Va, Wu et al. (1998) have been able to demonstrate its association with microtubules in a number of cell types. The specificity of this association was obvious from experiments using cells that were derived from mice with null (dilute gene –/–) phenotype, in which no association with microtubules could be detected.
ACTOMYOSIN ASSEMBLY Myosin thick filaments are composed of two MHCs of 220 kDa and four MLCs of 20 kDa molecular size. The N-terminal end of MHC forms the globular head. The tail region of the filament is an α-helical coiled coil that constitutes part of the long rigid tail, of which the part proximal to the head region is composed of the Cterminal half of MHC and the light chains form the distal end of the myosin tail. The light chains are of two classes: a phosphorylatable form found in heart muscle and the CNS, but not in skeletal muscle, and a nonphosphorylatable form. Indeed, the N-terminal section of MHC together with two light chains, one of each class, form the globular head. MLCs bind Ca2+ with great affinity and regulate myosinATPase activity. The conformation of the myosin globular heads is regulated by the phosphorylation of the MLC by MLCK, which binds to actin via residues 2–42 of the N-terminal end of the kinase (Gallagher and Stull, 1997). This phosphorylation is believed to be a Ca/CaM-dependent process. Although reversible phosphorylation of MLC is generally regarded as the regulatory event, other proteins, e.g., caldesmon and calponin, which are capable of binding to the actin–myosin assembly, could subserve important functions. The skeletal and heart muscle cells possess a characteristic striated pattern. The striations are due to individual fibrils within the muscle cells. The striations are produced because the fibrils are arranged in register, which accentuates the striation.
The Structure of Contractile Proteins
113
FIGURE 15 A sarcomere with its bands. The pattern is a result of the arrangement of actin, myosin, and titin. (Based on Gaub and Fernandez, 1998.)
The striations form three distinct zones: the dark and birefringent A-band with a lighter zone in the middle called the H-band, which in turn is divided by the Mline; the I-band, which is lighter than the A-band; and the Z-line, which is a dark line in the middle of the I-band (Figure 15). The contractile, regulatory, and structural components of these zones are summarised in Table 7. The A-band is composed of
114
Calcium Signalling in Cancer
TABLE 7 Contractile, Regulatory, and Structural Component Proteins of Myofibrils of Vertebrate Skeletal Muscle
Protein Contractile Myosin Actin Regulatory elements Troponin Tropomyosin M-protein C-protein α-actinin Structural component Titin Nebulin
Location Band
A I I I M-line A Z-line A–I I
Content % wt.
Molecular Weight (kDa)
43 22
ca. 500 42
5 5 2 2 2 10 5
70
ca. 110 3000 600–800
Source: The data in this table have been collated from references cited in the text.
thick myosin filaments. These are arranged in a parallel array and in register and therefore they determine the length of the A-band. Thin actin microfilaments form the lighter I bands. However, the thick myosin filaments form bridges with the microfilaments, especially in the region of overlap of A and I bands. In transverse section of the muscle, the organisation of the filaments can be described as a lattice. Each thick myosin filament has six thin actin microfilaments and each actin filament has two neighbouring myosin filaments. In the thin filaments, tropomyosin occurs in a head-to-tail orientation in one groove of actin helix by means of seven actinbinding sites. It is believed that molecular elasticity is regulated by a species of giant rod-like proteins called titin or connectin. Human titin is a ca. 3000-kDa protein consisting of variable numbers of immunoglobulin (Ig)- and FN-like repeat domains and a P (proline), E (glutamate), V (valine), and K (lysine)-rich region of variable length. Titin overlaps the A-band and the I-band, extending from the Z-line to the M-line (see Figure 15). It is believed that the part of titin that overlaps the I-band forms the elastic region of the molecule (Linke et al. 1998). Alternative splicing of the I-band titin is said to result in changes in the component Ig and FN modules and in the length of the PEVK region (K. Wang et al. 1991; Labeit and Kolmerer, 1995a). Another large protein called nebulin, of approximately 600 to 800 kDa molecular size, spans the whole length of the thin filaments of the I-band. Indeed, nebulin is regarded as the determinant of the length of the thin filaments (Kruger et al. 1991; Jin and Wang, 1991; Labeit et al. 1991; Trinick, 1994). The assembly of mature Z-discs occurs from precursors called I-Z-I bodies, which contain titin,
The Structure of Contractile Proteins
115
nebulin, actin, and α-actinin (Holtzer et al. 1997). Tropomyosin seems to be involved in nemaline myopathy. Two loci involved in this disease are the tropomyosin-3 locus and the nebulin locus on 2q21.2–q22 (Laing et al. 1995; Pelin et al. 1999). Mutations of both genes have been implicated. The formation of the complex of tropomyosin, titin, nebulin, α-actinin, and actin can conceivably be affected by these mutations, leading to abnormalities in Z-disc assembly and the formation of nemaline. The C-terminal region of nebulin contains an SH3 domain, which may anchor the nebulin filament system to the Z-disc (Labeit and Kolmerer, 1995b). This SH3 domain has been found to interact with actin, tropomyosin, troponin and calmodulin. This could suggest that nebulin, together with tropomyosin and troponin, might form a complex that is calcium-regulated (K. Wang et al. 1996). In cardiac muscle, a nebulin-related protein called nebulette substitutes for nebulin (Millevoi et al. 1998). Nebulette is similar to skeletal muscle nebulin in its organisation and contains four domains: an N-terminal domain followed by a domain that contains nebulin-like repeats, a linker domain connecting the nebulin repeats to the C-terminal SH3 domain. The nebulin repeats possess actin-binding ability and the linker zone appears to target the protein to the Z-line. This is suggested by the binding of recombinant nebulette fragments to actin, tropomyosin, and α-actinin in vitro (Moncman and Wang, 1999).
MYOSIN LIGHT CHAIN (MLC) PHOSPHORYLATION
AND
FUNCTION
As stated earlier, there are two classes of myosin light chain (MLC), viz. a nonphosphorylatable and a phosphorylatable regulatory chain. The reversible phosphorylation of the regulatory MLC is regarded as the key event in the regulation of myosin-ATPase and the generation of the contractile force. The phosphorylation of MLC is carried out by the MLCK. MLCK is a Ca2+/CaMdependent kinase (Stull et al. 1993) and is itself subject to regulation by kinases and phosphatases (Quadroni et al. 1998). MLCK is known to be able to bind to actin and thereby regulate actin–myosin interaction (Kohama et al. 1992; see also below). Naturally this will influence the function of the ATPase. On the other hand, binding of calponin and caldesmon to actin may inhibit myosin-ATPase and this inhibition may be reversed by calcium-binding S100 proteins and calmodulin (see Fattoum, 1997). Rho kinase also seems to be able to phosphorylate MLC, together with inactivation of myosin phosphatases (Fukata et al. 1999) (Figure 16). The regulation of the contractile machinery of the cell has obvious implications for cell motility and diapedesis of cells. The ability of activated PMN to traverse the endothelium appears to be related to the state of MLCs phosphorylation of endothelial cells. Hixenbaugh et al. (1997) found that activated PMNs increase phosphorylation of serine 19 and threonine 18 of MLCs of endothelial cells. Garcia et al. (1998) have confirmed the enhanced phosphorylation of MLC in endothelial cells and have further shown that inhibitors of MLCK significantly inhibit the diapedesis of activated PMNs across the endothelium. Phosphorylation of MLCK by protein kinase C also inhibits MLC phosphorylation and causes enhanced
116
Calcium Signalling in Cancer
Muscle contraction
Caldesmon Calponin
Actomyosin Mg-ATPase
Myosin
Actin
S100/S100A4 Caltropin Ca 2+/Calmodulin
RMLC +P PKC
+P
MLCK
Ca2+/CaM +P Casein Kinase II
-P PPIA/PPIB
FIGURE 16 Control of regulatory myosin light chain (MLC) function in muscle contraction. CaM, calmodulin; MLCK, MLC kinase; PKC, protein kinase C; PP1A/PPiB: protein phosphatases; RMLC, regulatory MLC.
epithelial resistance (Angle et al. 1998). The association with actin and the assembly of myosin II into the cytoskeleton is dependent on the phosphorylation of the regulatory chain. MLC associated with the cytoskeleton of cultured endothelial cells has been reported to show a fivefold greater phosphorylation than MLC in soluble form. The phosphorylation of serine 19 and threonine 18 appears to regulate the assembly of MLC in vitro. In contradistinction, soluble MLC seems to be phosphorylated at threonine 9 (Kolega and Kumar, 1999). It would seem that the phosphorylation of the cytoskeletal machinery could increase the intercellular gaps thus allowing cell penetration. It would be worthwhile to investigate whether, like activated PMNs, cancer cells affect the state of MLC phosphorylation of endothelial cells. Unquestionably, vascular permeability is an important determinant of metastatic spread of cancer. However, invasive ability is an intrinsic property of the cancer cell. Gillespie et al. (1999) have recently shown that the MLCK inhibitors, ML7 and KT5926, inhibit the invasive ability of glioma cells. MLC phosphorylation in both the invading tumour cell and the endothelial cell barrier might determine the degree of successful entry of the tumour cell into the vascular compartment (Figure 17). Some studies have implicated MLC phosphorylation in the regulation of certain other biological features such as cell growth and apoptosis. Mills et al. (1998) have reported that membrane blebbing associated with apoptotic cell death could be reduced by MLCK inhibitors, and, further, that there was increased phosphorylation
The Structure of Contractile Proteins
117
Diapedesis
MLC-P +P
Inhibitors
MLCK
+P
MLCK kinases (PKC)
+P MLC-P
Cancer Cell Invasion FIGURE 17 Possible involvement of MLC phosphorylation in the migration of cells across the endothelial membrane as well as with the intrinsic invasive potential of the tumour cell. MLC, myosin light chain; MLCK, MLC kinase; PKC, protein kinase C.
of MLCs in membrane blebbing. There are also suggestions based on preliminary findings that MLC phosphorylation may also be associated with cell proliferation (Bresnick et al. 1996; Yamakita et al. 1996). MLCK may affect actin reorganisation by a mechanism that is independent of its kinase activity. As stated earlier in this section, MLCK is known to be able to bind to actin and influence actin–myosin interaction. Another aspect of MLCK function is that it can bind to and result in actin bundling into filaments (Hayakawa et al. 1994). Two sites on MLCK have been identified and characterised; one of them is Ca2+/CaM sensitive and the other is Ca2+/CaM insensitive (Ye et al. 1997). These participate in actin filament assembly in vitro (Hayakawa et al. 1999). By inference from and in common with the properties of other actin-binding and bundling proteins, it would be reasonable to suggest that MLCK might influence cell shape and flexibility and thereby affect cell migration and diapedesis, quite independently of its kinase activity.
118
Calcium Signalling in Cancer
TROPONINS AND TROPOMYOSINS IN THE REGULATION OF MUSCLE CELL CONTRACTION THE REGULATORY ROLE MUSCLE CONTRACTION
OF
TROPONINS
AND
TROPOMYOSINS
IN
Troponins are CBPs that play a major regulatory role in cardiac and skeletal muscle contraction in consort with tropomyosins. Three troponin (Tn) molecules — TnT, TnI, and TnC — bind to each tropomyosin molecule. Many tropomyosin isoforms with a range of molecular sizes have been identified (see below). The high molecular weight isoforms bind actin more strongly than the others (Matsumura et al. 1985). There is a complex and specific form of association between the troponins and tropomyosin that produces conformational changes in actin that lead to muscle relaxation or contraction. TnT binds to the C-terminal region of tropomyosin and forms a link between TnI and TnC, which both bind to tropomyosin. The structural domain C and regulatory domain N of tropomyosin interact with specific amino acid sequence motifs of TnI (Pearlstone et al. 1997). Calcium binding to the N domain of TnC can alter the affinity of the N- and C-termini of TnI for TnC. In other words, calcium binding can provide a switch between these two sites for binding with TnC (Tripet et al. 1997). At any rate, the whole complex interacts with actin via TnI. TnI is the myosin-ATPase inhibitory protein. TnC is the calcium binding subunit. In the absence of Ca2+ binding to TnC, the conformation of actin filament is such that its interaction with myosin heads is weak and the muscle fibres are in a relaxed state. The ATP that is bound to myosin is hydrolysed by a myosin-catalysed ATPase. In the absence of calcium, the troponin/tropomyosin complex inhibits myosin-ATPase. But when intracellular calcium levels are raised, Ca2+ binds to TnC and myosinATPase inhibition is released, ATP hydrolysis occurs and muscle contraction ensues. The contracted state is maintained when Ca2+ and ATP levels are maintained at high levels (Figure 18). The SR around myofibrils stores Ca2+ as well as the membraneATPase that is required for the release of Ca2+ and raises intracellular levels. There is therefore a homeostatic mechanism at work, maintaining a 10-7 M Ca2+ level in the resting muscle, and the increase of this by an order of magnitude produces the cascade of events leading to muscle contraction. Tropomyosin
Tnl
TnT
Muscle contraction
TnC
Ca
Actin
FIGURE 18
Myosin-ATPase
2+
conformational change
Cascade of events leading to muscle contraction upon Ca2+ binding to TnC.
The Structure of Contractile Proteins
119
The calcium–TnC trigger leads to the contraction of cardiac and skeletal muscles. However, different mechanisms may be involved in the activation of myofilaments of the heart and skeletal muscles. In heart myofilaments, Ca2+ binds to one regulatory site on TnC but to two sites in skeletal myofilaments. Besides, there are also differences with regard to Ca2+-induced conformational changes between cardiac and skeletal muscle (Spyracopoulos et al. 1997). In the smooth muscle, i.e., involuntary muscle under CNS control and muscle tissue of invertebrates, there is no SR. In these, intracellular Ca2+ alterations tend to be slower than those found in striated muscle. Furthermore, Ca2+ regulation of contraction involves MLCs, which have a high affinity for Ca2+. At low calcium levels the interaction of myosin head with actin is weak, but when the light chains bind Ca2+, the myosin head–actin interaction activates myosin-ATPase leading to muscle contraction.
TROPOMYOSIN ISOFORMS
IN
BENIGN
AND
MALIGNANT CELLS
Tropomyosin isoforms are expressed in cells of muscle as well as nonmuscle origin. They are found in many organisms from unicellular ones to mammals (Pittenger et al. 1994). In human fibroblasts, eight isoforms have been identified and characterised. They are products of four genes (Novy et al. 1993a, 1993b). The isoforms of tropomyosin that have been identified range in molecular size from 32 to 40 kDa (J.J.C. Lin et al. 1985; Matsumura et al. 1983; Novy et al. 1993; Pittenger et al. 1994; Warren et al. 1985). The isoforms seem to differ with respect to the strength of their association with actin and may also differ in their function (Matsumura et al. 1985; Novy et al. 1993a; Gunning et al. 1997). The possible functional differences between the isoforms has been emphasised by the finding that they appear to be spatially sorted out or compartmentalised in neuronal development (Gunning et al. 1997). The localisation of tropomyosin isoforms shows a distinctive pattern in the kidney epithelial cells LLC-PK1. Temm-Grove et al. (1998) found that these cells expressed both high and low molecular weight isoforms of tropomyosin. The high molecular weight isoforms were associated with stress fibres but not with adhesion belts. In contrast, the low molecular weight isoforms were found on adhesion belts. These differences in localisation were also encountered when these isoforms were introduced into cells by microinjection or transfection. These observations support the view that the different isoforms might subserve different functions. The loss of cell shape, cell adhesion to the substratum, and the loss of stress fibres in cellular transformation has focused attention on the expression of tropomyosins in benign and malignant cells and tissues. The expression of tropomyosins has been reported to be frequently down-regulated in transformed cells (Cooper et al. 1985; Hendricks and Weintraub, 1981, 1984; Leavitt et al. 1986; J.J.C. Lin et al. 1985; Matsumura et al. 1983). In chick embryo fibroblasts transformed by RSV, a differential repression of tropomyosins has been reported to occur at the transcriptional level (Hendricks and Weintraub, 1984). The normal human fibroblast KD cells express four tropomyosin mRNAs. The expression of two of these of 1.1 and 3.0 kb was found to be markedly reduced in transformed cells and in a cell line derived from pancreatic cancer (Novy et al. 1993b). Leavitt et al. (1986) have reported alterations of tropomyosin isoforms that are expressed in human fibroblasts trans-
120
Calcium Signalling in Cancer
formed by chemical carcinogens. In these cells, the high molecular weight tropomyosins appeared to be down-regulated. However, there was a slight down-regulation of one and an up-regulation of another high molecular weight isoform in nontumorigenic immortalised cells. A change in pattern of isoform expression has also been reported to occur upon cell transformation by viruses (Matsumura et al. 1982, 1983). Oncogenic retroviral genes indeed have been shown to suppress tropomyosin synthesis (H.L. Cooper et al. 1985). Furthermore, the suppression of the tropomyosins appears to have a bearing on cellular morphology. Prasad et al. (1999) transfected v-src-transformed cells, which express the TM1 isoform at very low levels, with TM1 cDNA. This resulted in higher levels of TM1 expression in the transfected cells, which also showed a reduction in cell growth and enhanced cell spreading. These effects also were accompanied by alterations in the architecture of microfilaments. Therefore, differential expression of the isoforms could be seen as suggesting differences in their cell function. A loss of high molecular weight tropomyosin isoforms and MLCs has been reported in tumorigenic cell lines as compared with nontumorigenic cells derived from prostate epithelium transformed by SV40 or X-irradiation (Prasad et al. 1997). However, TPA, which is a tumour promoter, is able to induce a high molecular weight isoform in human melanocytes (Vogt et al. 1997). Ovarian carcinomas reportedly have lower levels of a high molecular weight isoform of tropomyosin as compared with benign tumours (Alaiya et al. 1997). Franzen et al. (1996) found that the average levels of high molecular weight isoforms were far lower in breast carcinomas and nonmalignant tumours. The level of expression of one of these isoforms seemed to relate to the presence of tumour in the axillary lymph nodes, with the primary tumours showing 1.7-fold greater expression as compared with those that showed no nodal dissemination. The same high molecular weight isoform was found to be expressed at higher levels in H-ras-transformed fibroblast cell lines that possessed high metastatic ability than in transformed cells with lower metastatic ability. It may be pointed out that this implies that the more malignant the cell the greater is the level of expression of the high molecular weight isoform. This contradicts the relationship subsisting between the normal cell and its transformed counterpart, where transformed cells show a down-regulation of tropomyosin expression. Nonetheless, such a comparison might lead to oversimplified conclusions. It should be recognised that viral transformation of cells does not always lead to metastatic spread. The criterion of tumorigenicity does not contain any element of metastasis. For instance, tumours formed by SV40-transformed 3T3 fibroblasts rarely, if at all, metastasise. Furthermore, tumours are too heterogeneous and therefore association of metastatic ability with specific isoforms requires a detailed investigation of specific subpopulations of the tumour. Also desirable would be an investigation of primary tumours and the corresponding metastatic tumours. Hashimoto et al. (1996) compared K-1735 murine melanoma cells with differing metastatic potential. They reported that the β isoform of tropomyosin was expressed only in the low metastasis variant of K-1735 melanoma. The differential expression of the high and low molecular weight isoforms in adhesion belts and stress fibres (Temm-Grove et al. 1998) underwrites these efforts at exploring differential expression of tropomyosin isoforms in the progression of tumours to the metastatic state.
The Structure of Contractile Proteins
121
Cell–cell and cell–substratum adhesion are important factors in tumour cell dissemination and their adhesion to metastatic target tissues. However significant might be the association between tropomyosins and neoplasia, it would be worth recalling here that TnI, which is the inhibitory component of the troponin/tropomyosin complex, might itself be associated with metastatic progression of cancer. As shown by Moses et al. (1999), TnI can inhibit angiogenesis both in vitro and in vivo and also inhibit metastatic dissemination.
THE REGULATORY ROLE
OF
CALDESMON
The cyclical interaction of the globular head domain myosin with thin actin filaments coupled with the breakdown of ATP drives muscle contraction. Although reversible phosphorylation of MLC is regarded as an important regulatory event, there is general recognition that not all the events in muscle contraction can be explained by invoking this mechanism alone. Additional mechanisms have been sought. Caldesmon and calponin are two major proteins, both capable of binding to the major components such as actin, myosin, tropomyosin, and phospholipids (see Fattoum, 1997; Childs et al. 1992; Szymanski and Tao, 1997; Bogatcheva and Gusev, 1995), and both have been seen as offering alternative modes of regulation. Furthermore, both proteins interact with calmodulin in the presence of Ca2+ (Medvedev et al. 1996; Zhang and Vogel, 1997; Graether et al. 1997). Whether caldesmon and calponin have individual roles in the regulation of smooth muscle contraction is being debated. Some argue that the two proteins interact with each other. Graceffa et al. (1996) showed that a strong binding occurred between calponin and the carboxyl domain of caldesmon. They have suggested that this interaction could lead to the stabilisation of the complex. However, Czurylo et al. (1997) subscribe to the view that these two proteins have independent roles in muscle contraction. Caldesmon is found in both smooth muscle and nonmuscle cells. It is a regulatory protein that occurs in the groove of the actin helix. Caldesmon and calponin inhibit actin-mediated activation of myosin-ATPase in smooth muscle fibres. Several segments of the C-terminal region of the caldesmon molecule may be involved in binding to actin and in its inhibitory function (Heubach et al. 1997). Whereas the C-terminal end binds to actin, the N-terminal end appears to be dissociated from but present in the close vicinity of actin and seems to mediate the link between myosin and actin filaments (Graceffa, 1995, 1997). In the C-terminal domain encompassing residues 663-763, three regions have been identified that take part in myosinATPase inhibition: a central segment encompassing residues 747–767, a segment that is N-terminal, and another segment C-terminal to this central segment. The central segment is essential but not sufficient to produce myosin-ATPase inhibition (I.D.C. Fraser et al. 1997). Two isoforms of caldesmon arising from alternative splicing of pre-mRNA are known. The high molecular weight (89–93 kDa) isoform is restricted to adult and fully differentiated smooth muscle cells, whereas the nonmuscle low molecular weight isoform is found in de-differentiated nonmuscle cells. There are several conserved domains in the caldesmon molecule, which determine its interaction with and binding to actin, calmodulin, myosin, and phospholipids. All the isoforms are
122
Calcium Signalling in Cancer
powerful inhibitors of myosin-ATPase, but the specific nature of their distribution suggests possible differences in function. In nonmuscle cells, caldesmon could be stabilising the microfilament network and in smooth muscle, it may be involved in the inhibition of muscle contraction (see Huber, 1997). The function of caldesmon in the regulation of cytoskeletal organisation and contractile processes is not limited only to animal cells. A caldesmon-like protein occurs in higher plants. A 107-kDa protein with properties similar and immunologically related to caldesmon has been isolated from extracts of pollen tubes of Ornithogalum virens. This protein binds to actin in a CaM/Ca2+-dependent manner (Krauze et al. 1998). This is consistent with the view that actomyosin cytoskeleton participates in the growth and elongation of pollen tubes. Pollen tube elongation is a calcium-dependent process (Masserli and Robinson, 1997). Caldesmon also can bind to S100 α and β proteins. The S100 binding site appears to be in the C-terminal region. Interestingly, the cross-linking of caldesmon via cysteine residues with S100 seems to reduce the inhibitory effect of caldesmon on myosin-ATPase activity, and S100 seems to be as effective as calmodulin in this respect (Polyakov et al. 1998). There are no implications, as yet, that the different isoforms of caldesmon differ functionally, because there is extensive sequence homology between isoforms occurring in different species (Novy et al. 1991). However, as stated above, the expression of some isoforms has been related to the state of differentiation. Furthermore, early studies by Novy et al. (1991) have shown a two- to four-fold reduction in the expression of caldesmon in certain transformed cell lines.
CALPONIN: ITS FUNCTION
AND
REGULATION
Calponin is a 33-kDa protein highly expressed in smooth muscle cells. The human smooth muscle calponin gene contains seven exons encompassing >11 kb and it has been assigned to chromosome 19p13.2 (Miano et al. 1997). Calponin is a thin filament-associated TnT-like protein. It is strongly implicated in smooth muscle contraction. As with caldesmon, calponin binds to actin, myosin, tropomyosin, and CBPs such as calmodulin. Actin possesses two calponin-binding sites (Kolakowski et al. 1997; Mino et al. 1998). The interaction between calponin and myosin occurs via defined regions of the calponin molecule (Szymanski and Tao, 1997). Three isoforms of calponin have been described: the basic h1 isoform, the neutral isoform h2, and the acidic isoform. Two distinct genes encode the isoforms h1 and h2. They are not generated by alternative splicing of pre-mRNA (Fukui et al. 1997). All three isoforms contain the calponin-homology (CH) actinbinding domain in the N-terminal region of the protein. The CH domain comprises a sequence motif containing approximately 100 amino acid residues. Some actincross-linking proteins may contain two distinct CH domains and have contested the rather generalised concept that a single CH domain is sufficient to confer actinbinding properties on these proteins (Stradal et al. 1998). CH domains also occur in other actin-interacting proteins. Fimbrin is an actin-cross-linking protein. Its association with F-actin is similar to that of calponin (Hanein et al. 1997b) and, furthermore, it contains two CH domains. The proto-oncogene vav, which is
The Structure of Contractile Proteins
123
expressed in haematopoietic cells, codes for a signalling molecule that contains a CH domain (Castresana and Saraste, 1995; Romero and Fischer, 1996). Nonmuscle isoforms of calponin have been reported in brain tissue. The h2 isoform was identified by Fukui et al. (1997) from human skin tissue and human keratinocytes in culture using antibodies raised against smooth muscle calponin. Calponin generally has been attributed with the ability to inhibit myosin-ATPase. In vivo, calponin occurs in the ratio of approximately one calponin molecule to seven actin monomers (Lehman and Kaminer, 1984; Takahashi et al. 1986; Lehman, 1991), but there is a view that higher levels of calponin may be required for an effective inhibition of myosin-ATPase (Gimona and Small, 1996). Exogenous calponin has been shown to inhibit Ca2+-responsive muscle contraction (Horowitz et al. 1996; Naka et al. 1998). Calponin serves as a substrate for several kinases and phosphatases, and its function seems to be regulated by phosphorylation. Pohl et al. (1997) have shown that unphosphorylated calponin is able to inhibit actin sliding, which is demonstrable using in vitro motility assays, but when calponin is phosphorylated by PKC this effect is inhibited. In vivo, calponin purified from tracheal smooth muscle stimulated with carbachol (carbamyl choline chloride), which is a Ca2+-mediated stimulator of phosphorylation, showed two-fold greater phosphorylation than unstimulated muscle. Naka et al. (1998) also demonstrated a correlation between calponin phosphorylation and contraction of porcine coronary artery. However, as discussed below mechanisms other than phosphorylation have been adduced for calponin regulation, e.g., one involving caltropin. Aside from being regulated by phosphorylation, it has been reported that calponin co-precipitates with MAPK, but there is no obvious phosphorylation of calponin. The latter also co-precipitated with PKC-ε. A translocation of calponin to the cell membrane occurs in cells that are stimulated with phenylephrine, when MAPK and PKC-ε are also translocated to the cell membrane. On the basis of these findings, Menice et al. (1997) have implicated calponin in signal transduction. Indeed, the targeting of these various components to the cell membrane might be a consequence of the tight binding of calponin to cytoplasmic β-actin (Parker et al. 1998). Calponin seems also to be able to regulate the amount of free actin available for cytoskeletal organisation. The h2 isoform, for instance, appears to be localised in the cytoplasm of basal cells in situ, whereas in cultured keratinocytes it occurs along the cell–cell contact areas, which suggests that it might play a part in the organisation of the cytoskeleton. Tang et al. (1997) believe that calponin, being polycationic in nature, could promote the formation of F-actin bundles by reducing the polyanionic repulsive interaction between actin filaments. Calponin can also bind to tubulin, which decreases with increases in Ca2+ concentration and ionic strength (Fujii et al. 1997). These authors also state that calponin has distinct sites for binding actin and tubulin. Furthermore, calponin seems to bind strongly to desmin and is incorporated into IF and, therefore, it is possible that it might mediate the association of desmin IF with actin (Mabuchi et al. 1997). The ability of calponin to promote cytoskeletal organisation may be reflected in its ability also to inhibit cell growth (Z. Jiang et al. 1997). It also has been reported recently that the expression of calponin and smooth muscle MHC expression can distinguish between in situ and invasive carcinoma of the breast. Antibodies against
124
Calcium Signalling in Cancer
MHC and calponin stain epithelial cells of ducts and acini of normal breast tissue and carcinomas in situ, but these antibodies hardly show any reactivity in invasive carcinomas (Wang et al. 1997). Calponin is prominently expressed in myofibrils of leiomyosarcomas (Meyer and Brinck, 1997). Overall, calponin seems to show a generally reduced expression in human leiomyosarcomas. Compatible with the lack of its expression in invasive breast carcinomas as compared with in situ tumours are the recent findings of Horiuchi et al. (1999). These authors transfected human calponin h1 into leiomyosarcoma cells. The transfectants showed a one third reduction in cell proliferation, together with reduction in anchorage-independent growth as well as tumorigenicity. Nonetheless, much further work is required before one can attribute a tumour suppressor function to calponin.
CALTROPIN-MEDIATED REVERSAL OF MYOSIN-ATPASE INHIBITION BY CALDESMON AND CALPONIN It is obvious from the above discussion that caldesmon and calponin both inhibit myosin-ATPase and influence muscle contraction. The binding of caldesmon and calponin to actin appears to produce this inhibition and this effect is reversible by calmodulin. Another CBP, i.e., caltropin, appears to be involved in the regulation of the inhibitory effects of caldesmon and calponin on myosin-ATPase. Caltropin is an 11-kDa protein derived from smooth muscle. It occurs as a dimer in the native form (Willis et al. 1994). Some years ago, Mani et al. (1992) demonstrated that caltropin, like CaM, was able to reverse the inhibition of myosin-ATPase by caldesmon in the presence of Ca2+. They found that caltropin directly interacted with caldesmon. This seemed to influence the interaction of caldesmon with the actin component of heavy meromyosin (Mani and Kay, 1993, 1995a). In vitro, caltropin seems to inhibit the polymerisation of G-actin (Mani and Kay, 1995b), thus providing further confirmation of interference by caltropin in caldesmon–actin interactions. Although Mani et al. (1992) state that caltropin is as effective as CaM in reversing caldesmon-mediated inhibition of myosin-ATPase, there is evidence that the binding affinity of caltropin to caldesmon is far greater than that of CaM (Zhuang et al. 1995). In consonance with these observations are the findings of Willis et al. (1994) that caltropin also is able to form a complex with calponin in a calcium-dependent fashion in the ratio of 2:1 and reverse the inhibitory action of caldesmon. Caltropin has been described as being more efficient than CaM. Thus there seems to be a reasonable body of evidence, albeit from the same laboratory, that caltropin has considerable implications in the regulation of myosin-ATPase function.
8
Structure and Biology of Calbindin
Calbindins D-28K (CBD) and D-9K (CBD-9K) are EF-hand proteins that are regarded as calcium buffer proteins together with parvalbumins (PV). CBD is a type III EF-hand protein possessing six EF-hands (see Table 4), all of which seem to be packed in one globular domain, but the folding and packing of individual domains within the globular domain appears to be specific (Linse et al. 1997). The rat CBD9K gene consists of three exons and two introns. Exon 2 contains sequences encoding the first EF-hand and exon 3 for the second EF-hand domain.
CALBINDIN IN NEURONAL POPULATIONS CBD is a calcium-binding protein that is expressed abundantly in a number of cell types, such as neuronal cells, mammalian and avian kidney, brain, and pancreas, and in avian intestines. Wasserman and Taylor (1966) isolated this calcium-binding EFhand protein from the intestine of chicken later found to be a